[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 5511
1. Peng H, Huang Y, Duan Z, Erdmann N, Xu D, Herek S, Zheng J: Cellular IAP1 regulates TRAIL-induced apoptosis in human fetal cortical neural progenitor cells. J Neurosci Res; 2005 Nov 1;82(3):295-305
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Neural stem/progenitor cells (NPCs) are present in the developing and adult central nervous system.
  • NPC apoptosis is an important aspect of normal brain development.
  • We show that tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor 2 is highly expressed on human NPCs derived from fetal cortex, yet TRAIL induces only minimal levels of apoptosis in NPCs.
  • [MeSH-major] Apoptosis / physiology. Apoptosis Regulatory Proteins / metabolism. Brain / embryology. Inhibitor of Apoptosis Proteins / metabolism. Membrane Glycoproteins / metabolism. Neurons / metabolism. Stem Cells / metabolism. Tumor Necrosis Factor-alpha / metabolism
  • [MeSH-minor] Caspase 3. Caspase 8. Caspases / genetics. Cells, Cultured. Cerebral Cortex / embryology. Cerebral Cortex / growth & development. Cerebral Cortex / metabolism. Dactinomycin / pharmacology. Enzyme Activation / drug effects. Enzyme Activation / genetics. Fetus. Humans. Nerve Degeneration / metabolism. Nerve Degeneration / physiopathology. Protein Synthesis Inhibitors / pharmacology. RNA Interference / physiology. RNA, Messenger / metabolism. Receptors, TNF-Related Apoptosis-Inducing Ligand. Receptors, Tumor Necrosis Factor / metabolism. TNF-Related Apoptosis-Inducing Ligand. Ubiquitin-Protein Ligases. Up-Regulation / drug effects. Up-Regulation / genetics

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 Wiley-Liss, Inc.
  • (PMID = 16180223.001).
  • [ISSN] 0360-4012
  • [Journal-full-title] Journal of neuroscience research
  • [ISO-abbreviation] J. Neurosci. Res.
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / P01 NS043985; United States / NCRR NIH HHS / RR / P20 RR15635; United States / NINDS NIH HHS / NS / R01 NS 41858
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; 0 / BIRC2 protein, human; 0 / Inhibitor of Apoptosis Proteins; 0 / Membrane Glycoproteins; 0 / Protein Synthesis Inhibitors; 0 / RNA, Messenger; 0 / Receptors, TNF-Related Apoptosis-Inducing Ligand; 0 / Receptors, Tumor Necrosis Factor; 0 / TNF-Related Apoptosis-Inducing Ligand; 0 / TNFRSF10B protein, human; 0 / TNFSF10 protein, human; 0 / Tumor Necrosis Factor-alpha; 1CC1JFE158 / Dactinomycin; EC 3.4.22.- / CASP3 protein, human; EC 3.4.22.- / CASP8 protein, human; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspase 8; EC 3.4.22.- / Caspases; EC 6.3.2.19 / Ubiquitin-Protein Ligases
  •  go-up   go-down


2. Iwamoto FM, Omuro AM, Raizer JJ, Nolan CP, Hormigo A, Lassman AB, Gavrilovic IT, Abrey LE: A phase II trial of vinorelbine and intensive temozolomide for patients with recurrent or progressive brain metastases. J Neurooncol; 2008 Mar;87(1):85-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II trial of vinorelbine and intensive temozolomide for patients with recurrent or progressive brain metastases.
  • PURPOSE: To investigate the efficacy and safety of the combination of vinorelbine and intensive temozolomide for recurrent or progressive brain metastases from solid tumors.
  • METHODS: Patients > or =18 years of age and with Karnofsky performance scale (KPS) > or = 60, adequate organ function and progressive or recurrent brain metastases were eligible.
  • The primary tumor sites were lung (n = 20), breast (n = 11), colorectal (n = 2), kidney (n = 2), bladder (n = 1), endometrium (n = 1), head and neck (n = 1).
  • Prior therapies included chemotherapy (97%), whole-brain radiation therapy (79%), brain metastasis resection (53%) and stereotatic radiosurgery (47%).
  • CONCLUSIONS: In this heavily pretreated population of patients with brain metastases, adding vinorelbine and increasing the intensity of temozolomide do not improve response rates compared to previous studies with single-agent temozolomide at standard doses.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / drug therapy. Brain Neoplasms / secondary. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Adult. Aged. Dacarbazine / administration & dosage. Dacarbazine / adverse effects. Dacarbazine / analogs & derivatives. Disease-Free Survival. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Survival Analysis. Vinblastine / administration & dosage. Vinblastine / adverse effects. Vinblastine / analogs & derivatives

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. VINORELBINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 2000 Jun;82(12):1907-13 [10864196.001]
  • [Cites] Br J Cancer. 2003 Apr 7;88(7):1004-11 [12671695.001]
  • [Cites] Ann Oncol. 2001 Feb;12 (2):249-54 [11300333.001]
  • [Cites] Breast Cancer Res. 2005;7(2):64-9 [15743513.001]
  • [Cites] Cancer Chemother Pharmacol. 2006 Jan;57(1):34-9 [16010592.001]
  • [Cites] Lancet. 2004 May 22;363(9422):1665-72 [15158627.001]
  • [Cites] J Clin Oncol. 2004 Jun 1;22(11):2101-7 [15169796.001]
  • [Cites] Neurology. 2004 Jun 8;62(11):2113-5 [15184628.001]
  • [Cites] Cancer Invest. 2002;20(3):293-302 [12025223.001]
  • [Cites] J Clin Oncol. 1999 Sep;17 (9):2762-71 [10561351.001]
  • [Cites] J Neurooncol. 2001 Jul;53(3):259-65 [11718258.001]
  • [Cites] Eur J Cancer. 2003 Jun;39(9):1271-6 [12763216.001]
  • [Cites] J Neurooncol. 2006 Jul;78(3):277-80 [16614943.001]
  • [Cites] Ann Oncol. 2001 Jan;12(1):59-67 [11249050.001]
  • [Cites] J Neurooncol. 2005 Jan;71(1):61-5 [15719277.001]
  • [Cites] Lung Cancer. 2005 Nov;50(2):247-54 [16039010.001]
  • [Cites] Curr Neurol Neurosci Rep. 2004 May;4(3):205-10 [15102346.001]
  • [Cites] Clin Cancer Res. 1997 Oct;3(10 ):1769-74 [9815562.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10 ):987-96 [15758009.001]
  • [Cites] N Engl J Med. 1990 Feb 22;322(8):494-500 [2405271.001]
  • (PMID = 17987262.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; Q6C979R91Y / vinorelbine; YF1K15M17Y / temozolomide
  •  go-up   go-down


3. Hours M, Bernard M, Montestrucq L, Arslan M, Bergeret A, Deltour I, Cardis E: [Cell Phones and Risk of brain and acoustic nerve tumours: the French INTERPHONE case-control study]. Rev Epidemiol Sante Publique; 2007 Oct;55(5):321-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cell Phones and Risk of brain and acoustic nerve tumours: the French INTERPHONE case-control study].
  • To evaluate the relationship between the use of cell phones and the development of tumors of the head, a multicentric international study (INTERPHONE), coordinated by the International Agency for Research on Cancer, was carried out in 13 countries.
  • METHODS: INTERPHONE is a case-control study focused on tumors of the brain and central nervous system: gliomas, meningiomas and neuromas of cranial nerves.
  • Eligible cases were men and women, residents of Paris or Lyon, aged 30-59, newly diagnosed with a first primary tumor between February 2001 and August 2003.
  • Although these results are not statistically significant, a general tendency was observed for an increased risk of glioma among the heaviest users: long-term users, heavy users, users with the largest numbers of telephones.
  • [MeSH-major] Brain Neoplasms / etiology. Cell Phones. Neuroma, Acoustic / etiology
  • [MeSH-minor] Adult. Case-Control Studies. Central Nervous System Neoplasms / etiology. Cranial Nerve Neoplasms / etiology. Female. Glioblastoma / etiology. Glioma / etiology. Humans. Male. Meningioma / etiology. Middle Aged. Neuroma / etiology. Risk Factors. Time Factors

  • MedlinePlus Health Information. consumer health - Acoustic Neuroma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17851009.001).
  • [ISSN] 0398-7620
  • [Journal-full-title] Revue d'épidémiologie et de santé publique
  • [ISO-abbreviation] Rev Epidemiol Sante Publique
  • [Language] fre
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Multicenter Study
  • [Publication-country] France
  •  go-up   go-down


Advertisement
4. Matsumura A, Yamamoto T, Tsurubuchi T, Matsuda M, Shirakawa M, Nakai K, Endo K, Tokuue K, Tsuboi K: Current practices and future directions of therapeutic strategy in glioblastoma: survival benefit and indication of BNCT. Appl Radiat Isot; 2009 Jul;67(7-8 Suppl):S12-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In PBT, the surrounding volume of 2 cm from main tumor mass and the volume of perifocal edema were irradiated at dose of 75.6 and 60 Gy, respectively.
  • On the other hand, in the patients who underwent CRT and ACNU-based chemotherapy, OS and 2-year survival rate were 14.2M and 17.9%, respectively.
  • Randomized trials of comparably selected patients are required to demonstrate conclusively that prolonged survival is a result of this tumor-selective radiotherapy.
  • [MeSH-major] Boron Neutron Capture Therapy / methods. Brain Neoplasms / radiotherapy. Glioblastoma / radiotherapy
  • [MeSH-minor] Adult. Combined Modality Therapy. Humans. Photons / therapeutic use. Prognosis. Protons / therapeutic use. Survival Rate

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19375923.001).
  • [ISSN] 1872-9800
  • [Journal-full-title] Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine
  • [ISO-abbreviation] Appl Radiat Isot
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Protons
  •  go-up   go-down


5. Toms SA, Lin WC, Weil RJ, Johnson MD, Jansen ED, Mahadevan-Jansen A: Intraoperative optical spectroscopy identifies infiltrating glioma margins with high sensitivity. Neurosurgery; 2005 Oct;57(4 Suppl):382-91; discussion 382-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Adult gliomas have indistinct borders.
  • We describe a device designed to augment intraoperative identification of both solid tumor and infiltrating tumor margins.
  • Samples were classified as solid tumor, infiltrating tumor, or normal gray or white matter.
  • A sensitivity of 80% and a specificity of 89% in discriminating solid tumor from normal tissues were obtained.
  • In addition, infiltrating tumor margins were distinguished from normal tissues with a sensitivity of 94% and a specificity of 93%.
  • [MeSH-major] Brain Neoplasms / surgery. Glioma / surgery. Intraoperative Period / methods. Neurosurgery / methods. Spectrum Analysis / methods
  • [MeSH-minor] Adult. Algorithms. Epilepsy, Temporal Lobe. Humans. Image Processing, Computer-Assisted / methods. Sensitivity and Specificity. Severity of Illness Index

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ReprintIn] Neurosurgery. 2007 Jul;61(1 Suppl):327-35; discussion 335-6 [18813157.001]
  • (PMID = 16234690.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA085989-01A1
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


6. Oshiro S, Tsugu H, Komatsu F, Abe H, Onishi H, Ohmura T, Iwaasa M, Sakamoto S, Fukushima T: Quantitative assessment of gliomas by proton magnetic resonance spectroscopy. Anticancer Res; 2007 Nov-Dec;27(6A):3757-63
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Increased ratios of choline (Cho) to N-acetylaspartate (NAA) (Cho/NAA) and Cho to creatine (Cr) (Cho/Cr) correlated highly with tumor malignancy.
  • [MeSH-major] Brain Neoplasms / diagnosis. Glioma / diagnosis. Magnetic Resonance Spectroscopy
  • [MeSH-minor] Adult. Aged. Diffusion Magnetic Resonance Imaging. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Protons

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17970039.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Protons
  •  go-up   go-down


7. Rhee W, Ray S, Yokoo H, Hoane ME, Lee CC, Mikheev AM, Horner PJ, Rostomily RC: Quantitative analysis of mitotic Olig2 cells in adult human brain and gliomas: implications for glioma histogenesis and biology. Glia; 2009 Apr 1;57(5):510-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quantitative analysis of mitotic Olig2 cells in adult human brain and gliomas: implications for glioma histogenesis and biology.
  • The capacity of adult human glial progenitor cells (AGPs), to proliferate and undergo multipotent differentiation, positions them as ideal candidate cells of origin for human gliomas.
  • To investigate this potential role we identified AGPs as mitotically active Olig2 cells in nonneoplastic adult human brain and gliomas.
  • Extrapolating from a mean Olig2/Mib-1 labeling index (LI) of 52% and total cell number of 100 billion, we estimated the overall prevalence of mitotic Olig2 AGPs in nonneoplastic human brain parenchyma at 10 million.
  • The novel framework provided by this quantitative and comparative analysis supports future studies to examine the histogenetic role of Olig2 AGPs in adult gliomas, their potential contribution to the tumor stroma and the molecular role of Olig2 in glioma pathogenesis.

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18837053.001).
  • [ISSN] 1098-1136
  • [Journal-full-title] Glia
  • [ISO-abbreviation] Glia
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / T32 NS007144; United States / NINDS NIH HHS / NS / T32 NS007144-25; United States / NINDS NIH HHS / NS / T32 NS007144-28; United States / NINDS NIH HHS / NS / T32 NS 0007144
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Antinuclear; 0 / Antibodies, Monoclonal; 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / MIB-1 antibody; 0 / Nerve Growth Factors; 0 / Nerve Tissue Proteins; 0 / OLIG2 protein, human; 0 / S100 Calcium Binding Protein beta Subunit; 0 / S100 Proteins; 0 / S100B protein, human
  • [Other-IDs] NLM/ NIHMS77469; NLM/ PMC4415884
  •  go-up   go-down


8. Cao Y, Tsien CI, Nagesh V, Junck L, Ten Haken R, Ross BD, Chenevert TL, Lawrence TS: Survival prediction in high-grade gliomas by MRI perfusion before and during early stage of RT [corrected]. Int J Radiat Oncol Biol Phys; 2006 Mar 01;64(3):876-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumor perfusion was classified as high, medium, or low.
  • The prognostic values of pre-RT perfusion and the changes during RT for early prediction of tumor response to RT were evaluated.
  • RESULTS: The fractional high-CBV tumor volume before RT and the fluid-attenuated inversion recovery imaging tumor volume were identified as predictors for survival (p = 0.01).
  • Changes in tumor CBV during the early treatment course also predicted for survival.
  • Better survival was predicted by a decrease in the fractional low-CBV tumor volume at Week 1 of RT vs. before RT, a decrease in the fractional high-CBV tumor volume at Week 3 vs. Week 1 of RT, and a smaller pre-RT fluid-attenuated inversion recovery imaging tumor volume (p = 0.01).
  • This might also open the opportunity to identify tumor subvolumes that are radioresistant and might benefit from intensified RT.
  • [MeSH-major] Astrocytoma / blood supply. Astrocytoma / radiotherapy. Brain Neoplasms / blood supply. Brain Neoplasms / radiotherapy. Cerebrovascular Circulation. Magnetic Resonance Imaging / methods
  • [MeSH-minor] Adult. Aged. Anti-Inflammatory Agents / pharmacology. Blood Volume. Brain / blood supply. Brain / radiation effects. Dexamethasone / pharmacology. Female. Glioblastoma / blood supply. Glioblastoma / mortality. Glioblastoma / radiotherapy. Humans. Male. Middle Aged. Prognosis. Regression Analysis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Int J Radiat Oncol Biol Phys. 2006 Jul 1;65(3):960
  • (PMID = 16298499.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R21 CA113699; United States / NCI NIH HHS / CA / R21 CA11369901; United States / NCI NIH HHS / CA / P01 CA85878; United States / NCI NIH HHS / CA / 2 PO1 CA59827
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 7S5I7G3JQL / Dexamethasone
  •  go-up   go-down


9. Scharenberg MA, Chiquet-Ehrismann R, Asparuhova MB: Megakaryoblastic leukemia protein-1 (MKL1): Increasing evidence for an involvement in cancer progression and metastasis. Int J Biochem Cell Biol; 2010 Dec;42(12):1911-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MKL1 regulates many processes, including muscle cell differentiation, cardiovascular development, remodeling of neuronal networks in the developing and adult brain, megakaryocytic differentiation and migration, modulation of cellular motile functions and epithelial-mesenchymal transition.
  • In addition, we discuss recent evidence that strongly suggests a dual role for MKL1 in oncogenic mechanisms, as a tumor-promoting or tumor-suppressing molecule.
  • [MeSH-major] DNA-Binding Proteins / physiology. Neoplasms / pathology. Oncogene Proteins, Fusion / physiology. Trans-Activators / physiology
  • [MeSH-minor] Animals. Disease Progression. Humans. Neoplasm Metastasis

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20816842.001).
  • [ISSN] 1878-5875
  • [Journal-full-title] The international journal of biochemistry & cell biology
  • [ISO-abbreviation] Int. J. Biochem. Cell Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / MKL1 protein, human; 0 / MKL1 protein, mouse; 0 / Oncogene Proteins, Fusion; 0 / Trans-Activators
  •  go-up   go-down


10. Toktas ZO, Akgun E, Ozkan A, Bozkurt SU, Bekiroglu N, Seker A, Konya D, Kilic T: Relationship of angiogenic potential with clinical features in cranial meningiomas: a corneal angiogenesis study. Neurosurgery; 2010 Dec;67(6):1724-32; discussion 1732
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Intracranial meningiomas constitute approximately one fourth of all primary intracranial tumors.
  • OBJECTIVE: To test the relationship between the angiogenetic potential of intracranial meningiomas and clinical/prognostic features such as World Health Organization (WHO) grade, peritumoral edema, tumor border shape, and recurrence using rat corneal angiogenesis assay.
  • Normal brain and glioblastoma multiforme tissues served as negative and positive controls, respectively.
  • RESULTS: The angiogenic potential of WHO grade II tumors was significantly lower than that of grade III tumors and higher than that of grade I tumors throughout the experiment.
  • Tumors with a smooth border shape and nonrecurrent tumors exhibited significantly lower angiogenic activity compared with the tumors with irregular border shape and recurrent tumors, respectively.
  • CONCLUSION: Our findings, based on a dynamic in vivo model to examine angiogenesis, demonstrate that the angiogenic potential of meningiomas is correlated with WHO grade, recurrence, and possibly with tumor border shape and peritumoral edema.
  • [MeSH-major] Corneal Neovascularization / etiology. Corneal Neovascularization / pathology. Meningeal Neoplasms / complications. Meningioma / complications
  • [MeSH-minor] Adult. Animals. Brain Edema / etiology. Disease Models, Animal. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Recurrence, Local. Rats. Rats, Sprague-Dawley. Retrospective Studies. Time Factors. Tissue Transplantation / methods. World Health Organization

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21107204.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


11. Loghin ME, Prados MD, Wen P, Junck L, Lieberman F, Fine H, Fink KL, Metha M, Kuhn J, Lamborn K, Chang SM, Cloughesy T, DeAngelis LM, Robins IH, Aldape KD, Yung WK: Phase I study of temozolomide and irinotecan for recurrent malignant gliomas in patients receiving enzyme-inducing antiepileptic drugs: a north american brain tumor consortium study. Clin Cancer Res; 2007 Dec 1;13(23):7133-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I study of temozolomide and irinotecan for recurrent malignant gliomas in patients receiving enzyme-inducing antiepileptic drugs: a north american brain tumor consortium study.
  • Thirty-one patients were evaluable for both tumor response and toxicity and two patients were evaluable for toxicity only.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18056194.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA062426; United States / NCI NIH HHS / CA / U01 CA062399; United States / NCI NIH HHS / CA / UM1 CA137443; United States / NCI NIH HHS / CA / U01CA62412; United States / NCI NIH HHS / CA / U01CA62426; United States / NCI NIH HHS / CA / U01 CA062412; United States / NCI NIH HHS / CA / U01CA62399
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticonvulsants; 7673326042 / irinotecan; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; XT3Z54Z28A / Camptothecin
  • [Other-IDs] NLM/ NIHMS761232; NLM/ PMC4802002
  •  go-up   go-down


12. Holodny AI, Gor DM, Watts R, Gutin PH, Ulug AM: Diffusion-tensor MR tractography of somatotopic organization of corticospinal tracts in the internal capsule: initial anatomic results in contradistinction to prior reports. Radiology; 2005 Mar;234(3):649-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Eight volunteers and two patients with brain tumor were imaged at 3 T.
  • [MeSH-major] Brain / anatomy & histology. Diffusion Magnetic Resonance Imaging / methods. Pyramidal Tracts / anatomy & histology
  • [MeSH-minor] Adult. Brain Neoplasms / pathology. Female. Humans. Image Processing, Computer-Assisted. Male

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15665224.001).
  • [ISSN] 0033-8419
  • [Journal-full-title] Radiology
  • [ISO-abbreviation] Radiology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Maesawa S, Fujii M, Nakahara N, Watanabe T, Wakabayashi T, Yoshida J: Intraoperative tractography and motor evoked potential (MEP) monitoring in surgery for gliomas around the corticospinal tract. World Neurosurg; 2010 Jul;74(1):153-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Tumor removal was performed in 28 patients with gliomas in and around the corticospinal tract (CST), in an operation theater equipped with an integrated high-field intraoperative magnetic resonance imaging and a neuronavigation system.
  • The results of the linear regression between distance and stimulation intensity were informative for guiding approaches to tumor remnants without impinging on the CST.
  • [MeSH-major] Brain Neoplasms / surgery. Cerebral Cortex / surgery. Diffusion Magnetic Resonance Imaging / methods. Evoked Potentials, Motor / physiology. Glioblastoma / surgery. Glioma / surgery. Image Processing, Computer-Assisted / methods. Monitoring, Intraoperative / methods. Neuronavigation. Pyramidal Tracts / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Cerebral Infarction / etiology. Cerebral Infarction / physiopathology. Craniotomy. Evoked Potentials, Somatosensory / physiology. Female. Humans. Male. Microsurgery. Middle Aged. Paresis / etiology. Paresis / physiopathology. Postoperative Complications / etiology. Postoperative Complications / physiopathology. Sensitivity and Specificity. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • [CommentIn] World Neurosurg. 2010 Jul;74(1):105-6 [21299993.001]
  • [CommentIn] World Neurosurg. 2010 Jul;74(1):107-8 [21299994.001]
  • (PMID = 21300007.001).
  • [ISSN] 1878-8769
  • [Journal-full-title] World neurosurgery
  • [ISO-abbreviation] World Neurosurg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Yan J, Chen C, Hu Q, Yang X, Lei J, Yang L, Wang K, Qin L, Huang H, Zhou C: The role of p53 in brain edema after 24 h of experimental subarachnoid hemorrhage in a rat model. Exp Neurol; 2008 Nov;214(1):37-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of p53 in brain edema after 24 h of experimental subarachnoid hemorrhage in a rat model.
  • We now hypothesize that p53 also plays an important role in brain edema by up-regulating the expression of MMP-9 via the NF-kappaB molecular signaling pathway.
  • Adult male rats (300-350 g) were divided into five groups (n=20 each): Sham, SAH treatment with DMSO or PFT-alpha (0.2 mg/kg and 2.0 mg/kg), intraperitoneally.
  • The blood-brain barrier (BBB) disruption, brain water content, MMP-9 activity, immunohistochemistry, treble fluorescence labeling, Western blot, and ultra-structural observations were performed.
  • Evans blue extravagation, BBB diffuse leakage of IgG protein and brain water content were significantly reduced by PFT-alpha treatment; and the expression of p53, NF-kappaB and MMP-9 were significantly increased.
  • The tight junction protein (Occludin) in endothelia cells and Collage IV in basal lamina were decreased in the brain of SAH rats, and were also modified by PFT-alpha treatment.
  • We thus conclude that the level of p53 in cerebral microvasculature significantly affects the BBB permeability and brain edema after 24 h of SAH in rats.
  • [MeSH-major] Blood-Brain Barrier / metabolism. Brain Edema / metabolism. Subarachnoid Hemorrhage / metabolism. Tumor Suppressor Protein p53 / metabolism
  • [MeSH-minor] Analysis of Variance. Animals. Blotting, Western. Brain / metabolism. Brain / pathology. Cerebrovascular Circulation / physiology. Endothelial Cells / metabolism. Immunohistochemistry. Male. Matrix Metalloproteinase 9 / metabolism. Membrane Proteins / metabolism. Microvessels / metabolism. Microvessels / pathology. Occludin. Rats. Rats, Sprague-Dawley. Signal Transduction / physiology. Up-Regulation / physiology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18691572.001).
  • [ISSN] 1090-2430
  • [Journal-full-title] Experimental neurology
  • [ISO-abbreviation] Exp. Neurol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Membrane Proteins; 0 / Occludin; 0 / Ocln protein, rat; 0 / Tumor Suppressor Protein p53; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


15. Bradford D, Cole SJ, Cooper HM: Netrin-1: diversity in development. Int J Biochem Cell Biol; 2009 Mar;41(3):487-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Netrin-1 also plays a role in the adult brain, suggesting that manipulating netrin signals may have novel therapeutic applications.
  • [MeSH-major] Morphogenesis / physiology. Nerve Growth Factors / metabolism. Neurons / physiology. Spinal Cord / embryology. Stem Cells / physiology. Tumor Suppressor Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18455953.001).
  • [ISSN] 1878-5875
  • [Journal-full-title] The international journal of biochemistry & cell biology
  • [ISO-abbreviation] Int. J. Biochem. Cell Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Caenorhabditis elegans Proteins; 0 / Nerve Growth Factors; 0 / Nerve Tissue Proteins; 0 / Receptors, Cell Surface; 0 / Tumor Suppressor Proteins; 0 / UNC-6 protein, C elegans; 149592-60-9 / UNC-5 protein, C elegans; 158651-98-0 / netrin-1
  • [Number-of-references] 24
  •  go-up   go-down


16. Hegedüs B, Marga F, Jakab K, Sharpe-Timms KL, Forgacs G: The interplay of cell-cell and cell-matrix interactions in the invasive properties of brain tumors. Biophys J; 2006 Oct 1;91(7):2708-16
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The interplay of cell-cell and cell-matrix interactions in the invasive properties of brain tumors.
  • We studied the in vitro invasion patterns of nine brain tumor cell lines in three-dimensional collagen gels.
  • [MeSH-major] Brain Neoplasms / pathology. Cell Adhesion / physiology. Extracellular Matrix / physiology
  • [MeSH-minor] Adult. Aged. Animals. Astrocytes / physiology. Astrocytes / ultrastructure. Cadherins / metabolism. Cell Line, Tumor. Child, Preschool. Collagen Type I / metabolism. Female. Humans. Infant. Male. Matrix Metalloproteinases / metabolism. Microscopy, Electron, Scanning. Middle Aged. Neoplasm Invasiveness. Rats. Tissue Inhibitor of Metalloproteinase-1 / metabolism

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2004 Feb 1;64(3):920-7 [14871821.001]
  • [Cites] Science. 1963 Aug 2;141(3579):401-8 [13983728.001]
  • [Cites] J Neurooncol. 2004 Mar-Apr;67(1-2):147-57 [15072462.001]
  • [Cites] J Neurooncol. 2004 May;67(3):295-303 [15164985.001]
  • [Cites] Int J Dev Biol. 2004;48(5-6):463-76 [15349821.001]
  • [Cites] Nature. 1978 Jun 1;273(5661):345-9 [661946.001]
  • [Cites] Br J Cancer. 1995 Sep;72(3):627-33 [7669572.001]
  • [Cites] J Neurooncol. 2004 Oct;70(1):3-15 [15527101.001]
  • [Cites] Matrix Biol. 2004 Oct;23(6):333-40 [15533754.001]
  • [Cites] Dev Biol. 2005 Feb 1;278(1):255-63 [15649477.001]
  • [Cites] Nat Cell Biol. 2005 Feb;7(2):157-64 [15654332.001]
  • [Cites] Int J Cancer. 2005 Apr 10;114(3):371-9 [15551307.001]
  • [Cites] Biophys J. 2005 Jul;89(1):635-50 [15849239.001]
  • [Cites] Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3280-7 [16740748.001]
  • [Cites] Development. 1996 May;122(5):1611-20 [8625847.001]
  • [Cites] Invasion Metastasis. 1995;15(5-6):179-88 [8765192.001]
  • [Cites] Nature. 1997 Feb 6;385(6616):537-40 [9020360.001]
  • [Cites] Int J Dev Neurosci. 1999 Aug-Oct;17(5-6):643-51 [10571424.001]
  • [Cites] J Cell Biol. 2000 Feb 7;148(3):399-404 [10662767.001]
  • [Cites] J Neurosurg. 2000 Mar;92(3):428-34 [10701529.001]
  • [Cites] J Neurochem. 2000 Apr;74(4):1489-97 [10737605.001]
  • [Cites] Neurosurg Rev. 2000 Mar;23(1):39-44 [10809486.001]
  • [Cites] Cancer Res. 2000 Jul 1;60(13):3650-4 [10910081.001]
  • [Cites] Philos Trans R Soc Lond B Biol Sci. 2000 Jul 29;355(1399):885-90 [11128982.001]
  • [Cites] J Cell Sci. 2001 Apr;114(Pt 8):1567-77 [11282032.001]
  • [Cites] Cancer Res. 2001 May 15;61(10):4190-6 [11358844.001]
  • [Cites] Biochim Biophys Acta. 2001 Nov 30;1552(1):39-45 [11781114.001]
  • [Cites] Nat Rev Cancer. 2001 Oct;1(1):46-54 [11900251.001]
  • [Cites] J Biomech Eng. 2002 Apr;124(2):214-22 [12002131.001]
  • [Cites] J Cell Biol. 2002 Jun 10;157(6):1083-91 [12058022.001]
  • [Cites] J Neurooncol. 2002 May;57(3):187-92 [12125981.001]
  • [Cites] J Neurochem. 2002 Oct;83(2):259-70 [12423237.001]
  • [Cites] Mol Cell Biol. 2003 Jan;23(2):566-78 [12509455.001]
  • [Cites] Gynecol Oncol. 2003 Apr;89(1):60-72 [12694655.001]
  • [Cites] Circ Res. 2003 May 2;92(8):827-39 [12730128.001]
  • [Cites] Endocr Rev. 2003 Aug;24(4):428-65 [12920150.001]
  • [Cites] Exp Cell Res. 2003 Sep 10;289(1):58-66 [12941604.001]
  • [Cites] Mol Cell Biochem. 2003 Nov;253(1-2):269-85 [14619979.001]
  • [Cites] J Neurosci Res. 2003 Dec 15;74(6):801-6 [14648584.001]
  • [Cites] Cell Adhes Commun. 1997 Mar;4(6):399-411 [9177902.001]
  • [Cites] Virchows Arch. 1998 Feb;432(2):163-7 [9504862.001]
  • [Cites] J Cell Sci. 1999 Oct;112 ( Pt 19):3249-58 [10504330.001]
  • [Cites] Lab Invest. 2004 Apr;84(4):397-405 [14990981.001]
  • (PMID = 16829558.001).
  • [ISSN] 0006-3495
  • [Journal-full-title] Biophysical journal
  • [ISO-abbreviation] Biophys. J.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cadherins; 0 / Collagen Type I; 0 / Tissue Inhibitor of Metalloproteinase-1; EC 3.4.24.- / Matrix Metalloproteinases
  • [Other-IDs] NLM/ PMC1562379
  •  go-up   go-down


17. Haapasalo JA, Nordfors KM, Hilvo M, Rantala IJ, Soini Y, Parkkila AK, Pastoreková S, Pastorek J, Parkkila SM, Haapasalo HK: Expression of carbonic anhydrase IX in astrocytic tumors predicts poor prognosis. Clin Cancer Res; 2006 Jan 15;12(2):473-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of carbonic anhydrase IX in astrocytic tumors predicts poor prognosis.
  • Ectopic CA IX expression has been observed in several tumors, whose normal counterparts do not express this enzyme.
  • Normal human brain tissue shows only slight or no expression of CA IX.
  • RESULTS: CA IX immunopositivity was observed in 284 cases of 362 (78%) tumors.
  • The CA IX immunoreactivity showed strong association with tumor malignancy grades (P < 0.0001).
  • Our results suggest that CA IX is a useful biomarker for predicting poor prognosis of astrocytic tumors.
  • [MeSH-major] Antigens, Neoplasm / metabolism. Astrocytoma / enzymology. Biomarkers, Tumor / metabolism. Brain Neoplasms / enzymology. Carbonic Anhydrases / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Apoptosis. Cell Proliferation. Female. Gene Expression Regulation, Neoplastic. Humans. Immunoenzyme Techniques. Male. Middle Aged. Neoplasm Recurrence, Local / enzymology. Neoplasm Recurrence, Local / genetics. Neoplasm Recurrence, Local / pathology. Prognosis. RNA, Messenger / genetics. RNA, Messenger / metabolism. Receptor, Epidermal Growth Factor / metabolism. Survival Rate. Tumor Suppressor Protein p53 / metabolism

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16428489.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 0 / Tumor Suppressor Protein p53; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 4.2.1.1 / CA9 protein, human; EC 4.2.1.1 / Carbonic Anhydrases
  •  go-up   go-down


18. Sakurada K, Akasaka M, Kuchiki H, Saino M, Mori W, Sato S, Nakazato Y, Kayama T: A rare case of extraventricular neurocytoma. Brain Tumor Pathol; 2007;24(1):19-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Eighteen years later (in 1996), recurrence of tumor in the fourth ventricle was noted and was treated with gamma-knife radiotherapy.
  • The tumor shrunk transiently, but 7 years later (in 2004), MRI study demonstrated a second recurrence and ventricular dissemination.
  • Partial removal was performed, and histological examination revealed that tumor cells had round or oval nuclei with halos.
  • Despite postoperative whole-brain radiotherapy to a total dose of 30 Gy, the tumor progressed, and she died at 4 months after the second surgery.
  • [MeSH-major] Brain Neoplasms / pathology. Diagnostic Errors. Neoplasm Recurrence, Local / pathology. Neuroblastoma / pathology. Neurocytoma / pathology. Oligodendroglioma / pathology
  • [MeSH-minor] Adolescent. Adult. Female. Fourth Ventricle / pathology. Frontal Lobe / pathology. Humans

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18095140.001).
  • [ISSN] 1433-7398
  • [Journal-full-title] Brain tumor pathology
  • [ISO-abbreviation] Brain Tumor Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


19. Agarwal JR, Griesinger F, Stühmer W, Pardo LA: The potassium channel Ether à go-go is a novel prognostic factor with functional relevance in acute myeloid leukemia. Mol Cancer; 2010;9:18
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The physiological expression of the human channel is restricted to the brain but it is frequently and abundantly expressed in many solid tumors, thereby making it a promising target for a specific diagnosis and therapy.
  • Because chronic lymphatic leukemia has been described not to express hEag1, it has been assumed that the channel is not expressed in hematopoietic neoplasms in general.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Aging / pathology. Cell Line, Tumor. Child. Child, Preschool. Female. Gene Expression Regulation, Leukemic. Humans. Infant. Male. Middle Aged. Prognosis. Survival Analysis. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] EMBO J. 2000 Jul 3;19(13):3263-71 [10880439.001]
  • [Cites] Pharmacol Rev. 2000 Dec;52(4):557-94 [11121510.001]
  • [Cites] Pflugers Arch. 2000 Dec;441(2-3):167-74 [11211100.001]
  • [Cites] Receptors Channels. 2001;7(5):345-56 [11697078.001]
  • [Cites] J Biol Chem. 2002 May 24;277(21):18528-34 [11893742.001]
  • [Cites] J Membr Biol. 2002 Jul 15;188(2):137-49 [12172639.001]
  • [Cites] Leukemia. 2002 Sep;16(9):1791-8 [12200695.001]
  • [Cites] Blood. 2002 Oct 15;100(8):2717-23 [12351377.001]
  • [Cites] Nucleic Acids Res. 2001 May 1;29(9):e45 [11328886.001]
  • [Cites] Leukemia. 2003 Jan;17(1):76-82 [12529663.001]
  • [Cites] Blood. 2003 Oct 1;102(7):2387-94 [12816873.001]
  • [Cites] J Gen Physiol. 2004 Oct;124(4):301-17 [15365094.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):6996-7001 [15466192.001]
  • [Cites] J Immunol Methods. 1987 Sep 24;102(2):243-9 [3655375.001]
  • [Cites] Environ Health Perspect. 1990 Aug;88:179-82 [2272312.001]
  • [Cites] Biochem Int. 1991 Feb;23(3):591-602 [1652248.001]
  • [Cites] Cancer Res. 1998 Feb 15;58(4):815-22 [9485040.001]
  • [Cites] J Physiol. 1998 Apr 1;508 ( Pt 1):49-56 [9490815.001]
  • [Cites] Leuk Res. 1998 Jun;22(6):537-47 [9678720.001]
  • [Cites] J Physiol. 1998 Oct 15;512 ( Pt 2):317-23 [9763622.001]
  • [Cites] J Cell Biol. 1998 Nov 2;143(3):767-75 [9813096.001]
  • [Cites] EMBO J. 1999 Oct 15;18(20):5540-7 [10523298.001]
  • [Cites] Clin Cancer Res. 2005 Feb 15;11(4):1416-24 [15746041.001]
  • [Cites] Nature. 2006 Mar 23;440(7083):463-9 [16554806.001]
  • [Cites] J Biol Chem. 2006 May 12;281(19):13030-7 [16537547.001]
  • [Cites] FEBS Lett. 2006 May 22;580(12):2850-2 [16783874.001]
  • [Cites] Mol Cancer. 2006;5:42 [17022811.001]
  • [Cites] Mol Cancer. 2006;5:41 [17022810.001]
  • [Cites] Cancer Res. 2007 Aug 1;67(15):7343-9 [17671204.001]
  • [Cites] Blood. 2007 Aug 15;110(4):1238-50 [17420287.001]
  • [Cites] Cancer Res. 2008 Mar 15;68(6):1611-3 [18339837.001]
  • [Cites] Blood. 2008 Jun 1;111(11):5371-9 [18378853.001]
  • [Cites] Neuroscience. 2008 Aug 26;155(3):833-44 [18650019.001]
  • [Cites] Int J Hematol. 2008 May;87(4):387-92 [18415658.001]
  • [Cites] J Biol Chem. 2008 Dec 26;283(52):36234-40 [18927085.001]
  • [Cites] Nat Rev Drug Discov. 2009 Dec;8(12):982-1001 [19949402.001]
  • (PMID = 20105281.001).
  • [ISSN] 1476-4598
  • [Journal-full-title] Molecular cancer
  • [ISO-abbreviation] Mol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / ERG1 potassium channel; 0 / Ether-A-Go-Go Potassium Channels
  • [Other-IDs] NLM/ PMC2835655
  •  go-up   go-down


20. Gabbay V, Coffey BJ, Guttman LE, Gottlieb L, Katz Y, Babb JS, Hamamoto MM, Gonzalez CJ: A cytokine study in children and adolescents with Tourette's disorder. Prog Neuropsychopharmacol Biol Psychiatry; 2009 Aug 31;33(6):967-71
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We hypothesized that children with TD would have increased levels of tumor necrosis factor (TNF)-alpha, interleukin (IL)-12, IL-1 beta and IL-6, and decreased IL-2.
  • There were no other significant cytokine differences between groups.

  • MedlinePlus Health Information. consumer health - Tourette Syndrome.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Annu Rev Immunol. 1992;10:411-52 [1590993.001]
  • [Cites] J Am Acad Child Adolesc Psychiatry. 2008 Oct;47(10):1166-72 [18724258.001]
  • [Cites] J Am Acad Child Adolesc Psychiatry. 1997 Jun;36(6):844-52 [9183141.001]
  • [Cites] J Am Acad Child Adolesc Psychiatry. 1997 Jul;36(7):980-8 [9204677.001]
  • [Cites] Biol Psychiatry. 1997 Dec 1;42(11):976-81 [9386848.001]
  • [Cites] Am J Psychiatry. 1998 Feb;155(2):264-71 [9464208.001]
  • [Cites] J Nerv Ment Dis. 1998 Apr;186(4):201-6 [9569887.001]
  • [Cites] Am J Psychiatry. 2000 Feb;157(2):281-3 [10671403.001]
  • [Cites] Am J Psychiatry. 2000 May;157(5):683-94 [10784457.001]
  • [Cites] Neuropsychopharmacology. 2000 Jun;22(6):566-80 [10788757.001]
  • [Cites] Arch Pediatr Adolesc Med. 2002 Apr;156(4):356-61 [11929370.001]
  • [Cites] Brain Behav Immun. 2002 Oct;16(5):525-32 [12401466.001]
  • [Cites] Immunity. 2003 Nov;19(5):641-4 [14614851.001]
  • [Cites] Mov Disord. 2003 Dec;18(12):1530-3 [14673893.001]
  • [Cites] Am J Med Genet B Neuropsychiatr Genet. 2004 Jan 1;124B(1):76-80 [14681920.001]
  • [Cites] Pediatrics. 2004 Jun;113(6):e578-85 [15173540.001]
  • [Cites] Psychoneuroendocrinology. 2004 Aug;29(7):945-52 [15177711.001]
  • [Cites] Am J Med Genet B Neuropsychiatr Genet. 2004 Aug 15;129B(1):64-8 [15274043.001]
  • [Cites] J Am Acad Child Adolesc Psychiatry. 1989 Jul;28(4):566-73 [2768151.001]
  • [Cites] Neuropharmacology. 1990 Feb;29(2):167-79 [1691831.001]
  • [Cites] Neuropsychobiology. 1998;37(4):182-5 [9648125.001]
  • [Cites] J Clin Invest. 1998 Aug 15;102(4):671-8 [9710434.001]
  • [Cites] Neurochem Int. 1998 Sep;33(3):251-4 [9759920.001]
  • [Cites] Nat Med. 1999 Feb;5(2):170-5 [9930864.001]
  • [Cites] Mol Psychiatry. 2005 Mar;10(3):258-75 [15611786.001]
  • [Cites] Biol Psychiatry. 2005 Mar 15;57(6):667-73 [15780855.001]
  • [Cites] J Immunol. 2005 Jul 15;175(2):641-5 [16002658.001]
  • [Cites] Mol Psychiatry. 2006 Jul;11(7):622-32 [16585942.001]
  • [Cites] Biol Psychiatry. 2007 Feb 1;61(3):273-8 [16996487.001]
  • [Cites] Mediators Inflamm. 2007;2007:65704 [17497035.001]
  • [Cites] Annu Rev Immunol. 2008;26:453-79 [18062768.001]
  • [Cites] Pediatrics. 2008 Jun;121(6):1198-205 [18519490.001]
  • [Cites] J Affect Disord. 2009 May;115(1-2):177-82 [18790541.001]
  • [Cites] Biol Psychiatry. 1996 Nov 1;40(9):908-12 [8896778.001]
  • (PMID = 19427348.001).
  • [ISSN] 1878-4216
  • [Journal-full-title] Progress in neuro-psychopharmacology & biological psychiatry
  • [ISO-abbreviation] Prog. Neuropsychopharmacol. Biol. Psychiatry
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / M01 RR000096-467639; United States / NCCIH NIH HHS / AT / R21 AT002395-02; United States / NCRR NIH HHS / RR / M01 RR000096; United States / NCRR NIH HHS / RR / RR000096-431025; United States / NIMH NIH HHS / MH / K23 MH077072-02; United States / NCRR NIH HHS / RR / M01 RR000096-431025; United States / NCRR NIH HHS / RR / M01 RR000096-467620; United States / NIMH NIH HHS / MH / MH077072-01A1; United States / NCRR NIH HHS / RR / RR000096-441025; United States / NCRR NIH HHS / RR / M01 RR000096-458315; United States / NCRR NIH HHS / RR / RR000096-458289; United States / NCCIH NIH HHS / AT / R21 AT002395-03; United States / NCRR NIH HHS / RR / M01-RR00096; United States / NCRR NIH HHS / RR / RR000096-467639; United States / NCRR NIH HHS / RR / RR000096-458315; United States / NCRR NIH HHS / RR / M01 RR000096-478526; United States / NIMH NIH HHS / MH / MH077072-02; United States / NCCIH NIH HHS / AT / AT002395; United States / NCRR NIH HHS / RR / RR000096-446253; United States / NCCIH NIH HHS / AT / AT002395-03; United States / NIMH NIH HHS / MH / MH077072-03; United States / NIMH NIH HHS / MH / K23 MH077072-01A1; United States / NCCIH NIH HHS / AT / AT002395-01A2; United States / NCRR NIH HHS / RR / M01 RR000096-441025; United States / NIMH NIH HHS / MH / MH077072; United States / NCCIH NIH HHS / AT / AT002395-02; United States / NCRR NIH HHS / RR / RR000096-478526; United States / NCCIH NIH HHS / AT / R21 AT002395-01A2; United States / NIMH NIH HHS / MH / K23 MH077072; United States / NCRR NIH HHS / RR / M01 RR000096-446253; United States / NCCIH NIH HHS / AT / R21 AT002395; United States / NIMH NIH HHS / MH / K23 MH077072-03; United States / NCRR NIH HHS / RR / M01 RR000096-458289; United States / NCRR NIH HHS / RR / RR000096-467620
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Interleukin-2; 187348-17-0 / Interleukin-12
  • [Other-IDs] NLM/ NIHMS150276; NLM/ PMC2770728
  •  go-up   go-down


21. Terauchi M, Kubota T, Aso T, Maehara T: Dysembryoplastic neuroepithelial tumor in pregnancy. Obstet Gynecol; 2006 Sep;108(3 Pt 2):730-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dysembryoplastic neuroepithelial tumor in pregnancy.
  • BACKGROUND: Dysembryoplastic neuroepithelial tumor is a rare, low-grade brain tumor that is characterized by intractable, partial seizures of juvenile onset.
  • Magnetic resonance imaging evaluation showed a 3-cm multicystic nodule in her right temporal lobe that was diagnosed, together with her history of recurrent anxiety attacks, as dysembryoplastic neuroepithelial tumor.
  • The tumor was successfully removed 2 months postpartum, and the patient has experienced no further seizures.
  • CONCLUSION: Dysembryoplastic neuroepithelial tumor was conservatively managed during pregnancy without neurosurgical intervention.
  • [MeSH-major] Brain Neoplasms / diagnosis. Neoplasms, Neuroepithelial / diagnosis. Pregnancy Complications, Neoplastic / diagnosis. Pregnancy, Multiple. Temporal Lobe. Twins
  • [MeSH-minor] Adult. Anxiety. Female. Humans. Magnetic Resonance Imaging. Male. Pregnancy. Pregnancy Outcome. Seizures


22. Sathornsumetee S, Reardon DA: Targeting multiple kinases in glioblastoma multiforme. Expert Opin Investig Drugs; 2009 Mar;18(3):277-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Glioblastoma multiforme (GBM), the most common primary malignant brain tumor in adults, is associated with high mortality.

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19243279.001).
  • [ISSN] 1744-7658
  • [Journal-full-title] Expert opinion on investigational drugs
  • [ISO-abbreviation] Expert Opin Investig Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Protein Kinase Inhibitors
  • [Number-of-references] 137
  •  go-up   go-down


23. Aydin O, Altaş M, Kahraman M, Bayrak OF, Culha M: Differentiation of healthy brain tissue and tumors using surface-enhanced Raman scattering. Appl Spectrosc; 2009 Oct;63(10):1095-100
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differentiation of healthy brain tissue and tumors using surface-enhanced Raman scattering.
  • SERS spectra from healthy brain tissue and tumors are obtained by sudden freezing of tissue in liquid nitrogen and crashing and mixing it with a concentrated silver colloidal suspension.
  • The acquired spectra from tissues show significant spectral differences that can be used to identify whether it is from a healthy region or tumor.
  • The most significant change on SERS spectra from the healthy/peripheral brain tissue to tumor is the increase of the ratio of the peaks at around 723 to 655 cm(-1).
  • In addition, the spectral changes indicate that the protein content in tumors increases compared to the peripheral/healthy tissue as observed with tumor invasion.
  • [MeSH-major] Brain Chemistry. Brain Neoplasms / chemistry. Spectrum Analysis, Raman / methods
  • [MeSH-minor] Adult. Aged. Amino Acids. Female. Histocytochemistry. Humans. Male. Metal Nanoparticles / chemistry. Middle Aged. Neoplasms / chemistry. Silver / chemistry. Surface Properties

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. SILVER, ELEMENTAL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19843358.001).
  • [ISSN] 1943-3530
  • [Journal-full-title] Applied spectroscopy
  • [ISO-abbreviation] Appl Spectrosc
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Amino Acids; 3M4G523W1G / Silver
  •  go-up   go-down


24. Korshunov A, Cherekaev V, Bekyashev A, Sycheva R: Recurrent cytogenetic aberrations in histologically benign, invasive meningiomas of the sphenoid region. J Neurooncol; 2007 Jan;81(2):131-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mean number of aberrations detected per tumor was significantly greater for invasive meningiomas-67.4 compared with 40.5 for non-invasive MSR.
  • [MeSH-major] Chromosome Aberrations. Meningeal Neoplasms / genetics. Meningioma / genetics. Neoplasm Recurrence, Local / genetics. Sphenoid Bone / pathology
  • [MeSH-minor] Adult. Aged. Female. Humans. In Situ Hybridization, Fluorescence. Karyotyping. Male. Middle Aged. Nucleic Acid Hybridization

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Brain Tumor Pathol. 2004;21(1):27-34 [15696966.001]
  • [Cites] Cancer Res. 2005 Apr 1;65(7):2653-61 [15805262.001]
  • [Cites] Surg Neurol. 2005 Jul;64(1):37-43; discussion 43 [15993178.001]
  • [Cites] Brain Tumor Pathol. 2003;20(2):59-63 [14756442.001]
  • [Cites] Clin Cancer Res. 2004 Feb 1;10 (3):869-80 [14871962.001]
  • [Cites] Cancer Genet Cytogenet. 2001 Aug;129(1):88-91 [11520574.001]
  • [Cites] Brain Tumor Pathol. 2004;21(3):127-33 [15696974.001]
  • [Cites] Arch Pathol Lab Med. 2002 Sep;126(9):1079-86 [12204057.001]
  • [Cites] Neurosurgery. 2004 Nov;55(5):1163-73 [15509323.001]
  • [Cites] J Neurooncol. 1999 Jan;41(2):167-74 [10222437.001]
  • [Cites] J Neuropathol Exp Neurol. 2001 Jun;60(6):628-36 [11398839.001]
  • [Cites] J Invest Dermatol. 2004 Feb;122(2):256-65 [15009703.001]
  • [Cites] Brief Funct Genomic Proteomic. 2003 Apr;2(1):37-45 [15239942.001]
  • [Cites] Brain Pathol. 2001 Jul;11(3):296-305 [11414472.001]
  • [Cites] Oncol Rep. 2005 Dec;14(6):1583-8 [16273260.001]
  • [Cites] Cancer Genet Cytogenet. 2005 Oct 1;162(1):63-7 [16157202.001]
  • [Cites] J Neurosurg. 2004 Feb;100(2):303-9 [15098535.001]
  • [Cites] J Neurosurg. 2005 Sep;103(3):491-7 [16235682.001]
  • [Cites] J Neurosurg. 2001 Oct;95(4):601-7 [11596954.001]
  • [Cites] Acta Neuropathol. 2006 May;111(5):465-74 [16557391.001]
  • [Cites] Cancer Genet Cytogenet. 1999 Apr 15;110(2):103-10 [10214357.001]
  • [Cites] Neurosurgery. 1999 Apr;44(4):742-6; discussion 746-7 [10201298.001]
  • [Cites] J Clin Oncol. 2003 Sep 1;21(17):3285-95 [12947064.001]
  • [Cites] Cancer Genet Cytogenet. 2000 Jul 1;120(1):30-6 [10913674.001]
  • [Cites] Am J Clin Pathol. 2001 Feb;115(2):213-8 [11211609.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Dec 23;94(26):14719-24 [9405679.001]
  • [Cites] J Neurooncol. 2004 Nov;70(2):183-202 [15674477.001]
  • [Cites] J Pathol. 2004 Jul;203(3):780-8 [15221937.001]
  • [Cites] Brain Pathol. 2002 Apr;12(2):145-53 [11958368.001]
  • [Cites] Neurol Res. 2005 Oct;27(7):747-54 [16197812.001]
  • [Cites] J Oral Pathol Med. 2006 Mar;35(3):136-9 [16454808.001]
  • [Cites] Neuro Oncol. 2004 Oct;6(4):281-9 [15494095.001]
  • [Cites] J Neuropathol Exp Neurol. 2004 Apr;63(4):275-86 [15099018.001]
  • [Cites] Cancer Res. 2005 Aug 15;65(16):7121-6 [16103061.001]
  • [Cites] Am J Clin Pathol. 2005 May;123(5):744-51 [15981814.001]
  • (PMID = 16850103.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Inoue T, Kumabe T, Kanamori M, Sonoda Y, Watanabe M, Tominaga T: Papillary tumor of the pineal region: a case report. Brain Tumor Pathol; 2008;25(2):85-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Papillary tumor of the pineal region: a case report.
  • We report a case of papillary tumor of the pineal region (PTPR) and describe the morphological, immunohistochemical, and neuroimaging findings.
  • The tumor consisted of columnar and cuboidal cells, with papillary growth pattern.
  • Postoperatively, the patient received radiochemotherapy, and maintenance chemotherapy at our outpatient clinic, and was doing well without tumor recurrence 1 year after the surgery.
  • [MeSH-minor] Adult. Fluorodeoxyglucose F18. Humans. Hydrocephalus / etiology. Hydrocephalus / pathology. Hydrocephalus / radiography. Image Processing, Computer-Assisted. Immunohistochemistry. Ki-67 Antigen. Magnetic Resonance Imaging. Male. Neoplasm Proteins / metabolism. Positron-Emission Tomography. Radiopharmaceuticals. Tomography, X-Ray Computed

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18987834.001).
  • [ISSN] 1433-7398
  • [Journal-full-title] Brain tumor pathology
  • [ISO-abbreviation] Brain Tumor Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Neoplasm Proteins; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


26. Abdelsalam M, El-Husseiny G, Akhtar S, Khafaga Y, Al-Shabana M, AlHusaini H, El Weshi A, Rahal M, Maghfoor I: Improved survival with combined chemo-radiotherapy in primary central nervous system lymphoma. Hematol Oncol Stem Cell Ther; 2010;3(3):128-34
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Primary CNS lymphoma (PCNSL) is an aggressive primary brain tumor.
  • We retrospectively analyzed data on the effect of adding high-dose methotrexate (HDMTX) prior to whole brain irradiation (WBI).
  • Patient characteristics were comparable between two groups except for higher multifocal tumor in the CMT group (92% vs. x22%, p=.029).
  • Univariate regression analysis using one-way analyses of variance (ANOVA) and multivariate Cox regression analysis for prognostic factors including age (<60 vs. >60 years), ECOG PS (0-2 vs. 3-4), extent of surgery (biopsy vs. debulking), solitary vs multifocal tumor and dose of radiation therapy (<50 Gy vs. >50 Gy) failed to identify any prognostic factor.
  • [MeSH-major] Central Nervous System Neoplasms / therapy. Lymphoma / therapy. Methotrexate / therapeutic use. Radiotherapy / methods
  • [MeSH-minor] Adult. Aged. Analysis of Variance. Antimetabolites, Antineoplastic / administration & dosage. Antimetabolites, Antineoplastic / therapeutic use. Combined Modality Therapy. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Humans. Male. Middle Aged. Prognosis. Radiotherapy Dosage. Regression Analysis. Retrospective Studies. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Central Nervous System Lymphoma, Primary.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20890070.001).
  • [ISSN] 1658-3876
  • [Journal-full-title] Hematology/oncology and stem cell therapy
  • [ISO-abbreviation] Hematol Oncol Stem Cell Ther
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Saudi Arabia
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


27. Yamamoto M, Iwaasa M, Nonaka M, Tsugu H, Nabeshima K, Fukushima T: Efficacy and feasibility of procarbazine, ranimustine and vincristine chemotherapy, and the role of surgical resection in anaplastic oligodendroglioma. Anticancer Res; 2005 Nov-Dec;25(6A):3715-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The cycles were repeated every 8 weeks until tumor progression was evident, or for a total of 6 cycles over a 1-year period.
  • However, 3 of the 5 patients showed relapse, with a time to tumor progression (TTP) of 50, 143 and 241 weeks, respectively.
  • Two of these patients received combined treatment with carboplatin, etoposide and recombinant human mutant tumor necrosis factor-alpha at the first relapse.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / drug therapy. Brain Neoplasms / surgery. Oligodendroglioma / drug therapy. Oligodendroglioma / surgery
  • [MeSH-minor] Adult. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Nitrosourea Compounds / administration & dosage. Nitrosourea Compounds / adverse effects. Procarbazine / administration & dosage. Procarbazine / adverse effects. Treatment Outcome. Vincristine / administration & dosage. Vincristine / adverse effects

  • Genetic Alliance. consumer health - Anaplastic Oligodendroglioma.
  • Genetic Alliance. consumer health - Oligodendroglioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16302731.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Nitrosourea Compounds; 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; RYH2T97J77 / ranimustine
  •  go-up   go-down


28. Cherekaev VA, Bekiashev AKh, Filippov IuA, Belov AI, Gol'bin DA: [Experience in using a molecular resonance coagulator in neurooncology]. Zh Vopr Neirokhir Im N N Burdenko; 2005 Jul-Sep;(3):33-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The paper analyzes the experience gained in using a molecular resonance coagulator in 145 patients with tumors of the base of the skull and brain.
  • The Vesalius NEUROsurgery N1 molecular resonance apparatus is an innovational bipolar device that is specially designed for neurosurgical application,(operations on the brain).
  • While working on brain tissues, it is particularly important that there is no thermal injury, tissue charring, or sticking effect due to low working temperatures.
  • The clinical case given in this paper demonstrates the universality of the Vesalius NEUROsurgery N1 molecular resonance apparatus used in an infiltrative tumor of the bases of the skull.
  • One forceps operated in different modes may provide sparing coagulation of minor cortical arteries, reduce the volume of a tumor through its bloodless dissection, arrest bleeding from the hyperostosis (wax sticking effect), prepare nerves in the upper lid slit and cavernous sinus.
  • The Vesalius NEUROsurgery N1 molecular resonance surgical apparatus is recommended for neurosurgical care to perform brain operations requiring great caution in handling the tissues being operated on.
  • [MeSH-major] Brain Neoplasms / surgery. Electrocoagulation / instrumentation. Electrocoagulation / methods. Neurosurgical Procedures / instrumentation. Neurosurgical Procedures / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Equipment Design. Female. Humans. Magnetic Resonance Imaging. Meningioma / pathology. Meningioma / surgery. Middle Aged

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16485825.001).
  • [ISSN] 0042-8817
  • [Journal-full-title] Zhurnal voprosy neĭrokhirurgii imeni N. N. Burdenko
  • [ISO-abbreviation] Zh Vopr Neirokhir Im N N Burdenko
  • [Language] rus
  • [Publication-type] Case Reports; Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


29. Potter N, Karakoula A, Phipps KP, Harkness W, Hayward R, Thompson DN, Jacques TS, Harding B, Thomas DG, Palmer RW, Rees J, Darling J, Warr TJ: Genomic deletions correlate with underexpression of novel candidate genes at six loci in pediatric pilocytic astrocytoma. Neoplasia; 2008 Aug;10(8):757-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To correlate differential gene expression and genomic copy number aberrations (CNAs) in PA, we have used Affymetrix GeneChip HG_U133A to generate gene expression profiles of 19 pediatric patients and the SpectralChip 2600 to investigate CNAs in 11 of these tumors.
  • Hierarchical clustering according to expression profile similarity grouped tumors and controls separately.
  • We identified 1844 genes that showed significant differential expression between tumor and normal controls, with a large number clearly influencing phosphatidylinositol and mitogen-activated protein kinase signaling in PA.
  • However, a small region of loss involving up to seven adjacent clones at 7q11.23 was observed in seven tumors and correlated with the underexpression of BCL7B.
  • Moreover, the down-regulation of FOXG1B at 14q12 correlated with loss within the gene promoter region in most tumors.
  • [MeSH-major] Astrocytoma / genetics. Brain Neoplasms / genetics. Gene Dosage / genetics. Gene Expression Regulation, Neoplastic / genetics. Proteins / genetics. Quantitative Trait Loci / genetics. Sequence Deletion / genetics
  • [MeSH-minor] Adaptor Proteins, Signal Transducing / genetics. Adult. Cell Adhesion Molecules, Neuronal / genetics. Child. Child, Preschool. Chromosome Aberrations. Chromosomes, Human, Pair 10 / genetics. Chromosomes, Human, Pair 12 / genetics. Chromosomes, Human, Pair 17 / genetics. Chromosomes, Human, Pair 7 / genetics. Chromosomes, Human, Pair 9 / genetics. Cluster Analysis. Female. Forkhead Transcription Factors / genetics. Gene Expression Profiling. Humans. Infant. Male. Microfilament Proteins / genetics. Nerve Tissue Proteins / genetics. Oligonucleotide Array Sequence Analysis. Oncogene Proteins / genetics. Receptors, Dopamine D1 / genetics. Reverse Transcriptase Polymerase Chain Reaction. Sequence Analysis, DNA

  • Genetic Alliance. consumer health - Pilocytic astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2005 Mar 15;65(6):2170-8 [15781628.001]
  • [Cites] Clin Cancer Res. 2005 Mar 15;11(6):2258-64 [15788675.001]
  • [Cites] Clin Cancer Res. 2005 Apr 15;11(8):2907-18 [15837741.001]
  • [Cites] Int J Cancer. 2005 Jul 1;115(4):503-10 [15700311.001]
  • [Cites] Am J Hum Genet. 2005 Jul;77(1):78-88 [15918152.001]
  • [Cites] Cancer Res. 2005 Jun 1;65(11):4598-606 [15930277.001]
  • [Cites] Oncogene. 2005 Jun 2;24(24):3896-905 [15750623.001]
  • [Cites] J Clin Oncol. 2005 Jun 10;23(17):3886-96 [15897551.001]
  • [Cites] Nucleic Acids Res. 2005 Jul 1;33(Web Server issue):W762-5 [15980579.001]
  • [Cites] Genes Chromosomes Cancer. 2005 Dec;44(4):392-404 [16110500.001]
  • [Cites] J Neuropathol Exp Neurol. 2005 Oct;64(10):891-901 [16215461.001]
  • [Cites] Mol Psychiatry. 2005 Dec;10(12):1117-25 [16172615.001]
  • [Cites] Cancer Res. 2005 Dec 15;65(24):11419-28 [16357150.001]
  • [Cites] Nat Genet. 2006 Jan;38(1):75-81 [16327808.001]
  • [Cites] J Biol Chem. 2006 Jan 27;281(4):1956-63 [16303762.001]
  • [Cites] Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2006 Apr;23(2):142-6 [16604482.001]
  • [Cites] Acta Neuropathol. 2006 May;111(5):483-8 [16596424.001]
  • [Cites] J Biol Chem. 2006 May 12;281(19):13126-33 [16565071.001]
  • [Cites] Nature. 2000 Feb 3;403(6769):503-11 [10676951.001]
  • [Cites] Cancer Metastasis Rev. 1999;18(2):215-30 [10728985.001]
  • [Cites] Br J Cancer. 2000 Mar;82(6):1218-22 [10735509.001]
  • [Cites] Genomics. 2000 Jul 15;67(2):164-70 [10903841.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Aug 18;275(1):209-16 [10944466.001]
  • [Cites] Cancer Genet Cytogenet. 2000 Aug;121(1):67-72 [10958944.001]
  • [Cites] Cancer Res. 2000 Dec 15;60(24):6868-74 [11156382.001]
  • [Cites] Brain Tumor Pathol. 2000;17(2):49-56 [11210171.001]
  • [Cites] Mol Cell Biol. 2001 Mar;21(6):1962-72 [11238932.001]
  • [Cites] J Biol Chem. 2001 Aug 10;276(32):30224-30 [11387330.001]
  • [Cites] Cancer Res. 2001 Sep 15;61(18):6885-91 [11559565.001]
  • [Cites] Nucleic Acids Res. 2002 Feb 15;30(4):e15 [11842121.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Mar;61(3):275-81 [11895042.001]
  • [Cites] Nat Biotechnol. 2002 Apr;20(4):393-6 [11923847.001]
  • [Cites] Oncogene. 2002 Apr 18;21(17):2741-9 [11965547.001]
  • [Cites] Br J Cancer. 2002 Sep 23;87(7):756-62 [12232760.001]
  • [Cites] Nat Genet. 2002 Dec;32 Suppl:496-501 [12454644.001]
  • [Cites] J Neurooncol. 2006 May;78(1):41-6 [16575538.001]
  • [Cites] Am J Hum Genet. 2006 Aug;79(2):275-90 [16826518.001]
  • [Cites] BMC Genomics. 2006;7:138 [16756668.001]
  • [Cites] Mol Cancer. 2006;5:39 [17002787.001]
  • [Cites] J Neuropathol Exp Neurol. 2006 Nov;65(11):1049-58 [17086101.001]
  • [Cites] Br J Cancer. 2006 Nov 20;95(10):1396-403 [17060937.001]
  • [Cites] Nature. 2006 Nov 23;444(7118):444-54 [17122850.001]
  • [Cites] Nat Genet. 2006 Dec;38(12):1413-8 [17115057.001]
  • [Cites] Genome Res. 2006 Dec;16(12):1566-74 [17122085.001]
  • [Cites] Cancer Res. 2006 Dec 1;66(23):11172-8 [17145861.001]
  • [Cites] J Neuropathol Exp Neurol. 2006 Dec;65(12):1149-56 [17146289.001]
  • [Cites] Clin Cancer Res. 2007 Jan 1;13(1):197-205 [17200355.001]
  • [Cites] Oncol Rep. 2007 Feb;17(2):457-64 [17203188.001]
  • [Cites] Cancer Res. 2007 Feb 1;67(3):890-900 [17283119.001]
  • [Cites] Hum Pathol. 2007 Mar;38(3):400-9 [17217994.001]
  • [Cites] Chin Med J (Engl). 2007 Mar 5;120(5):385-8 [17376308.001]
  • [Cites] Genomics. 2007 May;89(5):647-53 [17276656.001]
  • [Cites] BMC Genomics. 2007;8:167 [17565693.001]
  • [Cites] Cancer Cell. 2004 Apr;5(4):329-39 [15093540.001]
  • [Cites] J Neuropathol Exp Neurol. 2004 May;63(5):399-417 [15198120.001]
  • [Cites] Science. 2004 Jul 23;305(5683):525-8 [15273396.001]
  • [Cites] Clin Cancer Res. 2004 Aug 1;10(15):4971-82 [15297397.001]
  • [Cites] Nat Genet. 2004 Sep;36(9):949-51 [15286789.001]
  • [Cites] Cell. 1990 Sep 21;62(6):1073-85 [2205396.001]
  • [Cites] Acta Neuropathol. 1993;86(1):81-5 [8103960.001]
  • [Cites] Development. 1993 Sep;119(1):247-61 [8275860.001]
  • [Cites] Genes Chromosomes Cancer. 1995 Mar;12(3):165-72 [7536455.001]
  • [Cites] Hum Pathol. 1995 Sep;26(9):979-86 [7672798.001]
  • [Cites] Hum Genet. 1995 Dec;96(6):684-90 [8522328.001]
  • [Cites] Blood. 1996 Apr 15;87(8):3124-34 [8605326.001]
  • [Cites] Hum Pathol. 1996 Jun;27(6):586-9 [8666369.001]
  • [Cites] Nucleic Acids Res. 1996 Dec 15;24(24):5064-6 [9016686.001]
  • [Cites] J Clin Oncol. 1997 Aug;15(8):2792-9 [9256121.001]
  • [Cites] Nucleic Acids Res. 1997 Nov 1;25(21):4422-6 [9336479.001]
  • [Cites] Pediatr Neurosurg. 1997 Jul;27(1):1-11 [9486830.001]
  • [Cites] Int J Dev Neurosci. 1999 Aug-Oct;17(5-6):421-35 [10571405.001]
  • [Cites] Nucleic Acids Res. 2000 Jan 1;28(1):27-30 [10592173.001]
  • [Cites] Cereb Cortex. 2003 Feb;13(2):115-22 [12507942.001]
  • [Cites] Biotechniques. 2003 Feb;34(2):374-8 [12613259.001]
  • [Cites] Int J Mol Med. 2003 May;11(5):655-60 [12684707.001]
  • [Cites] Cancer Res. 2003 Apr 15;63(8):1865-70 [12702575.001]
  • [Cites] Oncogene. 2003 May 15;22(19):2984-92 [12771950.001]
  • [Cites] Cancer Res. 2003 Jun 15;63(12):3309-16 [12810664.001]
  • [Cites] Nucleic Acids Res. 2003 Jul 1;31(13):3775-81 [12824416.001]
  • [Cites] Brain. 2003 Aug;126(Pt 8):1755-66 [12805104.001]
  • [Cites] Blood. 2003 Aug 1;102(3):1042-50 [12689942.001]
  • [Cites] Oncogene. 2003 Jul 31;22(31):4918-23 [12894235.001]
  • [Cites] Clin Cancer Res. 2003 Aug 1;9(8):3034-41 [12912953.001]
  • [Cites] Neurosurgery. 2003 Sep;53(3):544-53; discussion 554-5 [12943571.001]
  • [Cites] Clin Cancer Res. 2003 Oct 15;9(13):4811-8 [14581352.001]
  • [Cites] Cancer Res. 2003 Oct 15;63(20):6613-25 [14583454.001]
  • [Cites] Clin Exp Med. 2003 Sep;3(2):113-8 [14598186.001]
  • [Cites] FASEB J. 2004 Apr;18(6):754-6 [14766798.001]
  • [Cites] Int J Cancer. 2004 Jun 10;110(2):212-8 [15069684.001]
  • [Cites] Cell. 2004 Apr 16;117(2):211-23 [15084259.001]
  • [Cites] Cancer Genet Cytogenet. 1998 Jul 15;104(2):157-60 [9666811.001]
  • [Cites] Dev Dyn. 1998 Jul;212(3):364-72 [9671940.001]
  • [Cites] Gene. 1998 Dec 11;224(1-2):35-44 [9931421.001]
  • [Cites] Brain Pathol. 1999 Jul;9(3):463-7 [10416986.001]
  • [Cites] World J Gastroenterol. 2004 Dec 1;10(23):3441-54 [15526363.001]
  • [Cites] J Clin Neurosci. 2005 Jan;12(1):1-5 [15639402.001]
  • [Cites] Cancer Res. 2005 Jan 1;65(1):76-84 [15665281.001]
  • [Cites] Neuro Oncol. 2005 Jan;7(1):20-31 [15701279.001]
  • [Cites] Cancer Res. 2005 Mar 1;65(5):1678-86 [15753362.001]
  • (PMID = 18670637.001).
  • [ISSN] 1476-5586
  • [Journal-full-title] Neoplasia (New York, N.Y.)
  • [ISO-abbreviation] Neoplasia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / BCL7A protein, human; 0 / BCL7B protein, human; 0 / CNTNAP1 protein, human; 0 / Cell Adhesion Molecules, Neuronal; 0 / FOXG1 protein, human; 0 / Forkhead Transcription Factors; 0 / Microfilament Proteins; 0 / Nerve Tissue Proteins; 0 / Oncogene Proteins; 0 / Proteins; 0 / Receptors, Dopamine D1; 0 / SH3GL2 protein, human
  • [Other-IDs] NLM/ PMC2481566
  •  go-up   go-down


30. Hu WW, Zheng XJ, Shen G, Liu WG, Shen H, Fu WM, Zhou JY: [Diagnosis and micro-neurosurgery for the fourth cerebral ventricle tumors]. Zhonghua Zhong Liu Za Zhi; 2007 Feb;29(2):144-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnosis and micro-neurosurgery for the fourth cerebral ventricle tumors].
  • OBJECTIVE: To investigate the diagnostic method and analyze the result of microneurosurgical treatment for tumors of the fourth cerebral ventricle.
  • METHODS: Tumor of the fourth ventricle was clinically diagnosed in 86 patients basing on the preliminary assessment of symptom and CT or MRI findings.
  • Of these 86 patients treated with micro-neurosurgery, the tumors in 62 were totally removed, subtotally in 19, and partially in 5.
  • CONCLUSION: Medulloblastoma, astrocytoma and hemangiblastoma are suggested to be removed totally whenever technically possible according to the site, character and volume of the tumor.
  • For ependymoma, if close to the brain stem, is recommended to be subtotally removed.
  • [MeSH-major] Cerebral Ventricle Neoplasms / diagnosis. Fourth Ventricle / pathology. Medulloblastoma / diagnosis. Microsurgery / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Astrocytoma / diagnosis. Astrocytoma / radiography. Astrocytoma / surgery. Child. Child, Preschool. Combined Modality Therapy. Ependymoma / diagnosis. Ependymoma / radiography. Ependymoma / surgery. Female. Follow-Up Studies. Hemangioblastoma / diagnosis. Hemangioblastoma / radiography. Hemangioblastoma / surgery. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Recurrence, Local. Survival Analysis. Survival Rate. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17645855.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


31. Huang DP, Yang M, Peng WP, Chen XS, Chen ZQ: [Prevention and management of lung infections with thymosin alpha1 in critical patients with tracheotomy]. Nan Fang Yi Ke Da Xue Xue Bao; 2006 Jan;26(1):128-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Compared with the control group, the infection rate, white blood cell count, C-reactive protein, tumor necrosis factor-alpha and interleukiu-6 were significantly lower in the treatment group.
  • [MeSH-major] Adjuvants, Immunologic / therapeutic use. Brain Injuries / drug therapy. Pneumonia / prevention & control. Thymosin / analogs & derivatives. Tracheotomy / adverse effects
  • [MeSH-minor] Adolescent. Adult. Aged. Cerebral Infarction / drug therapy. Critical Illness. Female. Humans. Intensive Care Units. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Pneumonia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16495194.001).
  • [ISSN] 1673-4254
  • [Journal-full-title] Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  • [ISO-abbreviation] Nan Fang Yi Ke Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Randomized Controlled Trial
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / thymalfasin; 61512-21-8 / Thymosin
  •  go-up   go-down


32. Jassen AK, Yang H, Miller GM, Calder E, Madras BK: Receptor regulation of gene expression of axon guidance molecules: implications for adaptation. Mol Pharmacol; 2006 Jul;70(1):71-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Axon guidance molecules, critical for neurodevelopment, are also implicated in morphological and other neurodaptative changes mediated by physiological or pharmacological events in adult brain.
  • As an example, the psychostimulant cocaine markedly alters axon guidance molecules in adult brain of cocaine-treated rats.
  • The dopamine receptor agonist dihydrexidine, which raised cAMP levels 22%, promoted regulatory changes in EphrinA1, EphrinA5, EphB1, DCC, and Semaphorin3C, whereas (+/-)-6-chloro-7,8-dihydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrobromide (SKF81297) altered EphA5, EphrinA1, EphrinA5, and neuropilin1. cAMP and other signal transduction pathways may regulate gene expression of axon guidance molecules, potentially linking monoamine receptor activation to signal transduction cascades, transcriptional regulation of axon guidance molecules, and alterations in neural networks.
  • [MeSH-minor] Adaptation, Physiological. Benzazepines / pharmacology. Blotting, Western. Cell Line, Tumor. Colforsin / pharmacology. Cyclic AMP / metabolism. Dopamine Agonists / pharmacology. Ephrins / genetics. Ephrins / metabolism. Humans. Neuropilin-1 / genetics. Neuropilin-1 / metabolism. Phenanthridines / pharmacology. Protein Isoforms / genetics. Protein Isoforms / metabolism. Receptors, Cell Surface / genetics. Receptors, Cell Surface / metabolism. Receptors, Dopamine / genetics. Receptors, Dopamine / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Semaphorins / genetics. Semaphorins / metabolism

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16595738.001).
  • [ISSN] 0026-895X
  • [Journal-full-title] Molecular pharmacology
  • [ISO-abbreviation] Mol. Pharmacol.
  • [Language] eng
  • [Grant] United States / NIDA NIH HHS / DA / DA06303; United States / NIDA NIH HHS / DA / DA11558; United States / NIDA NIH HHS / DA / DA15305; United States / NCRR NIH HHS / RR / RR00168
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Benzazepines; 0 / Dopamine Agonists; 0 / Ephrins; 0 / Intercellular Signaling Peptides and Proteins; 0 / Phenanthridines; 0 / Protein Isoforms; 0 / Receptors, Cell Surface; 0 / Receptors, Dopamine; 0 / Receptors, G-Protein-Coupled; 0 / Semaphorins; 0 / netrin receptors; 144713-63-3 / Neuropilin-1; 1F7A44V6OU / Colforsin; 32D64VH037 / dihydrexidine; 71636-61-8 / SK&F 81297; E0399OZS9N / Cyclic AMP
  •  go-up   go-down


33. Ozen O, Demirhan B, Altinörs N: Correlation between histological grade and MIB-1 and p53 immunoreactivity in meningiomas. Clin Neuropathol; 2005 Sep-Oct;24(5):219-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Meningiomas for the most part are slow-growing benign tumors, but complete removal can be difficult and recurrence is an issue.
  • The aim of this study was to re-evaluate tumors diagnosed as meningioma previously in our hospital, according to the latest World Health Organization classification.
  • We also examined the relationships among parameters such as brain invasion, histological grade and Ki-67 and p53 expression in these tumors.
  • MATERIALS AND METHODS: Meningioma biopsy specimens numbering 60 (48 grade I, 11 grade II, and 1 grade III tumors) were examined immunohistochemically using monoclonal antibodies for Ki-67 (MIB-1) and p53 protein.
  • The MIB-1 labeling index (LI) for each tumor was calculated as a percentage based on the number of stained cells per total cells counted.
  • RESULTS: Of the 60 meningiomas, 7 (11.7%) exhibited brain invasion.
  • The mean MIB-1 LI values for the grade I and grade II tumors were 1.1% and 2.3%, respectively.
  • Brain invasion was not correlated with histological grade, MIB-1 LI, or p53 expression.
  • The number of cases was limited, but the findings also suggest that brain invasion is a prognostic parameter independent of grade, MIB-1 LI and p53 expression.
  • [MeSH-major] Biomarkers, Tumor / analysis. Ki-67 Antigen / biosynthesis. Meningeal Neoplasms / pathology. Meningioma / pathology. Tumor Suppressor Protein p53 / biosynthesis
  • [MeSH-minor] Adult. Aged. Female. Humans. Immunohistochemistry. Male. Middle Aged. Prognosis. Retrospective Studies

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16167545.001).
  • [ISSN] 0722-5091
  • [Journal-full-title] Clinical neuropathology
  • [ISO-abbreviation] Clin. Neuropathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


34. Nimsky C, von Keller B, Schlaffer S, Kuhnt D, Weigel D, Ganslandt O, Buchfelder M: Updating navigation with intraoperative image data. Top Magn Reson Imaging; 2009 Jan;19(4):197-204
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: To localize overlooked tumor remnants by updating navigation with intraoperative magnetic resonance imaging compensating for the effects of brain shift.
  • Intraoperative image data were rigidly registered with the preoperative image data, the tumor remnant was segmented, and then the initial patient registration was restored so that the registration coordinate system of the preoperative image data was applied on the intraoperative images, allowing navigation updating without intraoperative patient re-registration.
  • Updated navigation allows achieving enlarged resections and compensates for the effects of brain shift.
  • [MeSH-major] Brain Diseases / pathology. Brain Diseases / surgery. Craniotomy / methods. Magnetic Resonance Imaging / methods. Surgery, Computer-Assisted / methods
  • [MeSH-minor] Adult. Female. Humans. Male. Patient Selection. Prognosis. Reproducibility of Results. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Brain Diseases.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19148036.001).
  • [ISSN] 1536-1004
  • [Journal-full-title] Topics in magnetic resonance imaging : TMRI
  • [ISO-abbreviation] Top Magn Reson Imaging
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


35. Buxbaum JD, Cai G, Chaste P, Nygren G, Goldsmith J, Reichert J, Anckarsäter H, Rastam M, Smith CJ, Silverman JM, Hollander E, Leboyer M, Gillberg C, Verloes A, Betancur C: Mutation screening of the PTEN gene in patients with autism spectrum disorders and macrocephaly. Am J Med Genet B Neuropsychiatr Genet; 2007 Jun 5;144B(4):484-91
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Screening of PTEN mutations is warranted in patients with autism and pronounced macrocephaly, even in the absence of other features of PTEN-related tumor syndromes.

  • Genetic Alliance. consumer health - Macrocephaly.
  • Genetic Alliance. consumer health - Autism.
  • Genetic Alliance. consumer health - Autism Spectrum Disorders.
  • MedlinePlus Health Information. consumer health - Craniofacial Abnormalities.
  • MedlinePlus Health Information. consumer health - Facial Injuries and Disorders.
  • MedlinePlus Health Information. consumer health - Genetic Testing.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. (L)-ASPARTIC ACID .
  • Hazardous Substances Data Bank. ASPARAGINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • [Cites] J Med Genet. 1997 Oct;34(10):849-51 [9350820.001]
  • [Cites] Science. 1998 Jun 5;280(5369):1614-7 [9616126.001]
  • [Cites] Lancet. 1997 Jun 14;349(9067):1744-5 [9193390.001]
  • [Cites] J Am Acad Child Adolesc Psychiatry. 1997 Feb;36(2):282-90 [9031582.001]
  • [Cites] Science. 1997 Jan 31;275(5300):661-5 [9005851.001]
  • [Cites] J Autism Dev Disord. 1994 Oct;24(5):659-85 [7814313.001]
  • [Cites] Eur J Pediatr. 1990 May;149(8):567-9 [2347353.001]
  • [Cites] J Pediatr. 1980 Jun;96(6):990-4 [7189556.001]
  • [Cites] Annu Rev Genomics Hum Genet. 2004;5:379-405 [15485354.001]
  • [Cites] Nat Neurosci. 2004 Oct;7(10):1059-69 [15378065.001]
  • [Cites] Pediatrics. 2004 Aug;114(2):451-7 [15286229.001]
  • [Cites] Science. 2004 Feb 20;303(5661):1179-81 [14976311.001]
  • [Cites] Neuron. 2003 Oct 30;40(3):501-14 [14642275.001]
  • [Cites] Fam Cancer. 2003;2(2):79-85 [14574156.001]
  • [Cites] Hum Mutat. 2003 Sep;22(3):183-98 [12938083.001]
  • [Cites] J Med Genet. 2003 Aug;40(8):e92 [12920084.001]
  • [Cites] Am J Med Genet. 1998 Dec 4;80(4):399-402 [9856571.001]
  • [Cites] Am J Med Genet A. 2003 Aug 1;120A(4):564-5 [12884441.001]
  • [Cites] Am J Hum Genet. 2003 Aug;73(2):404-11 [12844284.001]
  • [Cites] J Autism Dev Disord. 1998 Dec;28(6):567-71 [9932243.001]
  • [Cites] J Autism Dev Disord. 1999 Apr;29(2):113-9 [10382131.001]
  • [Cites] Hum Mol Genet. 1999 Aug;8(8):1461-72 [10400993.001]
  • [Cites] J Cell Biol. 1999 Jul 26;146(2):389-403 [10427092.001]
  • [Cites] Eur J Paediatr Neurol. 2004;8(6):327-32 [15542389.001]
  • [Cites] J Med Genet. 2005 Apr;42(4):318-21 [15805158.001]
  • [Cites] Prog Neurobiol. 2005 Feb;75(3):161-205 [15882774.001]
  • [Cites] Nat Neurosci. 2005 Jul;8(7):925-31 [15937483.001]
  • [Cites] J Neurosci. 2005 Dec 7;25(49):11300-12 [16339025.001]
  • [Cites] J Dev Behav Pediatr. 2006 Feb;27(1):63-74 [16511373.001]
  • [Cites] Am J Hum Genet. 2006 Jul;79(1):23-30 [16773562.001]
  • [Cites] Neuron. 2006 May 4;50(3):377-88 [16675393.001]
  • [Cites] Cell. 1999 Oct 29;99(3):323-34 [10555148.001]
  • [Cites] Cancer Res. 2000 Jun 15;60(12):3147-51 [10866302.001]
  • [Cites] Am J Med Genet. 2000 Sep 11;94(2):149-52 [10982971.001]
  • [Cites] Cancer Res. 2000 Dec 15;60(24):7033-8 [11156408.001]
  • [Cites] Am J Med Genet. 2000 Dec 11;95(4):339-50 [11186888.001]
  • [Cites] J Med Genet. 2001 Jan;38(1):52-8 [11332402.001]
  • [Cites] Am J Hum Genet. 2001 Aug;69(2):463-6 [11452364.001]
  • [Cites] Am J Med Genet. 2001 Aug 8;105(6):521-4 [11496368.001]
  • [Cites] Neuron. 2001 Sep 13;31(5):841-51 [11567621.001]
  • [Cites] Autism. 2001 Mar;5(1):57-66 [11708390.001]
  • [Cites] J Med Genet. 2001 Dec;38(12):820-3 [11748304.001]
  • [Cites] Am J Hum Genet. 2002 Apr;70(4):829-44 [11875759.001]
  • [Cites] Brain Res Brain Res Rev. 2002 Jun;39(1):29-54 [12086707.001]
  • [Cites] Int J Dev Neurosci. 2002 Jun-Aug;20(3-5):187-97 [12175854.001]
  • (PMID = 17427195.001).
  • [ISSN] 1552-4841
  • [Journal-full-title] American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics
  • [ISO-abbreviation] Am. J. Med. Genet. B Neuropsychiatr. Genet.
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / NS-042165; United States / NIMH NIH HHS / MH / MH066673; United States / NINDS NIH HHS / NS / R01 NS042165; None / None / / U54 MH066673-020001; United States / NIMH NIH HHS / MH / U54 MH066673; United States / NIMH NIH HHS / MH / U54 MH066673-020001
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 30KYC7MIAI / Aspartic Acid; 7006-34-0 / Asparagine; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase
  • [Other-IDs] NLM/ NIHMS239214; NLM/ PMC3381648
  •  go-up   go-down


36. Wu WC, Lai CC, Liu JH, Singh T, Li LM, Peumans WJ, Van Damme EJ, Wu AM: Differential binding to glycotopes among the layers of three mammalian retinal neurons by man-containing N-linked glycan, T(alpha) (Galbeta1-3GalNAcalpha1-), Tn (GalNAcalpha1-Ser/Thr) and I (beta)/II (beta) (Galbeta1-3/4GlcNAcbeta-) reactive lectins. Neurochem Res; 2006 May;31(5):619-28
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Since relevant knowledge is still in the primary stage, glycotopes on the adult retina of mongrel canines (dog), micropigs and Sprague-Dawley rats were examined by lectino-histochemistry, using a panel of 16 different lectins.
  • [MeSH-major] Antigens, Tumor-Associated, Carbohydrate / metabolism. Epitopes. Glycoconjugates / metabolism. Lectins / metabolism. Mannose / chemistry. Polysaccharides / metabolism. Retina / cytology

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Life Sci. 2003 Apr 4;72(20):2285-302 [12628448.001]
  • [Cites] Adv Exp Med Biol. 2001;491:551-85 [14533822.001]
  • [Cites] Brain Res. 1981 Feb 9;206(1):51-70 [7470893.001]
  • [Cites] Anal Biochem. 1994 Sep;221(2):266-72 [7810865.001]
  • [Cites] J Biomed Sci. 2004 Nov-Dec;11(6):874-85 [15591785.001]
  • [Cites] J Biomed Sci. 2003 Nov-Dec;10(6 Pt 2):676-88 [14631106.001]
  • [Cites] Curr Eye Res. 1987 Apr;6(4):639-46 [3107909.001]
  • [Cites] Biochem J. 2003 Apr 15;371(Pt 2):311-20 [12467495.001]
  • [Cites] Am J Epidemiol. 1993 Apr 1;137(7):749-57 [8484366.001]
  • [Cites] Adv Exp Med Biol. 1988;228:205-63 [3051916.001]
  • [Cites] J Comp Neurol. 1984 Feb 10;223(1):77-87 [6546767.001]
  • [Cites] Am J Ophthalmol. 2000 Feb;129(2):205-14 [10682974.001]
  • [Cites] Adv Exp Med Biol. 2001;491:55-64 [14533789.001]
  • [Cites] Invest Ophthalmol Vis Sci. 1992 Feb;33(2):364-76 [1740367.001]
  • [Cites] Glycobiology. 1993 Aug;3(4):403-12 [8400552.001]
  • [Cites] Exp Eye Res. 1993 May;56(5):531-41 [8500564.001]
  • [Cites] Eye (Lond). 1990;4 ( Pt 2):333-9 [2199241.001]
  • [Cites] Exp Eye Res. 1986 Sep;43(3):343-54 [3780878.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1987;410(6):471-9 [3105166.001]
  • [Cites] Ophthalmic Res. 2002 Mar-Apr;34(2):70-6 [11914608.001]
  • [Cites] Ann Anat. 1992 Aug;174(4):279-85 [1416054.001]
  • [Cites] FEBS Lett. 2004 Mar 26;562(1-3):51-8 [15044001.001]
  • [Cites] J Comp Neurol. 1983 Nov 20;221(1):31-41 [6643744.001]
  • [Cites] Am J Ophthalmol. 2003 Jul;136(1):155-60 [12834683.001]
  • [Cites] Exp Eye Res. 1995 Dec;61(6):763-6 [8846849.001]
  • [Cites] Cell Tissue Res. 1987 Aug;249(2):277-88 [3621302.001]
  • [Cites] Exp Eye Res. 1993 Apr;56(4):429-41 [8500556.001]
  • [Cites] Invest Ophthalmol Vis Sci. 1980 Jul;19(7):728-42 [6156139.001]
  • [Cites] Glycoconj J. 2000 Jul-Sep;17(7-9):543-51 [11421347.001]
  • [Cites] Jpn J Ophthalmol. 1994;38(4):360-3 [7723202.001]
  • [Cites] Exp Eye Res. 1991 Jun;52(6):699-713 [1855544.001]
  • [Cites] Invest Ophthalmol Vis Sci. 1993 Oct;34(11):3056-67 [8407213.001]
  • [Cites] Exp Eye Res. 1987 Dec;45(6):845-63 [3428401.001]
  • [Cites] Arch Biochem Biophys. 1981 Jun;209(1):204-18 [7283438.001]
  • (PMID = 16770733.001).
  • [ISSN] 0364-3190
  • [Journal-full-title] Neurochemical research
  • [ISO-abbreviation] Neurochem. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Tumor-Associated, Carbohydrate; 0 / Epitopes; 0 / Glycoconjugates; 0 / Glycoproteins; 0 / Lectins; 0 / Monosaccharides; 0 / Polysaccharides; 0 / Tn antigen; PHA4727WTP / Mannose
  •  go-up   go-down


37. Meng Y, Kujas M, Marie Y, Paris S, Thillet J, Delattre JY, Carpentier AF: Expression of TLR9 within human glioblastoma. J Neurooncol; 2008 May;88(1):19-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • No significant relationships between TLR9 expression and age, sex, tumor location, lymphocytes infiltration, oligodendroglial components or survival were found.
  • TLR9 is unlikely to be expressed by tumor cells as no TLR9 expression was detected in pure human GBM xenografts.
  • [MeSH-major] Brain Neoplasms / genetics. Glioblastoma / genetics. Toll-Like Receptor 9 / biosynthesis. Toll-Like Receptor 9 / genetics
  • [MeSH-minor] Adult. Aged. Animals. Female. Fluorescent Antibody Technique. Humans. Immunohistochemistry. Karnofsky Performance Status. Lymphocytes / pathology. Male. Mice. Mice, Nude. Middle Aged. Neoplasm Transplantation. Neurosurgical Procedures. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. Reverse Transcriptase Polymerase Chain Reaction. Survival

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 2005 Oct 10;116(6):992-7 [15856470.001]
  • [Cites] Glia. 2003 Sep;43(3):281-91 [12898707.001]
  • [Cites] J Immunol. 2002 May 15;168(10):4854-63 [11994434.001]
  • [Cites] Lancet. 2003 Jan 25;361(9354):323-31 [12559880.001]
  • [Cites] J Immunol Methods. 2005 May;300(1-2):93-9 [15894327.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Nov;61(11):1013-21 [12430718.001]
  • [Cites] J Immunol. 2001 Oct 1;167(7):3555-8 [11564765.001]
  • [Cites] Glia. 2006 Nov 1;54(6):526-35 [16906541.001]
  • [Cites] J Neurosci Res. 2005 Aug 1;81(3):447-55 [15959903.001]
  • [Cites] Cancer Res. 1999 Nov 1;59(21):5429-32 [10554011.001]
  • [Cites] Curr Oncol Rep. 2004 Mar;6(2):88-95 [14751085.001]
  • [Cites] J Clin Microbiol. 2000 Jun;38(6):2362-5 [10835003.001]
  • [Cites] Respir Res. 2005 Jan 04;6:1 [15631627.001]
  • [Cites] Clin Cancer Res. 2000 Jun;6(6):2469-73 [10873101.001]
  • [Cites] Cancer Res. 2004 Jul 1;64(13):4648-53 [15231677.001]
  • [Cites] Ann Neurol. 1978 Sep;4(3):219-24 [718133.001]
  • [Cites] J Neurosurg Sci. 1990 Apr-Jun;34(2):145-8 [2092095.001]
  • [Cites] J Immunol. 2005 Oct 1;175(7):4320-30 [16177072.001]
  • [Cites] J Immunol. 1998 Jul 15;161(2):740-8 [9670950.001]
  • [Cites] Neuro Oncol. 2006 Jan;8(1):60-6 [16443949.001]
  • [Cites] Neuro Oncol. 2006 Jul;8(3):261-79 [16775224.001]
  • [Cites] Leukemia. 2006 Jun;20(6):1130-7 [16628189.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10 ):987-96 [15758009.001]
  • (PMID = 18253698.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / Toll-Like Receptor 9
  •  go-up   go-down


38. Hottinger AF, Yoon H, DeAngelis LM, Abrey LE: Neurological outcome of long-term glioblastoma survivors. J Neurooncol; 2009 Dec;95(3):301-305
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Twenty-seven had tumor progression a median of 29.2 months after diagnosis (range: 1.2-167 months); 18 had multiple relapses.
  • [MeSH-major] Brain Neoplasms / mortality. Cognition Disorders / mortality. Glioblastoma / mortality. Quality of Life. Survivors / statistics & numerical data
  • [MeSH-minor] Adolescent. Adult. Aged. Databases, Factual. Follow-Up Studies. Humans. Karnofsky Performance Status. Middle Aged. Neoplasm Recurrence, Local / mortality. Retrospective Studies. Survival Analysis. Young Adult


39. Maza S, Kiewe P, Munz DL, Korfel A, Hamm B, Jahnke K, Thiel E: First report on a prospective trial with yttrium-90-labeled ibritumomab tiuxetan (Zevalin) in primary CNS lymphoma. Neuro Oncol; 2009 Aug;11(4):423-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Anti-CD20 immunotherapy has expanded treatment options in systemic B-cell lymphoma; however, its use is limited by reconstitution of the blood-brain barrier after tumor shrinkage.
  • In six patients, biodistribution of the antibody was measured by indium-111 ((111)In) ibritumomab tiuxetan whole-body scans and single-photon-emission CT (SPECT) of the brain.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Central Nervous System Neoplasms / radiotherapy. Neoplasm Recurrence, Local / radiotherapy. Radioimmunotherapy
  • [MeSH-minor] Adult. Aged. Female. Humans. Lymphoma, B-Cell / immunology. Lymphoma, B-Cell / pathology. Lymphoma, B-Cell / radiotherapy. Lymphoma, Large B-Cell, Diffuse / immunology. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, Large B-Cell, Diffuse / radiotherapy. Male. Middle Aged. Prognosis. Prospective Studies. Remission Induction. Survival Rate. Tissue Distribution. Yttrium Radioisotopes / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurooncol. 1999 Jul;43(3):249-57 [10563431.001]
  • [Cites] J Clin Oncol. 2002 May 15;20(10):2453-63 [12011122.001]
  • [Cites] Blood. 2003 Jan 15;101(2):466-8 [12393404.001]
  • [Cites] Eur J Cancer. 1991;27(11):1356-61 [1835848.001]
  • [Cites] Blood. 1998 Sep 15;92(6):1927-32 [9731049.001]
  • [Cites] Eur J Haematol. 2005 Apr;74(4):348-52 [15777348.001]
  • [Cites] Cancer. 2007 Dec 1;110(11):2528-34 [17932895.001]
  • [Cites] Ann Oncol. 2005 Oct;16(10):1710-1 [15972281.001]
  • [Cites] J Neurooncol. 2006 Mar;77(1):53-8 [16283435.001]
  • [Cites] Clin Lymphoma Myeloma. 2006 Nov;7(3):236-8 [17229341.001]
  • [Cites] J Neurooncol. 2007 Jul;83(3):291-3 [17245621.001]
  • [Cites] Leuk Lymphoma. 2007 Sep;48(9):1712-20 [17786706.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):5034-43 [15955902.001]
  • (PMID = 19060176.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Yttrium Radioisotopes; 0 / ibritumomab tiuxetan
  • [Other-IDs] NLM/ PMC2743222
  •  go-up   go-down


40. Martin-Blondel G, Rousseau A, Boch AL, Cacoub P, Sène D: Primary pineal melanoma with leptomeningeal spreading: case report and review of the literature. Clin Neuropathol; 2009 Sep-Oct;28(5):387-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histological examination showed a malignant melanocytic tumor cell proliferation expressing Melan-A, but not HMB-45 or S100 protein.
  • Even if we have no proof that the tumor actually arose in the pineal gland, based on the radiological and histological findings, and on the unremarkable dermatologic and ophthalmologic examinations, a primary pineal melanoma with leptomeningeal dissemination was diagnosed.
  • The patient received temozolomide-based chemotherapy followed by whole brain irradiation.
  • The diagnosis is provided by pathological examination of tumor specimens obtained at surgical resection or at leptomeningeal biopsy.
  • [MeSH-major] Melanoma / pathology. Meningeal Neoplasms / secondary. Pinealoma / pathology
  • [MeSH-minor] Adult. Antigens, Neoplasm / metabolism. Brain / pathology. Brain / radiography. Brain / radionuclide imaging. Diagnosis, Differential. Fatal Outcome. Humans. MART-1 Antigen. Magnetic Resonance Imaging. Male. Melanoma-Specific Antigens. Neoplasm Proteins / metabolism. Prognosis. S100 Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19788056.001).
  • [ISSN] 0722-5091
  • [Journal-full-title] Clinical neuropathology
  • [ISO-abbreviation] Clin. Neuropathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / MART-1 Antigen; 0 / MLANA protein, human; 0 / Melanoma-Specific Antigens; 0 / Neoplasm Proteins; 0 / S100 Proteins
  • [Number-of-references] 20
  •  go-up   go-down


41. Zhou GF, Wang XY, Gong CG, Liu F, Wang RW: [Value of proton magnetic resonance spectroscopy with two-dimensional chemical-shift imaging in evaluating brain gliomas]. Nan Fang Yi Ke Da Xue Xue Bao; 2008 Aug;28(8):1342-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Value of proton magnetic resonance spectroscopy with two-dimensional chemical-shift imaging in evaluating brain gliomas].
  • OBJECTIVE: To study the value of proton magnetic resonance spectroscopy ((1)H-MRS) with two-dimensional (2D) chemical-shift imaging (CSI) in evaluating brain gliomas.
  • The VOI of MRS included the tumor, peritumoral edematous and nonedematous areas, and the contralateral normal tissue.
  • RESULTS: Significant differences were found in the ratios of NAA/Cr, Cho/Cr and NAA/Cho between low-grade gliomas and contralateral normal brain tissue, and between high-grade gliomas and the contralateral normal tissue (P<0.01).
  • These ratios also showed significant differences between peritumoral edematous area and the glioma tissue, between the peritumoral edematous area and contralateral normal brain tissue (P<0.05), and between the peritumoral nonedematous area and the glioma tissue (P<0.05).
  • Between the peritumoral nonedematous area and contralateral normal brain tissue, NAA/Cr and NAA/Cho ratios were significantly different (P<0.05) but the Cho/Cr ratio was similar (P>0.05).
  • [MeSH-major] Brain Neoplasms / diagnosis. Glioma / diagnosis. Magnetic Resonance Imaging / methods. Magnetic Resonance Spectroscopy / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Image Processing, Computer-Assisted. Male. Middle Aged. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18753055.001).
  • [ISSN] 1673-4254
  • [Journal-full-title] Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  • [ISO-abbreviation] Nan Fang Yi Ke Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


42. Martins DC, Malheiros SM, Santiago LH, Stávale JN: Gemistocytes in astrocytomas: are they a significant prognostic factor? J Neurooncol; 2006 Oct;80(1):49-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Out of 24 who presented clinical and neuroimaging worsening, characterized as tumor progression or recurrence, 16 had histological confirmation and were also analyzed.
  • [MeSH-major] Astrocytoma / mortality. Astrocytoma / pathology. Brain Neoplasms / mortality. Brain Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Cell Proliferation. Disease-Free Survival. Female. Humans. Immunohistochemistry. Ki-67 Antigen / metabolism. Male. Middle Aged. Prognosis. Proto-Oncogene Proteins c-bcl-2 / metabolism. Retrospective Studies. Survival Analysis. Tumor Suppressor Protein p53 / metabolism

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pathol Res Pract. 1998;194(12):831-6 [9894248.001]
  • [Cites] Cancer. 1999 Aug 15;86(4):672-83 [10440696.001]
  • [Cites] J Neurooncol. 2006 Jan;76(2):175-83 [16132490.001]
  • [Cites] Acta Neurochir (Wien). 1998;140(12):1213-22 [9932120.001]
  • [Cites] Acta Neuropathol. 1998 Jun;95(6):559-64 [9650746.001]
  • [Cites] Am J Surg Pathol. 1996 Sep;20(9):1086-90 [8764745.001]
  • [Cites] Arch Pathol Lab Med. 2001 Feb;125(2):218-23 [11175638.001]
  • [Cites] Lab Invest. 1997 Feb;76(2):277-84 [9042164.001]
  • [Cites] J Neurosurg. 1991 Mar;74(3):399-406 [1993905.001]
  • [Cites] Acta Neuropathol. 1996;91(1):99-103 [8773153.001]
  • [Cites] Brain Pathol. 1996 Jul;6(3):217-23; discussion 23-4 [8864278.001]
  • [Cites] Ann N Y Acad Sci. 2000 Jun;910:121-37; discussion 137-9 [10911910.001]
  • [Cites] Pathol Oncol Res. 1999;5(1):21-7 [10079373.001]
  • [Cites] Clin Cancer Res. 1997 Apr;3(4):523-30 [9815715.001]
  • [Cites] J Neuropathol Exp Neurol. 1975 May;34(3):263-81 [167133.001]
  • [Cites] Neurosurgery. 2001 Jan;48(1):187-93; discussion 193-4 [11152345.001]
  • [Cites] Acta Neuropathol. 1994;87(6):586-93 [8091951.001]
  • [Cites] J Clin Pathol. 1999 Aug;52(8):574-80 [10645226.001]
  • [Cites] Acta Neurochir (Wien). 2003 Dec;145(12):1097-103; discussion 1103 [14663567.001]
  • [Cites] Acta Neuropathol. 2001 Nov;102(5):422-5 [11699553.001]
  • [Cites] Am J Pathol. 1997 Mar;150(3):805-14 [9060818.001]
  • [Cites] Hum Pathol. 1991 Jan;22(1):33-40 [1985075.001]
  • (PMID = 16645716.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


43. Calvar JA, Meli FJ, Romero C, Calcagno ML, Yánez P, Martinez AR, Lambre H, Taratuto AL, Sevlever G: Characterization of brain tumors by MRS, DWI and Ki-67 labeling index. J Neurooncol; 2005 May;72(3):273-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of brain tumors by MRS, DWI and Ki-67 labeling index.
  • With the advent of fast imaging hardware and specialized software, additional non-invasive magnetic resonance characterization of tumors has become available through proton magnetic resonance spectroscopy (MRS), hemodynamic imaging and diffusion-weighted imaging (DWI).
  • Thus, patterns could be discerned to discriminate different types of tumors and even to infer their possible evolution in time.
  • The purpose of this study was to investigate the correlation between MRS, DWI, histopathology and Ki-67 labeling index in a large number of brain tumors.
  • Localized proton spectra were obtained in 47 patients with brain tumors who subsequently underwent surgery (biopsy or tumor removal).
  • In most tumors the histological diagnosis and Ki-67 labeling index had been determined on our original surgical specimen.
  • A novel finding was that high Glx/Cr in vivo MRS index (similar to other known indexes) was a good predictor of tumor grading.
  • [MeSH-major] Aspartic Acid / analogs & derivatives. Brain Neoplasms / diagnosis. Ki-67 Antigen
  • [MeSH-minor] Adult. Aged. Cell Proliferation. Choline / metabolism. Creatinine / metabolism. Diffusion Magnetic Resonance Imaging. Female. Humans. Image Processing, Computer-Assisted. Lipid Metabolism. Magnetic Resonance Spectroscopy. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. (L)-ASPARTIC ACID .
  • Hazardous Substances Data Bank. CHOLINE CHLORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Neurochir (Wien). 1987;89(3-4):117-21 [3324650.001]
  • [Cites] J Neurosurg. 1988 Dec;69(6):839-42 [3193189.001]
  • [Cites] AJNR Am J Neuroradiol. 2003 May;24(5):937-41 [12748097.001]
  • [Cites] AJNR Am J Neuroradiol. 2003 Feb;24(2):225-33 [12591638.001]
  • [Cites] J Magn Reson. 1997 Nov;129(1):35-43 [9405214.001]
  • [Cites] No To Shinkei. 1989 Jan;41(1):55-60 [2470401.001]
  • [Cites] J Neurooncol. 1997 Aug;34(1):61-78 [9210053.001]
  • [Cites] Magn Reson Med. 1999 Jan;41(1):2-7 [10025604.001]
  • [Cites] Curr Opin Oncol. 2002 May;14(3):292-8 [11981274.001]
  • [Cites] Eur J Radiol. 2003 Mar;45(3):208-13 [12595105.001]
  • [Cites] J Neurooncol. 2000 Dec;50(3):215-26 [11263501.001]
  • [Cites] AJNR Am J Neuroradiol. 1998 Mar;19(3):401-5 [9541289.001]
  • [Cites] MAGMA. 2001 May;12(2-3):141-52 [11390270.001]
  • [Cites] J Neurosurg. 2003 Jan;98(1):74-81 [12546355.001]
  • [Cites] Neuroradiology. 2003 Jan;45(1):1-10 [12525947.001]
  • [Cites] Magn Reson Med. 2001 Sep;46(3):451-6 [11550235.001]
  • [Cites] NMR Biomed. 2003 Feb;16(1):12-8 [12577293.001]
  • [Cites] Magn Reson Med. 2003 Jan;49(1):29-36 [12509817.001]
  • [Cites] Neurosurgery. 2003 Sep;53(3):565-74; discussion 574-6 [12943573.001]
  • [Cites] AJNR Am J Neuroradiol. 1999 Jan;20(1):117-23 [9974066.001]
  • [Cites] AJNR Am J Neuroradiol. 2002 Feb;23(2):322-33 [11847064.001]
  • [Cites] AJNR Am J Neuroradiol. 1999 May;20(5):882-5 [10369360.001]
  • [Cites] Biosci Rep. 1985 May;5(5):393-400 [3896338.001]
  • [Cites] Nat Med. 2001 Sep;7(9):1010-5 [11533703.001]
  • [Cites] AJNR Am J Neuroradiol. 1995 Sep;16(8):1593-603 [7502961.001]
  • [Cites] Anticancer Res. 2003 Mar-Apr;23(2A):1149-54 [12820363.001]
  • [Cites] Eur Radiol. 2003 Mar;13(3):582-91 [12594562.001]
  • [Cites] Neuroradiology. 2002 May;44(5):371-81 [12012120.001]
  • [Cites] AJNR Am J Neuroradiol. 2001 Apr;22(4):604-12 [11290466.001]
  • [Cites] NMR Biomed. 2003 May;16(3):123-31 [12884355.001]
  • [Cites] Magn Reson Med. 1996 May;35(5):633-9 [8722812.001]
  • [Cites] J Clin Oncol. 2003 Mar 15;21(6):1094-100 [12637476.001]
  • [Cites] NMR Biomed. 1994 May;7(3):149-55 [8080717.001]
  • [Cites] AJNR Am J Neuroradiol. 2001 May;22(5):969-76 [11337344.001]
  • [Cites] NMR Biomed. 1998 Jun-Aug;11(4-5):148-56 [9719569.001]
  • [Cites] AJNR Am J Neuroradiol. 1996 Jan;17(1):1-15 [8770242.001]
  • [Cites] Eur Radiol. 2001;11(9):1784-91 [11511902.001]
  • [Cites] AJNR Am J Neuroradiol. 2000 Apr;21(4):659-65 [10782774.001]
  • [Cites] Radiology. 2002 Nov;225(2):556-66 [12409595.001]
  • (PMID = 15937653.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 30KYC7MIAI / Aspartic Acid; 997-55-7 / N-acetylaspartate; AYI8EX34EU / Creatinine; N91BDP6H0X / Choline
  •  go-up   go-down


44. Momota H, Narita Y, Matsushita Y, Miyakita Y, Shibui S: p53 abnormality and tumor invasion in patients with malignant astrocytoma. Brain Tumor Pathol; 2010 Oct;27(2):95-101
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] p53 abnormality and tumor invasion in patients with malignant astrocytoma.
  • Malignant astrocytomas are characterized by diffusely infiltrating nature, and the abnormality of p53 is a cytogenetic hallmark of astrocytic tumors.
  • To elucidate the relationship between p53 abnormality and invasiveness of the tumors, we studied mutation and protein expression of p53 in 48 consecutive patients with malignant astrocytoma (14 anaplastic astrocytomas and 34 glioblastoma multiformes).
  • The tumors were classified into three categories according to the features of magnetic resonance imaging, and 5, 7, and 36 tumors were classified into diffuse, multiple, and single type, respectively.
  • We then examined how these tumor types correlate with MIB-1 staining index, TP53 gene mutation, and p53 protein expression.
  • Furthermore, diffuse- and multiple-type tumors were significantly correlated with poor progression-free survival, whereas only multiple-type tumors were significantly correlated with poor overall survival.
  • As diffuse and multiple features on imaging modalities represent invasive characteristics of the tumors, p53 abnormalities may affect the invasive and aggressive nature of malignant astrocytomas.
  • [MeSH-major] Astrocytoma / genetics. Astrocytoma / pathology. Brain Neoplasms / genetics. Brain Neoplasms / pathology. Genes, p53 / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. DNA, Neoplasm / genetics. Female. Glial Fibrillary Acidic Protein / genetics. Glial Fibrillary Acidic Protein / metabolism. Humans. Immunohistochemistry. Male. Middle Aged. Mitotic Index. Mutation / genetics. Mutation / physiology. Neoplasm Invasiveness / genetics. Neoplasm Invasiveness / pathology. Survival Analysis. Tumor Suppressor Protein p53 / genetics. Tumor Suppressor Protein p53 / metabolism. Vascular Endothelial Growth Factor A / metabolism. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21046311.001).
  • [ISSN] 1861-387X
  • [Journal-full-title] Brain tumor pathology
  • [ISO-abbreviation] Brain Tumor Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Glial Fibrillary Acidic Protein; 0 / Tumor Suppressor Protein p53; 0 / Vascular Endothelial Growth Factor A
  •  go-up   go-down


46. Hill HC: Challenges of utilizing immunostains to facilitate the diagnosis and management of metastatic adenocarcinoma. J Natl Med Assoc; 2008 Dec;100(12):1469-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Treatment is based upon the results of several diagnostic radiographic modalities that may locate the occult primary and determine the extent of metastatic tumor burden.
  • The patient completed the chemotherapy and had stable metastatic tumor burden with an acceptable quality of life.
  • [MeSH-major] Adenocarcinoma / secondary. Lung Neoplasms / diagnosis. Lung Neoplasms / pathology. Neoplasms, Unknown Primary / diagnosis
  • [MeSH-minor] Adult. Bone Neoplasms / secondary. Brain Neoplasms / secondary. Bromhexine. Fatal Outcome. Female. Humans. Immunohistochemistry. Pericardial Effusion / pathology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Natl Med Assoc. 2009 May;101(5):478 [19476202.001]
  • (PMID = 19110917.001).
  • [ISSN] 1943-4693
  • [Journal-full-title] Journal of the National Medical Association
  • [ISO-abbreviation] J Natl Med Assoc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] Q1J152VB1P / Bromhexine
  •  go-up   go-down


47. Innominato PF, Focan C, Gorlia T, Moreau T, Garufi C, Waterhouse J, Giacchetti S, Coudert B, Iacobelli S, Genet D, Tampellini M, Chollet P, Lentz MA, Mormont MC, Lévi F, Bjarnason GA, Chronotherapy Group of the European Organization for Research and Treament of Cancer: Circadian rhythm in rest and activity: a biological correlate of quality of life and a predictor of survival in patients with metastatic colorectal cancer. Cancer Res; 2009 Jun 1;69(11):4700-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In a prior single-institution study, the extent of CircAct perturbation independently predicted for survival and tumor response in 192 patients receiving chemotherapy for metastatic colorectal cancer.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • University of Turin Instituional Repository AperTO. Full Text from .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2001 Oct 17;93(20):1563-8 [11604480.001]
  • [Cites] J Clin Sleep Med. 2008 Oct 15;4(5):441-9 [18853702.001]
  • [Cites] Br J Cancer. 2002 Apr 22;86(8):1243-9 [11953880.001]
  • [Cites] Chronobiol Int. 2002 Jan;19(1):313-23 [11962684.001]
  • [Cites] J Natl Cancer Inst. 2002 May 1;94(9):690-7 [11983758.001]
  • [Cites] Cell. 2002 May 3;109(3):307-20 [12015981.001]
  • [Cites] Support Care Cancer. 2002 May;10(4):329-36 [12029433.001]
  • [Cites] Ann Oncol. 2002 Jun;13(6):965-73 [12123343.001]
  • [Cites] Nature. 2002 Aug 29;418(6901):935-41 [12198538.001]
  • [Cites] Sleep. 2003 May 1;26(3):342-92 [12749557.001]
  • [Cites] J Natl Cancer Inst. 2003 Jun 4;95(11):825-8 [12783938.001]
  • [Cites] J Biol Rhythms. 2003 Jun;18(3):183-94 [12828276.001]
  • [Cites] Nat Rev Neurosci. 2003 Aug;4(8):649-61 [12894240.001]
  • [Cites] Brain Behav Immun. 2003 Oct;17(5):321-8 [12946654.001]
  • [Cites] Sleep Med Rev. 2004 Jun;8(3):199-212 [15144962.001]
  • [Cites] Semin Neurol. 2004 Sep;24(3):315-25 [15449224.001]
  • [Cites] N Engl J Med. 1983 Aug 25;309(8):469-76 [6348541.001]
  • [Cites] N Engl J Med. 1983 Sep 1;309(9):530-6 [6348546.001]
  • [Cites] J Natl Cancer Inst. 1993 Mar 3;85(5):365-76 [8433390.001]
  • [Cites] Int J Cancer. 1997 Jan 17;70(2):241-7 [9009166.001]
  • [Cites] J Natl Cancer Inst. 2000 Jun 21;92(12):994-1000 [10861311.001]
  • [Cites] Clin Cancer Res. 2000 Aug;6(8):3038-45 [10955782.001]
  • [Cites] J Natl Cancer Inst. 2001 Oct 17;93(20):1557-62 [11604479.001]
  • [Cites] Lancet. 1997 Nov 29;350(9091):1611-6 [9393352.001]
  • [Cites] J Pain Symptom Manage. 1999 May;17(5):320-32 [10355211.001]
  • [Cites] Cancer Res. 2004 Nov 1;64(21):7879-85 [15520194.001]
  • [Cites] Sleep. 2004 Dec 15;27(8):1453-62 [15683134.001]
  • [Cites] Nat Rev Neurosci. 2005 May;6(5):407-14 [15861183.001]
  • [Cites] J Biol Rhythms. 2005 Aug;20(4):339-52 [16077153.001]
  • [Cites] Nature. 2005 Oct 27;437(7063):1257-63 [16251950.001]
  • [Cites] Br J Cancer. 2005 Nov 28;93(11):1202-8 [16265345.001]
  • [Cites] Eur J Cancer. 2006 Jan;42(1):42-9 [16298522.001]
  • [Cites] Support Care Cancer. 2006 Mar;14(3):201-9 [16010529.001]
  • [Cites] J Clin Oncol. 2006 Aug 1;24(22):3562-9 [16877722.001]
  • [Cites] Am J Epidemiol. 2006 Sep 15;164(6):549-55 [16829554.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2007;47:593-628 [17209800.001]
  • [Cites] J Pain Symptom Manage. 2007 Apr;33(4):398-409 [17397701.001]
  • [Cites] Lancet. 2007 Mar 31;369(9567):1117-29 [17398311.001]
  • [Cites] J Support Oncol. 2007 Apr;5(4):167-74; discussion 176-7 [17500504.001]
  • [Cites] Nat Chem Biol. 2007 Oct;3(10):630-9 [17876320.001]
  • [Cites] Cancer Res. 2007 Nov 1;67(21):10618-22 [17975006.001]
  • [Cites] Clin Cancer Res. 2007 Nov 1;13(21):6379-85 [17975150.001]
  • [Cites] J Clin Oncol. 2008 Feb 20;26(6):971-82 [18281672.001]
  • [Cites] J Clin Oncol. 2008 Apr 20;26(12):2020-6 [18421055.001]
  • [Cites] J Clin Oncol. 2008 May 20;26(15):2431-2 [18487562.001]
  • [Cites] J Clin Oncol. 2008 May 20;26(15):2464-72 [18487566.001]
  • [Cites] J Pain Symptom Manage. 2008 Aug;36(2):191-9 [18400460.001]
  • [Cites] Nat Rev Genet. 2008 Oct;9(10):764-75 [18802415.001]
  • [Cites] Ann Oncol. 2002 Feb;13(2):308-17 [11886010.001]
  • (PMID = 19470769.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA011488-32; United States / NCI NIH HHS / CA / 5U10CA11488-32; United States / NCI NIH HHS / CA / CA011488-29; United States / NCI NIH HHS / CA / U10 CA011488; United States / NCI NIH HHS / CA / CA011488-30; United States / NCI NIH HHS / CA / 2U10CA11488-28; United States / NCI NIH HHS / CA / U10 CA011488-31; United States / NCI NIH HHS / CA / U10 CA011488-32; United States / NCI NIH HHS / CA / U10 CA011488-29; United States / NCI NIH HHS / CA / CA011488-31; United States / NCI NIH HHS / CA / U10 CA011488-30
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS110033; NLM/ PMC2690615
  •  go-up   go-down


48. Hashiguchi A, Morioka M, Ichimura H, Mimata C, Kuratsu J: Glioblastoma with an intratumoral feeding-artery aneurysm. Clin Neurol Neurosurg; 2007 Apr;109(3):302-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report a patient with recurrent glioblastoma, in whom serial magnetic resonance angiography (MRA) demonstrated gradual enlargement of an artery feeding the tumor and the development of an intratumoral aneurysm that led to intratumoral hemorrhage.
  • [MeSH-major] Brain Neoplasms / diagnosis. Cerebral Arteries / pathology. Cerebral Arteries / radiography. Glioblastoma / blood supply. Glioblastoma / diagnosis. Intracranial Aneurysm / pathology. Intracranial Aneurysm / radiography
  • [MeSH-minor] Adult. Aneurysm, Ruptured / radiography. Aneurysm, Ruptured / surgery. Female. Frontal Lobe / blood supply. Frontal Lobe / pathology. Frontal Lobe / surgery. Humans. Magnetic Resonance Angiography. Magnetic Resonance Imaging. Neoplasm Recurrence, Local. Neurosurgical Procedures. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Aneurysm.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17222964.001).
  • [ISSN] 0303-8467
  • [Journal-full-title] Clinical neurology and neurosurgery
  • [ISO-abbreviation] Clin Neurol Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


49. Lamari F, La Schiazza R, Guillevin R, Hainque B, Foglietti MJ, Beaudeux JL, Bernard M: [Biochemical exploration of energetic metabolism and oxidative stress in low grade gliomas: central and peripheral tumor tissue analysis]. Ann Biol Clin (Paris); 2008 Mar-Apr;66(2):143-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Biochemical exploration of energetic metabolism and oxidative stress in low grade gliomas: central and peripheral tumor tissue analysis].
  • Gliomas represent 50% of primary brain tumors, and their prognosis remains poor despite the advances in diagnosis and therapeutic strategies.
  • Low grade gliomas (LGG) are infiltrative tumors and they constantly undergo malignant transformation.
  • Metabolic exploration of human gliomas in vivo, in animals and by using cell culture models showed important differences between tumor tissues and normal brain tissues, which can provide new markers for diagnosis, prognosis and therapeutic targets.
  • In this study, energetic and oxidant metabolisms were explored in biopsy extracts of LGG obtained from the centre and the periphery of tumors.
  • Metabolic pattern of these tumors was explored and the differences between the centre and the periphery pointed.
  • Our study showed a metabolic heterogeneity between tumors, with hypermetabolic and hypometabolic profiles.
  • Lactate to pyruvate ratio was>1, suggesting that the energy metabolism in LGG is glycolytic in nature, particularly in the centre of the tumors.
  • Peripheral samples of tumors showed increased glucose consumption and cytochrome c oxidase activity.
  • Lipid peroxidation and catalase activity were also increased in the periphery compared to the centre of tumors.
  • A relationship between the main antioxidant and energy metabolism enzymes activities was observed, suggesting that periphery of tumors is more active metabolically and more resistant to free radical injury.
  • [MeSH-major] Brain Neoplasms / metabolism. Energy Metabolism. Glioma / metabolism. Oxidative Stress
  • [MeSH-minor] Adult. Aged. Biopsy. Brain / pathology. Catalase / metabolism. Cohort Studies. Data Interpretation, Statistical. Electron Transport Complex IV / metabolism. Female. Humans. Male. Middle Aged. Prognosis. Spectrometry, Fluorescence. Spectrophotometry

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18390424.001).
  • [ISSN] 0003-3898
  • [Journal-full-title] Annales de biologie clinique
  • [ISO-abbreviation] Ann. Biol. Clin. (Paris)
  • [Language] fre
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] EC 1.11.1.6 / Catalase; EC 1.9.3.1 / Electron Transport Complex IV
  •  go-up   go-down


50. de Groot M, Toering ST, Boer K, Spliet WG, Heimans JJ, Aronica E, Reijneveld JC: Expression of synaptic vesicle protein 2A in epilepsy-associated brain tumors and in the peritumoral cortex. Neuro Oncol; 2010 Mar;12(3):265-73
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of synaptic vesicle protein 2A in epilepsy-associated brain tumors and in the peritumoral cortex.
  • Since knockout of SV2A in mice leads to seizures, we hypothesized that a reduction in SV2A expression promotes seizure generation in epilepsy-associated brain tumors.
  • We compared the SV2A expression and distribution in surgically removed tumor tissue (n = 63) and peritumoral cortex (n = 31) of patients with glial and glioneuronal tumors to normal control cortex obtained at autopsy in nonbrain tumor patients (n = 6).
  • Additionally, we compared the SV2A expression and distribution in tumor patients with epilepsy (n = 39) with SV2A expression in tumor patients without epilepsy (n = 24).
  • Modest SV2A IR was observed within the tumor area.
  • The SV2A-positive cells detected within the tumor area were mainly entrapped neurons.
  • Oligodendrogliomas and glioneuronal tumors displayed variable SV2A neuropil staining.
  • In both GG and dysembryoplastic neuroepithelial tumors, SV2A IR was occasionally observed within the neuronal perikarya.
  • We found no differences in SV2A expression in the peritumoral cortex between the patients with and without epilepsy, which suggests that the role of SV2A in epileptogenesis in patients with glial tumors is questionable.
  • The distinct pattern of SV2A IR in glioneuronal tumors suggests a redistribution of SV2A.
  • [MeSH-major] Brain Neoplasms / metabolism. Epilepsy / metabolism. Membrane Glycoproteins / biosynthesis. Nerve Tissue Proteins / biosynthesis
  • [MeSH-minor] Adolescent. Adult. Blotting, Western. Female. Humans. Immunohistochemistry. Male. Middle Aged. Young Adult

  • Genetic Alliance. consumer health - Epilepsy.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Epilepsy.
  • SciCrunch. DrugBank: Data: Chemical .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]
  • [Cites] Neurobiol Dis. 2007 Jun;26(3):497-511 [17412602.001]
  • [Cites] Epilepsia. 2009 Jun;50(6):1409-18 [19220410.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Dec 21;96(26):15268-73 [10611374.001]
  • [Cites] Neuron. 1999 Dec;24(4):1003-16 [10624962.001]
  • [Cites] Epilepsy Res. 2001 Mar;43(3):179-91 [11248530.001]
  • [Cites] Neuropathol Appl Neurobiol. 2001 Jun;27(3):223-37 [11489142.001]
  • [Cites] J Clin Neurosci. 2002 Mar;9(2):165-9 [11922706.001]
  • [Cites] Curr Opin Oncol. 2002 May;14(3):299-307 [11981275.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Jul;61(7):575-84 [12125736.001]
  • [Cites] Ann Neurol. 2003 Oct;54(4):514-20 [14520665.001]
  • [Cites] Seizure. 2003 Dec;12(8):585-6 [14630498.001]
  • [Cites] Brain Topogr. 2003 Winter;16(2):85-93 [14977201.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jun 29;101(26):9861-6 [15210974.001]
  • [Cites] J Clin Psychiatry. 2004 Sep;65(9):1162-3 [15367040.001]
  • [Cites] Anal Biochem. 1985 Oct;150(1):76-85 [3843705.001]
  • [Cites] Hum Pathol. 1990 Mar;21(3):271-6 [2107138.001]
  • [Cites] J Neurosci. 1994 Sep;14(9):5223-35 [8083732.001]
  • [Cites] J Neuropathol Exp Neurol. 1995 Sep;54(5):689-97 [7666058.001]
  • [Cites] Acta Neuropathol. 1997 Nov;94(5):436-43 [9386775.001]
  • [Cites] Am J Surg Pathol. 1998 May;22(5):550-6 [9591724.001]
  • [Cites] AJNR Am J Neuroradiol. 1998 May;19(5):879-87 [9613504.001]
  • [Cites] Neuropathol Appl Neurobiol. 1998 Aug;24(4):302-8 [9775396.001]
  • [Cites] J Neurosci. 2006 Jan 25;26(4):1303-13 [16436618.001]
  • [Cites] Neurobiol Dis. 2006 Apr;22(1):64-75 [16309916.001]
  • [Cites] Eur J Pharmacol. 2006 Apr 24;536(1-2):102-8 [16556440.001]
  • [Cites] J Neurooncol. 2006 May;78(1):99-102 [16541329.001]
  • [Cites] Funct Neurol. 2006 Jan-Mar;21(1):15-9 [16734997.001]
  • [Cites] Neurobiol Dis. 2006 Oct;24(1):128-43 [16860990.001]
  • [Cites] J Neurosci. 2006 Oct 25;26(43):11083-110 [17065450.001]
  • [Cites] Neurotherapeutics. 2007 Jan;4(1):18-61 [17199015.001]
  • [Cites] Neurotherapeutics. 2007 Jan;4(1):84-7 [17199019.001]
  • [Cites] Neurotherapeutics. 2007 Jan;4(1):117-22 [17199025.001]
  • [Cites] Epilepsy Res. 2007 Apr;74(1):33-44 [17267178.001]
  • [Cites] Lancet Neurol. 2007 May;6(5):421-30 [17434097.001]
  • [Cites] Epilepsia. 2009 Mar;50(3):422-33 [18717715.001]
  • (PMID = 20167814.001).
  • [ISSN] 1523-5866
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Membrane Glycoproteins; 0 / Nerve Tissue Proteins; 148845-93-6 / SV2A protein, human
  • [Other-IDs] NLM/ PMC2940585
  •  go-up   go-down


51. Janicki-Deverts D, Cohen S, Doyle WJ: Cynical hostility and stimulated Th1 and Th2 cytokine production. Brain Behav Immun; 2010 Jan;24(1):58-63
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PHA-stimulated interleukin (IL)-2, tumor necrosis factor (TNF)-alpha, and interferon (IFN)-gamma were used to measure Th1 activity; PHA-stimulated IL-4, IL-5, and IL-10 were used to measure Th2 activity.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Health Psychol. 1988;7(5):447-59 [3215156.001]
  • [Cites] Psychosom Med. 2003 Jul-Aug;65(4):582-7 [12883108.001]
  • [Cites] Am J Cardiol. 1990 Feb 1;65(5):297-302 [2405620.001]
  • [Cites] Psychosom Med. 1991 Jan-Feb;53(1):36-49 [2011649.001]
  • [Cites] Health Psychol. 1991;10(1):18-24 [2026126.001]
  • [Cites] Psychophysiology. 1993 Nov;30(6):615-26 [8248453.001]
  • [Cites] Psychosom Med. 2003 Jul-Aug;65(4):652-7 [12883117.001]
  • [Cites] J Behav Med. 2003 Dec;26(6):501-15 [14677209.001]
  • [Cites] Psychoneuroendocrinology. 2004 Oct;29(9):1119-28 [15219635.001]
  • [Cites] Psychosom Med. 2004 Sep-Oct;66(5):629-32 [15385683.001]
  • [Cites] Am J Epidemiol. 1978 Sep;108(3):161-75 [707484.001]
  • [Cites] Ann Rheum Dis. 1999 Nov;58 Suppl 1:I121-8 [10577988.001]
  • [Cites] JAMA. 2000 May 17;283(19):2546-51 [10815118.001]
  • [Cites] BMJ. 2000 Jul 22;321(7255):199-204 [10903648.001]
  • [Cites] Circulation. 2001 Aug 14;104(7):746-9 [11502695.001]
  • [Cites] Am Heart J. 1986 Feb;111(2):383-90 [3946178.001]
  • [Cites] J Immunol. 1986 Apr 1;136(7):2348-57 [2419430.001]
  • [Cites] Health Psychol. 1985;4(6):503-20 [3830702.001]
  • [Cites] Psychol Rep. 1987 Aug;61(1):87-90 [3671626.001]
  • [Cites] Psychosom Med. 1994 Nov-Dec;56(6):519-25 [7871107.001]
  • [Cites] Psychol Bull. 1996 Mar;119(2):322-48 [8851276.001]
  • [Cites] JAMA. 1997 Jun 25;277(24):1940-4 [9200634.001]
  • [Cites] J Immunol. 1998 Feb 1;160(3):1514-21 [9570575.001]
  • [Cites] N Engl J Med. 1999 Jan 14;340(2):115-26 [9887164.001]
  • [Cites] Adv Exp Med Biol. 1999;461:25-46 [10442165.001]
  • [Cites] Am Psychol. 2004 Nov;59(8):676-84 [15554821.001]
  • [Cites] Annu Rev Public Health. 2005;26:469-500 [15760298.001]
  • [Cites] J Reprod Immunol. 2005 Aug;66(2):175-91 [16029895.001]
  • [Cites] Nat Rev Immunol. 2006 Jul;6(7):508-19 [16778830.001]
  • [Cites] Scand J Immunol. 2006 Sep;64(3):336-44 [16918703.001]
  • [Cites] Am Heart J. 2006 Nov;152(5):982.e7-13 [17070176.001]
  • [Cites] Arch Intern Med. 2007 Jan 22;167(2):174-81 [17242319.001]
  • [Cites] Brain Behav Immun. 2008 Jul;22(5):753-61 [18226879.001]
  • [Cites] Cardiovasc Res. 2008 Aug 1;79(3):360-76 [18487233.001]
  • [Cites] J Mol Cell Cardiol. 2008 Aug;45(2):168-75 [18502445.001]
  • [Cites] Nat Clin Pract Cardiovasc Med. 2008 Sep;5(9):531-40 [18607396.001]
  • [Cites] Brain Behav Immun. 2002 Dec;16(6):675-84 [12480498.001]
  • [Cites] Circ Res. 2001 Oct 26;89(9):763-71 [11679405.001]
  • [Cites] Arch Intern Med. 2009 Jan 12;169(1):62-7 [19139325.001]
  • [Cites] Am J Cardiol. 2003 Jan 15;91(2):133-6 [12521622.001]
  • [Cites] Circulation. 2003 Jan 28;107(3):363-9 [12551853.001]
  • [Cites] Circulation. 2003 Jan 28;107(3):499-511 [12551878.001]
  • [Cites] Psychosom Med. 2003 Jul-Aug;65(4):523-7 [12883100.001]
  • [Cites] Psychosom Med. 1989 Jan-Feb;51(1):46-57 [2928460.001]
  • (PMID = 19647069.001).
  • [ISSN] 1090-2139
  • [Journal-full-title] Brain, behavior, and immunity
  • [ISO-abbreviation] Brain Behav. Immun.
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / HL065112-01; United States / NHLBI NIH HHS / HL / P50 HL065112; None / None / / P50 HL065111-01; United States / NHLBI NIH HHS / HL / P50 HL065111; United States / NHLBI NIH HHS / HL / HL65112; United States / NHLBI NIH HHS / HL / P50 HL065112-01; United States / NHLBI NIH HHS / HL / HL65111; United States / NHLBI NIH HHS / HL / P50 HL065111-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Cytokines
  • [Other-IDs] NLM/ NIHMS135965; NLM/ PMC2787805
  •  go-up   go-down


52. Mastrangelo S, Lauriola L, Coccia P, Puma N, Massimi L, Riccardi R: Two cases of pediatric high-grade astroblastoma with different clinical behavior. Tumori; 2010 Jan-Feb;96(1):160-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Astroblastoma is a rare glial tumor occurring in older children and defined by histological criteria as low or high-grade.
  • The first patient, with multiple recurrences of a frontoparietal tumor, died 10 years from diagnosis after progression of the disease despite surgery, radiotherapy and chemotherapy.
  • The second patient underwent subtotal resection of a temporal mass; the residual tumor progressed five months after radiotherapy, but after a subsequent gross total resection the patient is now in complete remission 54 months from diagnosis.
  • Although both patients had high-grade astroblastomas, there were histological differences between the two tumors, in particular regarding the proliferative index, which was 30% and 5-10%, respectively.
  • High-grade astroblastoma is usually treated with surgery and radiotherapy, but may have an unpredictable behavior even when tumor excision is deemed complete.
  • The two cases reported here illustrate the variable clinical course of this rare tumor.
  • [MeSH-major] Brain Neoplasms / diagnosis. Brain Neoplasms / therapy. Cranial Irradiation. Neoplasms, Neuroepithelial / diagnosis. Neoplasms, Neuroepithelial / therapy
  • [MeSH-minor] Chemotherapy, Adjuvant. Child. Fatal Outcome. Female. Humans. Radiotherapy Dosage. Radiotherapy, Adjuvant. Treatment Outcome. Young Adult


53. Liu HE, Hsiao PY, Lee CC, Lee JA, Chen HY: NAT2*7 allele is a potential risk factor for adult brain tumors in Taiwanese population. Cancer Epidemiol Biomarkers Prev; 2008 Mar;17(3):661-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] NAT2*7 allele is a potential risk factor for adult brain tumors in Taiwanese population.
  • The association of NAT2 polymorphisms with adult brain tumors has been unclear.
  • To investigate whether the NAT2 genotype is a risk factor of brain tumors, we determined the frequencies of three common polymorphisms in the NAT2 gene, NAT2*5 (T341C), NAT2*6 (G590A), and NAT2*7(G857A), in brain tumor patients and in age- and gender-matched control subjects (n = 27 in each group).
  • The odds ratio of NAT2*7 allele frequency was significantly higher in patients with brain tumor than in controls (odds ratio, 6.786; 95% confidence interval, 2.06-22.37; P = 0.003); in the mean time, NAT2*4/*7 genotype was significantly more common in the patient group than in controls (odds ratio, 6.19; 95% confidence interval, 1.68-22.79; P = 0.0039).
  • The tumors in the patients with NAT2*7 allele tended to be high-grade astrocytoma or glioblastoma multiforme (P = 0.016).
  • In conclusion, these data suggest that the presence of NAT2*7 allele might be a potential risk factor for the development of brain tumors in Taiwan.
  • [MeSH-major] Arylamine N-Acetyltransferase / genetics. Brain Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18349284.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.3.1.5 / Arylamine N-Acetyltransferase; EC 2.3.1.5 / NAT2 protein, human
  •  go-up   go-down


54. Carpentino JE, Hartman NW, Grabel LB, Naegele JR: Region-specific differentiation of embryonic stem cell-derived neural progenitor transplants into the adult mouse hippocampus following seizures. J Neurosci Res; 2008 Feb 15;86(3):512-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Region-specific differentiation of embryonic stem cell-derived neural progenitor transplants into the adult mouse hippocampus following seizures.
  • Embryonic stem (ES) cells can generate neural progenitors and neurons in vitro and incorporate into the adult central nervous system (CNS) following transplantation, suggesting their therapeutic potential for treating neurological disorders.
  • However, our understanding of the conditions that direct ES-derived neural progenitor (ESNP) migration and differentiation within different regions of the adult CNS is incomplete.
  • To examine the potential for ESNPs to incorporate into the adult hippocampus and differentiate into hippocampal neurons or glia following seizure-induced damage, we compared the fates of ESNPs after they were transplanted into the CA3 region or fimbria 1 week following KA-induced seizures.
  • Hippocampal grafts in mice not subjected to seizures displayed a marked tendency to form tumors, and this effect was more pronounced in the DG than in the fimbria.
  • Taken together, these data suggest that seizures induce molecular changes in the CA3 region and DG that promote region-specific neural differentiation and suppress tumor formation.

  • MedlinePlus Health Information. consumer health - Seizures.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17918739.001).
  • [ISSN] 1097-4547
  • [Journal-full-title] Journal of neuroscience research
  • [ISO-abbreviation] J. Neurosci. Res.
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / R01 NS042826; United States / NINDS NIH HHS / NS / R01 NS042826-05; United States / NINDS NIH HHS / NS / NS42826
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Convulsants; 0 / Excitatory Amino Acid Agonists; SIV03811UC / Kainic Acid
  •  go-up   go-down


55. Nicholson HS, Kretschmar CS, Krailo M, Bernstein M, Kadota R, Fort D, Friedman H, Harris MB, Tedeschi-Blok N, Mazewski C, Sato J, Reaman GH: Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group. Cancer; 2007 Oct 1;110(7):1542-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group.
  • BACKGROUND: Effective chemotherapy is lacking for most types of central nervous system (CNS) tumors in children.
  • Temozolomide, an agent with activity against adult brain tumors, was investigated in children and adolescents with recurrent CNS tumors.
  • RESULTS: The cohort comprised 122 patients, including 113 with CNS tumors.
  • Among 104 evaluable patients with CNS tumors, 5 PRs and 1 CR were observed.
  • PRs occurred in 1 of 23 evaluable patients with high-grade astrocytoma, 1 of 21 with low-grade astrocytoma, and 3 of 25 with medulloblastoma/primitive neuroectodermal tumor (PNET).
  • No responses were observed in patients with ependymoma, brain-stem glioma, or other CNS tumors.
  • CONCLUSIONS: Although overall objective responses were limited, further exploration of temozolomide may be warranted in children with medulloblastoma and other PNETs, or in patients with low-grade astrocytoma, perhaps in a setting of less pretreatment than the patients in the current study, or in the context of multiagent therapy.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Brain Neoplasms / drug therapy. Dacarbazine / analogs & derivatives. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Administration, Oral. Adolescent. Adult. Astrocytoma / drug therapy. Central Nervous System Neoplasms / drug therapy. Child. Child, Preschool. Drug Administration Schedule. Ependymoma / drug therapy. Female. Humans. Infant. Male. Medulloblastoma / drug therapy. Neuroectodermal Tumors, Primitive / drug therapy. Treatment Outcome


56. Pang LJ, Chang B, Zou H, Qi Y, Jiang JF, Li HA, Hu WH, Chen YZ, Liu CX, Zhang WJ, Li F: Alveolar soft part sarcoma: a bimarker diagnostic strategy using TFE3 immunoassay and ASPL-TFE3 fusion transcripts in paraffin-embedded tumor tissues. Diagn Mol Pathol; 2008 Dec;17(4):245-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alveolar soft part sarcoma: a bimarker diagnostic strategy using TFE3 immunoassay and ASPL-TFE3 fusion transcripts in paraffin-embedded tumor tissues.
  • A specific chromosomal translocation, t(X;17)(p11.2;q25), results in the ASPL-TFE3 fusion gene: it is detectable using reverse-transcription polymerase chain reaction (RT-PCR) in frozen tumor tissues of ASPS.
  • Their tumors presented predominantly in the extremities (8/16), and were often located in the region of the orbit when affecting infants and children (3/16).
  • Others had tumors in the chest wall, breast, and right pubis, respectively.
  • One patient exhibited a tumor in the renal hilum, a location that had not been previously reported.
  • Two patients had tumor metastases in the lung and the brain.
  • ASPS tumors showed the best immunoreactivity to the TFE3 antibody (16/16).
  • However, their immunoreactivity to other antibodies, including myoglobin (13/16), actin (10/16), desmin (2/16), and vimentin (2/16), was of various degrees.
  • Using a strategy of RT-PCR, followed by a nested PCR with a different primer set, we were able to detect the expression of the chimeric ASPL-TFE3 mRNA in 11 of the 16 ASPS tumors.
  • Of these 11, 7 were type 1 ASPL-TFE3 and 4 were type 2 ASPL-TFE3, including the tumor located in the renal hilum.
  • No expression of ASPL-TFE3 fusion transcripts was detectable in all 38 control tumors.
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Female. Humans. Immunoassay / methods. Male. Middle Aged. Polymerase Chain Reaction / methods. Reverse Transcriptase Polymerase Chain Reaction / methods. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Alveolar Soft Part Sarcoma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18382356.001).
  • [ISSN] 1533-4066
  • [Journal-full-title] Diagnostic molecular pathology : the American journal of surgical pathology, part B
  • [ISO-abbreviation] Diagn. Mol. Pathol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ASPSCR1 protein, human; 0 / Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; 0 / Oncogene Proteins, Fusion; 0 / RNA Precursors; 0 / TFE3 protein, human
  •  go-up   go-down


57. Shenkier TN, Blay JY, O'Neill BP, Poortmans P, Thiel E, Jahnke K, Abrey LE, Neuwelt E, Tsang R, Batchelor T, Harris N, Ferreri AJ, Ponzoni M, O'Brien P, Rubenstein J, Connors JM: Primary CNS lymphoma of T-cell origin: a descriptive analysis from the international primary CNS lymphoma collaborative group. J Clin Oncol; 2005 Apr 1;23(10):2233-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To describe the demographic and tumor related characteristics and outcomes for patients with primary T-cell CNS lymphoma (TPCNSL).
  • Twenty-six (58%) had involvement of a cerebral hemisphere and sixteen (36%) had lesions of deeper sites in the brain.
  • [MeSH-major] Central Nervous System Neoplasms / pathology. Lymphoma, T-Cell / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antimetabolites, Antineoplastic / therapeutic use. Child. Child, Preschool. Cohort Studies. Female. Health Status. Humans. Male. Methotrexate / therapeutic use. Middle Aged. Multivariate Analysis. Prognosis. Retrospective Studies. Survival Analysis

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15800313.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


58. Jung TY, Jung S, Kim IY, Park SJ, Kang SS, Kim SH, Lim SC: Application of neuronavigation system to brain tumor surgery with clinical experience of 420 cases. Minim Invasive Neurosurg; 2006 Aug;49(4):210-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Application of neuronavigation system to brain tumor surgery with clinical experience of 420 cases.
  • Herein, we report our clinical experience using a neuronavigation system with different surgical applications and techniques for a variety of brain tumors.
  • We operated on 420 cases having various types of brain tumor with the help of this system.
  • We utilized this system to effectively make bone flaps, to detect critically located, deep-seated, subcortical, skull-base and skull bone tumors, and to operate on intraparenchymal lesions with grossly unclear margins, such as gliomas.
  • We also performed tumor biopsy using the combination of a conventional stereotactic biopsy instrument and an endoscope.
  • [MeSH-major] Brain / surgery. Brain Neoplasms / diagnosis. Brain Neoplasms / surgery. Monitoring, Intraoperative / methods. Neuronavigation / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biopsy / instrumentation. Biopsy / methods. Child. Child, Preschool. Cranial Sinuses / anatomy & histology. Cranial Sinuses / surgery. Craniotomy / methods. Endoscopy / methods. Female. Humans. Infant. Intraoperative Complications / prevention & control. Magnetic Resonance Imaging / instrumentation. Magnetic Resonance Imaging / methods. Male. Middle Aged. Predictive Value of Tests. Preoperative Care / instrumentation. Preoperative Care / methods. Skull / anatomy & histology. Skull / surgery. Tomography, X-Ray Computed / instrumentation. Tomography, X-Ray Computed / methods

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17041831.001).
  • [ISSN] 0946-7211
  • [Journal-full-title] Minimally invasive neurosurgery : MIN
  • [ISO-abbreviation] Minim Invasive Neurosurg
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


59. Emmer BJ, van der Bijl AE, Huizinga TW, Breedveld FC, Steens SC, Th Bosma GP, van Buchem MA, van der Grond J: Brain involvement in rheumatoid arthritis: a magnetic resonance spectroscopy study. Arthritis Rheum; 2009 Nov;60(11):3190-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brain involvement in rheumatoid arthritis: a magnetic resonance spectroscopy study.
  • OBJECTIVE: Tumor necrosis factor alpha was recently implicated as an important mediator of communication between the peripheral and cerebral immune systems in an animal model of chronic inflammation.
  • CONCLUSION: Our data show that systemic inflammation in RA is associated with metabolic changes in the brain.
  • [MeSH-major] Arthritis, Rheumatoid / metabolism. Arthritis, Rheumatoid / pathology. Brain / metabolism. Brain / pathology
  • [MeSH-minor] Adult. Aged. Aspartic Acid / analogs & derivatives. Aspartic Acid / metabolism. Blood Sedimentation. Case-Control Studies. Choline / metabolism. Creatine / metabolism. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Severity of Illness Index


60. Law M, Oh S, Johnson G, Babb JS, Zagzag D, Golfinos J, Kelly PJ: Perfusion magnetic resonance imaging predicts patient outcome as an adjunct to histopathology: a second reference standard in the surgical and nonsurgical treatment of low-grade gliomas. Neurosurgery; 2006 Jun;58(6):1099-107; discussion 1099-107
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To determine whether relative cerebral blood volume (rCBV) can predict patient outcome, specifically tumor progression, in low-grade gliomas (LGGs) and thus provide a second reference standard in the surgical and postsurgical management of LGGs.
  • Tumor volumes and CBV measurements were obtained at the initial examination and again at follow-up to determine the association of rCBV with tumor volume progression.
  • Lesions with low baseline rCBV (< 1.75) demonstrated stable tumor volumes when followed up over time, and lesions with high baseline rCBV (> 1.75) demonstrated progressively increasing tumor volumes over time.
  • [MeSH-major] Astrocytoma / therapy. Brain Neoplasms / therapy. Magnetic Resonance Imaging. Oligodendroglioma / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Blood Volume. Cerebrovascular Circulation. Child. Child, Preschool. Disease Progression. Female. Humans. Male. Middle Aged. Predictive Value of Tests. Reference Standards. Survival Analysis. Treatment Outcome


61. Xiangsong Z, Xinjian W, Yong Z, Weian C: 13N-NH3: a selective contrast-enhancing tracer for brain tumor. Nucl Med Commun; 2008 Dec;29(12):1052-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 13N-NH3: a selective contrast-enhancing tracer for brain tumor.
  • PURPOSE: The purpose of this study is to determine whether there is a qualitative and quantitative relationship between the breakdown of the blood-brain barrier, defined radiologically by the contrast enhancement of MRI, and the uptake of N-NH3 in brain tumors.
  • METHODS: The results of N-NH3 PET in 42 patients suspected of having brain tumors were compared with the findings of contrast-enhanced MRI.
  • RESULTS: Contrast enhancement of MRIs was seen in 20 of 29 brain tumors (69%).
  • Increased uptake of N-NH3 was seen in 24 of 29 brain tumors (83%).
  • Nineteen of 20 contrast-enhancing brain tumors exhibited the increased uptake of N-NH3 (95%).
  • Five out of nine nonenhancing tumors exhibited increased uptake of N-NH3 (56%).
  • None of the nonneoplastic lesions showed increased uptake of N-NH3, yielding a specificity of 100% for brain tumors (0 of 13).
  • CI for tumor tissue was 1.46+/-0.64.
  • UI of N-NH3 for tumor tissue was 1.64+/-0.71.
  • CI and UI for tumor tissue were significantly correlated (r=0.86, P<0.01).
  • A statistically significant difference in uptake levels of N-NH3 between contrast-enhancing tumors and nonenhancing tumors (1.88+/-0.66, n=20 vs. 1.11+/-0.52, n=9, P<0.01) was observed.
  • UI was higher in brain tumors compared with the nonneoplastic lesions (1.64+/-0.71 vs. 0.71+/-0.19, P<0.01).
  • CONCLUSION: N-NH3 is a potential selective contrast-enhanced tracer for brain tumor, and may prove especially useful for evaluating the contrast-enhancing lesions on MRI to distinguish brain tumors from nonneoplastic lesions.
  • [MeSH-major] Brain Neoplasms / diagnosis. Contrast Media. Quaternary Ammonium Compounds / chemistry
  • [MeSH-minor] Adolescent. Adult. Aged. Astrocytoma / diagnosis. Astrocytoma / metabolism. Astrocytoma / pathology. Astrocytoma / radionuclide imaging. Blood-Brain Barrier / metabolism. Child. Female. Glioblastoma / diagnosis. Glioblastoma / metabolism. Glioblastoma / pathology. Glioblastoma / radionuclide imaging. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Nitrogen Radioisotopes / chemistry. Positron-Emission Tomography. Radioactive Tracers. Sensitivity and Specificity. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18987525.001).
  • [ISSN] 0143-3636
  • [Journal-full-title] Nuclear medicine communications
  • [ISO-abbreviation] Nucl Med Commun
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Nitrogen Radioisotopes; 0 / Quaternary Ammonium Compounds; 0 / Radioactive Tracers
  •  go-up   go-down


62. Zhou W, Jiang Z, Li X, Xu F, Liu Y, Wen P, Kong L, Hou M, Yu J: EMP3 overexpression in primary breast carcinomas is not associated with epigenetic aberrations. J Korean Med Sci; 2009 Feb;24(1):97-103
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, no significant correlations were found between methylation status of EMP3 and mRNA expression levels as well as other clinical parameters.
  • In conclusion, EMP3 may be a novel marker of tumor aggressiveness.
  • [MeSH-major] Breast Neoplasms / genetics. Carcinoma / genetics. Membrane Glycoproteins / genetics
  • [MeSH-minor] Adult. DNA Methylation. Epigenesis, Genetic. Female. Gene Expression Regulation, Neoplastic. Humans. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. RNA, Messenger / metabolism. Receptor, ErbB-2 / genetics. Receptor, ErbB-2 / metabolism. Severity of Illness Index

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anticancer Res. 1997 Jan-Feb;17(1A):13-20 [9066625.001]
  • [Cites] Gene. 1996 Dec 12;183(1-2):69-75 [8996089.001]
  • [Cites] Genomics. 1998 May 1;49(3):443-7 [9615230.001]
  • [Cites] Hum Hered. 2004;57(4):172-8 [15583422.001]
  • [Cites] Cancer Res. 2005 Apr 1;65(7):2565-71 [15805250.001]
  • [Cites] BMC Cancer. 2006;6:48 [16512896.001]
  • [Cites] Int J Cancer. 2007 Feb 15;120(4):947-50 [17187361.001]
  • [Cites] Brain Pathol. 2007 Oct;17(4):363-70 [17610521.001]
  • [Cites] J Korean Med Sci. 2007 Sep;22 Suppl:S24-31 [17923751.001]
  • [Cites] J Neurosci Res. 1999 Dec 1;58(5):624-31 [10561690.001]
  • [Cites] Oncogene. 2001 May 28;20(24):3139-55 [11420731.001]
  • [Cites] Nucleic Acids Res. 2001 Jul 1;29(13):E65-5 [11433041.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • [Cites] J Biol Chem. 2002 Sep 13;277(37):34017-23 [12107182.001]
  • [Cites] Oncogene. 2003 May 1;22(17):2680-8 [12730682.001]
  • [Cites] Tumour Biol. 2003 Aug-Sep;24(4):189-98 [14654713.001]
  • [Cites] Biochem Biophys Res Commun. 1985 Jul 16;130(1):118-26 [2992457.001]
  • [Cites] Gene. 1996 Oct 10;175(1-2):115-20 [8917086.001]
  • [Cites] Adv Cancer Res. 1998;72:141-96 [9338076.001]
  • (PMID = 19270820.001).
  • [ISSN] 1598-6357
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / EMP3 protein, human; 0 / Membrane Glycoproteins; 0 / RNA, Messenger; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2
  • [Other-IDs] NLM/ PMC2650972
  • [Keywords] NOTNLM ; Breast Neoplasms / DNA Methylation / Epigenetics, Genetic / Metastasis / PMP22/EMP/MP20 Gene Family
  •  go-up   go-down


63. Ochiai N, Masumoto S, Sakagami H, Yoshimura Y, Yamauchi T: Rat leucine-rich protein binds and activates the promoter of the beta isoform of Ca2+/calmodulin-dependent protein kinase II gene. Neurosci Res; 2007 May;58(1):67-76
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We previously found the neuronal cell-type specific promoter and binding partner of the beta isoform of Ca(2+)/calmodulin-dependent protein kinase II (beta CaM kinase II) in rat brain [Donai, H., Morinaga, H., Yamauchi, T., 2001.
  • Genomic organization and neuronal cell type specific promoter activity of beta isoform of Ca(2+)/calmodulin-dependent protein kinase II of rat brain. Mol. Brain Res. 94, 35-47].
  • The expression of rLRP157 mRNA was paralleled with that of beta CaM kinase II in the adult and embryo rat brain detected by in situ hybridization.
  • [MeSH-minor] Animals. Binding Sites / genetics. Brain / enzymology. Brain / growth & development. Calcium-Calmodulin-Dependent Protein Kinase Type 2. Cell Nucleus / enzymology. Cell Nucleus / genetics. Gene Expression Regulation, Enzymologic / genetics. Genes, Reporter / genetics. Hybridomas. Luciferases / genetics. Mice. Protein Binding / genetics. Rats. Tandem Mass Spectrometry. Transfection. Tumor Cells, Cultured. Up-Regulation / genetics

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17339062.001).
  • [ISSN] 0168-0102
  • [Journal-full-title] Neuroscience research
  • [ISO-abbreviation] Neurosci. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / LRP157 protein, rat; 0 / RNA-Binding Proteins; EC 1.13.12.- / Luciferases; EC 2.7.11.17 / Calcium-Calmodulin-Dependent Protein Kinase Type 2; EC 2.7.11.17 / Calcium-Calmodulin-Dependent Protein Kinases; EC 2.7.11.17 / Camk2b protein, mouse; EC 2.7.11.17 / Camk2b protein, rat
  •  go-up   go-down


64. DiLuna ML, Two AM, Levy GH, Patel T, Huttner AJ, Duncan CC, Piepmeier JM: Primary, non-exophytic, optic nerve germ cell tumors. J Neurooncol; 2009 Dec;95(3):437-443
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary, non-exophytic, optic nerve germ cell tumors.
  • Tumors of the optic chiasm are relatively uncommon and usually associated with phakomatoses such as neurofibromatosis.
  • Even more rare is the presentation of a primary, non-exophytic, isolated optic chiasm germ cell tumor (GCT).
  • These tumors have imaging characteristics nearly indistinguishable from optic chiasmatic gliomas (OCGs).
  • Brain imaging was non-diagnostic and suggestive of an OCG.
  • This case series highlights the importance of tissue biopsy for patients with progressive symptoms from optic chiasm tumors.
  • [MeSH-major] Magnetic Resonance Imaging. Neoplasms, Germ Cell and Embryonal / pathology. Optic Chiasm / pathology. Optic Nerve Neoplasms / pathology
  • [MeSH-minor] Biopsy. Child. Craniotomy. Diabetes Insipidus / pathology. Diabetes Insipidus / surgery. Diabetes Insipidus / therapy. Humans. Male. Young Adult

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurooncol. 1998 May;37(3):229-39 [9524081.001]
  • [Cites] Neurosurgery. 1996 Jun;38(6):1114-8; discussion 1118-9 [8727140.001]
  • [Cites] J Neurooncol. 2004 Jun;68(2):153-9 [15218952.001]
  • [Cites] Br J Cancer. 1999 Mar;79(7-8):1199-204 [10098759.001]
  • [Cites] J Neurosurg. 1999 Feb;90(2):258-64 [9950496.001]
  • [Cites] Neurol Med Chir (Tokyo). 2000 Jan;40 Suppl:1-106 [10732440.001]
  • [Cites] Curr Treat Options Oncol. 2006 Nov;7(6):467-78 [17032559.001]
  • [Cites] Pediatr Neurol. 2002 May;26(5):369-73 [12057797.001]
  • [Cites] Oncologist. 2008 Jun;13(6):690-9 [18586924.001]
  • [Cites] Noshuyo Byori. 1996 Nov;13(2):95-8 [8958513.001]
  • [Cites] Pediatr Neurosurg. 1995;23(1):1-5; discussion 6 [7495660.001]
  • [Cites] Oncologist. 2000;5(4):312-20 [10964999.001]
  • [Cites] Neurol Med Chir (Tokyo). 2003 Sep;43 Suppl:i-vii, 1-111 [14705327.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]
  • [Cites] Pediatr Neurol. 2003 Apr;28(4):262-70 [12849878.001]
  • [Cites] Eur J Cancer. 1998 Jan;34(1):104-10 [9624246.001]
  • [Cites] J Neurosurg. 1997 Mar;86(3):446-55 [9046301.001]
  • [Cites] Curr Neurol Neurosci Rep. 2004 May;4(3):253-62 [15102352.001]
  • [Cites] J Neurooncol. 2004 Jan;66(1-2):225-40 [15015791.001]
  • [Cites] J Clin Oncol. 2004 Mar 1;22(5):846-53 [14990640.001]
  • [Cites] J Clin Neurosci. 2004 Jun;11(5):559-61 [15177413.001]
  • [Cites] Radiol Clin North Am. 1999 Jan;37(1):59-71, ix [10026729.001]
  • [Cites] Brain Pathol. 1997 Apr;7(2):799-806 [9161730.001]
  • [Cites] J Clin Neuroophthalmol. 1990 Mar;10(1):9-17 [2139058.001]
  • [Cites] Klin Padiatr. 2004 May-Jun;216(3):141-9 [15175958.001]
  • [Cites] Bull Soc Ophtalmol Fr. 1988 Jan;88(1):145-8 [3168113.001]
  • [Cites] Br J Cancer. 2005 Aug 22;93(4):412-7 [16106248.001]
  • (PMID = 19554263.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


65. Pan HC, Sun MH, Chen CC, Chen CJ, Lee CH, Sheehan J: Neuroimaging and quality-of-life outcomes in patients with brain metastasis and peritumoral edema who undergo Gamma Knife surgery. J Neurosurg; 2008 Dec;109 Suppl:90-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neuroimaging and quality-of-life outcomes in patients with brain metastasis and peritumoral edema who undergo Gamma Knife surgery.
  • OBJECT: Gamma Knife surgery (GKS) has been shown to be effective for treating many patients with brain metastasis.
  • Some brain metastases demonstrate significant peritumoral edema; radiation may induce cerebral edema or worsening preexisting edema.
  • METHODS: Between August 2003 and January 2008, 63 cases of brain metastasis with significant peritumoral edema (> 20 cm(3)) were prospectively studied.
  • A neurological assessment and Brain Cancer Module (BCM-20) questionnaire were obtained every 2-3 months.
  • The mean tumor volume (+/- standard deviation) was 5.2 +/- 4.6 cm(3) with corresponding T2-weighted imaging and FLAIR volumes of 59.25 +/- 37.3 and 62.1 +/- 38.8 cm(3), respectively (R(2) = 0.977, p < 0.001).
  • The mean edema index (volume of peritumoral edema/tumor volume) was 17.5 +/- 14.5.
  • The longer survival was related to KPS scores >or= 70 (p = 0.008), age < 65 years (p = 0.022), and a reduction of > 6 in BCM-20 score (p = 0.007), but survival was not related to preexisting edema or tumor volume.
  • Thirty-eight (79.2%) of 48 patients demonstrated decreased tumor volume and accompanied by decreased T2-weighted imaging and FLAIR volume.
  • Eight (16.7%) of the 48 patients exhibited increased or stable tumor volume.
  • A margin dose > 18 Gy was more likely to afford tumor reduction and resolution of peritumoral edema (p = 0.005 and p = 0.006, respectively).
  • Significant preexisting edema did not influence the tumor response or clinical outcome.
  • [MeSH-major] Brain Edema / pathology. Brain Edema / surgery. Brain Neoplasms / surgery. Carcinoma / surgery. Quality of Life. Radiosurgery
  • [MeSH-minor] Adult. Aged. Cohort Studies. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Retrospective Studies. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Edema.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19123894.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


66. Romano A, Fasoli F, Ferrante M, Ferrante L, Fantozzi LM, Bozzao A: Fiber density index, fractional anisotropy, adc and clinical motor findings in the white matter of patients with glioblastoma. Eur Radiol; 2008 Feb;18(2):331-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The FDi, FA and ADC values were calculated in areas of white matter in close proximity to the tumor (perWM) and encompassing fibers of cortico-spinal tract and in the contralateral normal-appearing white matter (nWM).
  • [MeSH-major] Brain / pathology. Brain / physiopathology. Brain Neoplasms / diagnosis. Diffusion Magnetic Resonance Imaging / methods. Glioblastoma / diagnosis. Nerve Fibers / pathology
  • [MeSH-minor] Adult. Aged. Anisotropy. Brain Mapping / methods. Contrast Media / administration & dosage. Female. Functional Laterality. Humans. Image Enhancement / methods. Male. Meglumine. Middle Aged. Observer Variation. Organometallic Compounds. Paresis / diagnosis. Pyramidal Tracts / physiopathology. Reproducibility of Results

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AJNR Am J Neuroradiol. 2007 Mar;28(3):462-9 [17353313.001]
  • [Cites] AJNR Am J Neuroradiol. 2006 Aug;27(7):1426-31 [16908551.001]
  • [Cites] AJNR Am J Neuroradiol. 2003 May;24(5):937-41 [12748097.001]
  • [Cites] AJNR Am J Neuroradiol. 2005 Oct;26(9):2183-6 [16219820.001]
  • [Cites] Clin Radiol. 2003 Jun;58(6):455-62 [12788314.001]
  • [Cites] Surg Neurol. 2005 Jan;63(1):56-61; discussion 61 [15639528.001]
  • [Cites] J Magn Reson Imaging. 2004 Jan;19(1):6-18 [14696215.001]
  • [Cites] NMR Biomed. 2002 Nov-Dec;15(7-8):468-80 [12489096.001]
  • [Cites] J Neurooncol. 2005 Jun;73(2):137-44 [15981104.001]
  • [Cites] Eur J Radiol. 2005 Nov;56(2):197-204 [15916876.001]
  • [Cites] J Magn Reson Imaging. 2001 Apr;13(4):534-46 [11276097.001]
  • [Cites] Phys Ther. 1966 Apr;46(4):357-75 [5907254.001]
  • [Cites] J Magn Reson Imaging. 2004 Oct;20(4):555-62 [15390227.001]
  • [Cites] Radiology. 2004 Jul;232(1):221-8 [15220505.001]
  • [Cites] Radiology. 2004 Aug;232(2):451-60 [15215555.001]
  • [Cites] AJNR Am J Neuroradiol. 2005 Apr;26(4):791-6 [15814922.001]
  • [Cites] Eur Radiol. 2007 Jul;17(7):1675-84 [17219140.001]
  • (PMID = 17899109.001).
  • [ISSN] 0938-7994
  • [Journal-full-title] European radiology
  • [ISO-abbreviation] Eur Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Organometallic Compounds; 6HG8UB2MUY / Meglumine; L0ND3981AG / gadoterate meglumine
  •  go-up   go-down


67. Miyata S, Sugimoto T, Kodama T, Akiyama Y, Nakano S, Wakisaka S, Itoh H, Kataoka H: Adenoid glioblastoma arising in a patient with neurofibromatosis type-1. Pathol Int; 2005 Jun;55(6):348-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • From the neuroradiological findings the patient was diagnosed as having glioblastoma, and the tumor was surgically resected.
  • Histologically, the tumor consisted mainly of dark basophilic cells showing prominent tubular or glandular structures surrounded by large eosinophilic cells, in addition to the typical glioblastoma features in the periphery of the tumor.
  • Both cells showed strong stainability with glial fibrillary acidic protein (GFAP) and S-100 protein immunohistochemically, so that the tumor was classified as adenoid glioblastoma.
  • The patients with NF1 are prone to develop malignant tumors including glioblastoma, but no cases representing adenoid glioblastoma associated with NF1 have been reported.
  • The recognition of the existence of epithelial features of glioblastoma would be important in differential diagnosis of epithelioid tumors of the brain including metastatic carcinomas.
  • [MeSH-major] Brain Neoplasms / pathology. Glioblastoma / pathology. Neurofibromatosis 1 / pathology
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Glial Fibrillary Acidic Protein / analysis. Headache / etiology. Humans. Immunohistochemistry. Magnetic Resonance Imaging. Nausea / etiology. S100 Proteins / analysis. Vomiting / etiology


68. Johansson A, Palte G, Schnell O, Tonn JC, Herms J, Stepp H: 5-Aminolevulinic acid-induced protoporphyrin IX levels in tissue of human malignant brain tumors. Photochem Photobiol; 2010 Nov-Dec;86(6):1373-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 5-Aminolevulinic acid-induced protoporphyrin IX levels in tissue of human malignant brain tumors.
  • Protoporphyrin IX (PpIX) produced from exogenous, orally administered 5-aminolevulinic acid (ALA) displays high tumor-selective uptake and is being successfully employed for fluorescence-guided resection (FGR) of human malignant gliomas.
  • Furthermore, the phototoxicity of PpIX can be utilized for photodynamic therapy (PDT) of brain tumors, which has been shown previously.
  • Here, the absolute PpIX concentration in human brain tissue was investigated following oral ALA administration (20 mg kg(-1) b.w.).
  • The PpIX concentration was significantly higher in vital grade IV tumors (5.8 ± 4.8 μm, mean ± SD, range 0-28.2 μm, n = 8) as compared with grade III tumors (0.2 ± 0.4 μm, mean ± SD, range 0-0.9 μm, n = 4).
  • There was also a large heterogeneity within grade IV tumors with PpIX displaying significantly lower levels in infiltration zones and necrotic regions as compared with vital tumor parts.
  • The average PpIX concentration in vital grade IV tumor parts was in the range previously shown sufficient for PDT-induced tissue damage following irradiation.
  • However, the feasibility of PDT for grade III brain tumors and for grade IV brain tumors displaying mainly necrotic tissue areas without solid tumor parts needs to be further investigated.
  • [MeSH-major] Aminolevulinic Acid. Brain Neoplasms / diagnosis. Protoporphyrins / metabolism
  • [MeSH-minor] Administration, Oral. Adult. Aged. Female. Glioblastoma / diagnosis. Glioblastoma / drug therapy. Glioblastoma / metabolism. Glioblastoma / surgery. Glioma / diagnosis. Glioma / drug therapy. Glioma / metabolism. Glioma / surgery. Humans. Male. Middle Aged. Photochemotherapy. Photosensitizing Agents / administration & dosage

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 The Authors. Journal Compilation. The American Society of Photobiology.
  • (PMID = 20854414.001).
  • [ISSN] 1751-1097
  • [Journal-full-title] Photochemistry and photobiology
  • [ISO-abbreviation] Photochem. Photobiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 0 / Protoporphyrins; 553-12-8 / protoporphyrin IX; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


69. Narayana A, Kelly P, Golfinos J, Parker E, Johnson G, Knopp E, Zagzag D, Fischer I, Raza S, Medabalmi P, Eagan P, Gruber ML: Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival. J Neurosurg; 2009 Jan;110(1):173-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A possible change in the invasiveness of the tumor following therapy is worrisome and must be closely monitored.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Antibodies, Monoclonal / therapeutic use. Brain Neoplasms / drug therapy. Glioma / drug therapy. Neovascularization, Pathologic / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Antibodies, Monoclonal, Humanized. Bevacizumab. Disease Progression. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Patient Compliance. Prospective Studies. Survival Analysis. Young Adult

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18834263.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 2S9ZZM9Q9V / Bevacizumab
  •  go-up   go-down


70. Greenfield JP, Jin DK, Young LM, Christos PJ, Abrey L, Rafii S, Gutin PH: Surrogate markers predict angiogenic potential and survival in patients with glioblastoma multiforme. Neurosurgery; 2009 May;64(5):819-26; discussion 826-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: The neovascularization of malignant brain tumors is a poorly understood phenomenon.
  • Circulating endothelial progenitor cells are unique vascular precursors recruited from the bone marrow through the circulation to form new tumor blood vessels.
  • We hypothesized that this might reflect the extent of tumor vascularity, predict prognosis, or be useful as an assay to assess response to antiangiogenesis therapies.
  • In addition, all patients with GBM had measurable numbers of bone marrow-derived endothelial precursor cells coexpressing CD133 and vascular endothelial growth factor receptor 2 in their peripheral circulation at the time of tumor resection.
  • CONCLUSION: These studies suggest that plasma and circulating CD133+ vascular endothelial growth factor receptor 2+ proangiogenic cells are present in the peripheral blood of patients with glioma and can be used as a surrogate biomarker to measure tumor angiogenicity.
  • These assays can be used to predict tumor aggressiveness.
  • Also promising is their potential to identify patients with increased angiogenic activity who might respond maximally to antiangiogenesis therapies or to assess tumor response in patients using those therapies as the use of these adjuvant molecular modalities becomes more prevalent in neuro-oncology.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Brain Neoplasms / blood. Glioblastoma / blood. Neovascularization, Pathologic / blood
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, CD / metabolism. Biological Assay / methods. Endothelial Cells / metabolism. Endothelial Cells / pathology. Enzyme-Linked Immunosorbent Assay / methods. Female. Flow Cytometry. Follow-Up Studies. Glycoproteins / metabolism. Humans. Male. Middle Aged. Peptides / metabolism. Stem Cells / metabolism. Stem Cells / pathology. Umbilical Veins / pathology. Vascular Endothelial Growth Factor Receptor-2 / metabolism


71. Wang SJ, Choi M, Fuller CD, Salter BJ, Fuss M: Intensity-modulated Radiosurgery for patients with brain metastases: a mature outcomes analysis. Technol Cancer Res Treat; 2007 Jun;6(3):161-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intensity-modulated Radiosurgery for patients with brain metastases: a mature outcomes analysis.
  • The purpose of this study was to evaluate the outcomes of patients with brain metastases treated by tomotherapeutic Intensity-modulated Radiosurgery (IMRS).
  • Using retrospective chart review, we analyzed the outcomes of 78 patients (age 33-83 years, median 57 years) who underwent 111 sessions of IMRS (1 to 7 sessions per patient, median 1) for brain metastases (1 to 4 targets per IMRS session, median 1) treated between 2000 and 2005 using a serial tomotherapeutic intensity-modulated radiotherapy treatment (IMRT) planning and delivery system (Peacock, Nomos Corp., Cranberry Township, PA).
  • To determine the effects of prognostic variables on survival, univariate and multivariate analyses using proportional hazards were performed to assess the effects of age, tumor size, the combination with whole brain irradiation, presence of multiple brain metastases, and presence of extracranial disease.
  • We conclude that tomotherapeutic IMRS is safe and effective to treat patients with brain metastases.
  • [MeSH-major] Brain Neoplasms / secondary. Brain Neoplasms / surgery. Radiosurgery / instrumentation. Radiotherapy, Intensity-Modulated / instrumentation
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17535023.001).
  • [ISSN] 1533-0346
  • [Journal-full-title] Technology in cancer research & treatment
  • [ISO-abbreviation] Technol. Cancer Res. Treat.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


72. Hazrati SM, Aghazadeh J, Mohtarami F, Abouzari M, Rashidi A: Immunotherapy of prolactinoma with a T helper 1 activator adjuvant and autoantigens: a case report. Neuroimmunomodulation; 2006;13(4):205-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To date, efforts to reliably manipulate the immune system to promote tumor regression in the brain have been disappointing.
  • METHODS: A 31-year-old woman with an established history of pituitary macroprolactinoma who had undergone tumor resection followed by radiation was admitted to our clinic.
  • The diagnosis had been made due to the patient's symptoms, a serum prolactin (PRL) level of 29,600 mIU/l, a brain MRI revealing a 23 x 19 x 18 mm pituitary mass and a positive PRL immunohistochemistry of the mass.
  • Brain MRI revealed a pituitary mass (3 x 6 x 8 mm) compatible with a pituitary adenoma.
  • A follow-up brain MRI revealed almost complete disappearance of the tumor.
  • CONCLUSION: Activation of both nonspecific (natural killer cells) and specific (cytotoxic T lymphocytes) immunity in relation to the T helper 1 cytokine network is a promising strategy for the treatment of tumors of the central nervous system in humans, especially pituitary macroprolactinomas.
  • [MeSH-major] Adjuvants, Immunologic / therapeutic use. Autoantigens / immunology. Immunotherapy / methods. Pituitary Neoplasms / therapy. Prolactinoma / therapy. Th1 Cells / immunology
  • [MeSH-minor] Adult. Bromocriptine / therapeutic use. Female. Hormone Antagonists / therapeutic use. Humans. Lymphocyte Activation / immunology. Magnetic Resonance Imaging. Neoplasm Recurrence, Local / therapy. Prolactin / blood

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17337912.001).
  • [ISSN] 1021-7401
  • [Journal-full-title] Neuroimmunomodulation
  • [ISO-abbreviation] Neuroimmunomodulation
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Autoantigens; 0 / Hormone Antagonists; 3A64E3G5ZO / Bromocriptine; 9002-62-4 / Prolactin
  •  go-up   go-down


73. Cui W, Wu R, Cao H, Gao J, Wang X, Ren Q: P53 gene mutation and expression of MDM2, P53, P16 protein and their relationship in human glioma. J Huazhong Univ Sci Technolog Med Sci; 2005;25(6):622-4, 635
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To investigate the effect of P53 protein accumulation and p53 gene mutation in the pathogenesis of glioma and to study the role of MDM2, P53 and P16 protein in glioma formation and progression and their relationship with each other, LSAB immunohistochemical staining method and non-isotopic PCR-SSCP techniques were used to detect the expression of MDM2, P53 and P16 protein and p53 gene mutation in 48 cases of gliomas.
  • P53 gene mutation and the level of MDM2, P53 and P16 protein were not related to age, gender of the patients, tumor location and size.
  • It is concluded that the mutation of p53 and deletion of p16 might play important roles in the tumorigenesis of gliomas and it was significantly associated with the grade of tumor differentiation.
  • [MeSH-major] Brain Neoplasms / genetics. Cyclin-Dependent Kinase Inhibitor p16 / biosynthesis. Genes, p53 / genetics. Glioma / genetics. Proto-Oncogene Proteins c-mdm2 / biosynthesis. Tumor Suppressor Protein p53 / biosynthesis
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Female. Humans. Male. Middle Aged. Mutation

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2000 Oct;6(10 ):3937-43 [11051241.001]
  • [Cites] Cancer Genet Cytogenet. 2003 Jul 15;144(2):156-64 [12850379.001]
  • [Cites] J Neurooncol. 2004 Jun;68(2):113-21 [15218947.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Mar 24;269(3):718-25 [10720483.001]
  • [Cites] Cancer. 2003 Feb 15;97(4):1063-71 [12569607.001]
  • [Cites] Int J Cancer. 1999 Mar 15;80(6):930-4 [10074928.001]
  • [Cites] Pathologica. 1995 Oct;87(5):498-502 [8868174.001]
  • [Cites] Hum Mutat. 1993;2(5):338-46 [8257985.001]
  • [Cites] Mol Cancer Res. 2003 Dec;1(14 ):993-1000 [14707282.001]
  • (PMID = 16696307.001).
  • [ISSN] 1672-0733
  • [Journal-full-title] Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban
  • [ISO-abbreviation] J. Huazhong Univ. Sci. Technol. Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Tumor Suppressor Protein p53; EC 2.3.2.27 / MDM2 protein, human; EC 2.3.2.27 / Proto-Oncogene Proteins c-mdm2
  •  go-up   go-down


74. Yang LS, Wang YQ, Huang FP: [Correlation between the prognosis of medulloblastoma and relevant clinical factors: analysis of 73 cases]. Zhonghua Yi Xue Za Zhi; 2007 May 22;87(19):1322-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The correlation between the prognosis and the clinical factors, such and sex, age, tumor location, extent of tumor resection, brainstem invasion, radiotherapy, chemotherapy, ventriculoperitoneal shunt and glial differentiation was analyzed.
  • RESULTS: Six patients died postoperatively, and average survival time of the other 49 patients was 61 months.
  • Those undergoing whole brain/posterior fossa plus spinal axis radiotherapy showed a better prognosis than those undergoing whole brain/posterior fossa radiotherapy.
  • [MeSH-major] Central Nervous System Neoplasms / therapy. Medulloblastoma / therapy
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Kaplan-Meier Estimate. Male. Prognosis. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Medulloblastoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17727776.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


75. Lee YH, Park EK, Park YS, Shim KW, Choi JU, Kim DS: Treatment and outcomes of primary intracranial teratoma. Childs Nerv Syst; 2009 Dec;25(12):1581-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Until recently, postoperative adjuvant treatment for intracranial teratomas has remained controversial because of the rarity of the tumors and the heterogeneity of histologic types.
  • CONCLUSION: Treatment of intracranial teratomas is very difficult because of the heterogeneity of the tumor cells from totipotent origins.
  • [MeSH-major] Brain Neoplasms / therapy. Teratoma / therapy
  • [MeSH-minor] Adolescent. Adult. Chemotherapy, Adjuvant. Child. Child, Preschool. Drug Administration Schedule. Female. Humans. Infant. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Recurrence, Local. Prognosis. Treatment Outcome

  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neuropediatrics. 1994 Feb;25(1):26-32 [8208347.001]
  • [Cites] J Neurosurg. 1985 Aug;63(2):155-67 [2991485.001]
  • [Cites] Acta Neurochir (Wien). 1995;134(3-4):130-5 [8748771.001]
  • [Cites] Neurosurgery. 2005;56(1):188 [15617603.001]
  • [Cites] Neurosurgery. 1994 Mar;34(3):524-9; discussion 529 [7514765.001]
  • [Cites] Childs Nerv Syst. 1997 Oct;13(10 ):556-9 [9403206.001]
  • [Cites] Klin Padiatr. 1997 Jul-Aug;209(4):222-7 [9293454.001]
  • [Cites] J Neurosurg. 1998 Nov;89(5):728-37 [9817409.001]
  • [Cites] Childs Nerv Syst. 2007 Jun;23(6):713-8 [17187270.001]
  • [Cites] Med Pediatr Oncol. 1995 Jan;24(1):53-7 [7968794.001]
  • [Cites] Pediatr Neurosurg. 1996 Nov;25(5):240-6; discussion 247 [9309787.001]
  • [Cites] Curr Opin Neurol. 1996 Dec;9(6):419-23 [9007398.001]
  • [Cites] J Neurosurg. 1991 Apr;74(4):545-51 [1848284.001]
  • [Cites] J Neurosurg. 1997 Mar;86(3):446-55 [9046301.001]
  • [Cites] Med Pediatr Oncol. 1994;22(2):137-9 [7505047.001]
  • [Cites] Cancer. 2003 Jul 15;98(2):369-76 [12872359.001]
  • (PMID = 19693515.001).
  • [ISSN] 1433-0350
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


76. Bobola MS, Kolstoe DD, Blank A, Silber JR: Minimally cytotoxic doses of temozolomide produce radiosensitization in human glioblastoma cells regardless of MGMT expression. Mol Cancer Ther; 2010 May;9(5):1208-18
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Concurrent treatment with the methylating agent temozolomide during radiotherapy has yielded the first significant improvement in the survival of adult glioblastomas (GBM) in the last three decades.
  • However, improved survival is observed in a minority of patients, most frequently those whose tumors display CpG methylation of the O(6)-methylguanine (O(6)-meG)-DNA methyltransferase (MGMT) promoter, and adult GBMs remain invariably fatal.

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2000 Nov 9;343(19):1350-4 [11070098.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Jun 1;47(3):779-84 [10837964.001]
  • [Cites] J Neurooncol. 2003 Feb;61(3):203-7 [12675312.001]
  • [Cites] J Biol Chem. 2003 May 30;278(22):20303-12 [12660252.001]
  • [Cites] J Cell Biochem. 2004 Feb 1;91(2):250-7 [14743385.001]
  • [Cites] J Biol Chem. 2004 May 7;279(19):20067-75 [14982920.001]
  • [Cites] DNA Repair (Amst). 2004 Jun 3;3(6):629-38 [15135730.001]
  • [Cites] Clin Cancer Res. 2004 Jun 1;10(11):3728-36 [15173079.001]
  • [Cites] Biochemistry. 1992 Sep 1;31(34):7998-8008 [1510986.001]
  • [Cites] Radiat Res. 1995 Jun;142(3):362-8 [7761586.001]
  • [Cites] Cancer Treat Rev. 1997 Jan;23(1):35-61 [9189180.001]
  • [Cites] J Biol Chem. 1998 Feb 27;273(9):5412-8 [9479003.001]
  • [Cites] Clin Cancer Res. 1996 Apr;2(4):735-41 [9816224.001]
  • [Cites] Crit Rev Oncol Hematol. 2005 Mar;53(3):241-52 [15718149.001]
  • [Cites] Mol Cancer Ther. 2005 Sep;4(9):1364-8 [16170028.001]
  • [Cites] Cancer Treat Rev. 2005 Dec;31(8):603-17 [16298073.001]
  • [Cites] Nat Rev Genet. 2006 Jan;7(1):45-54 [16369571.001]
  • [Cites] J Neurochem. 2006 Feb;96(3):766-76 [16405512.001]
  • [Cites] J Biol Chem. 2006 Aug 11;281(32):22674-83 [16772289.001]
  • [Cites] Clin Cancer Res. 2006 Aug 1;12(15):4738-46 [16899625.001]
  • [Cites] Nat Clin Pract Neurol. 2005 Dec;1(2):88-95 [16932504.001]
  • [Cites] Annu Rev Genet. 2006;40:363-83 [16895466.001]
  • [Cites] Neurologist. 2006 Nov;12(6):279-92 [17122724.001]
  • [Cites] Chem Res Toxicol. 2006 Dec;19(12):1580-94 [17173371.001]
  • [Cites] Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):612-20 [17255284.001]
  • [Cites] Clin Cancer Res. 2007 Apr 1;13(7):2038-45 [17404084.001]
  • [Cites] DNA Repair (Amst). 2007 Jul 1;6(7):994-1003 [17382606.001]
  • [Cites] DNA Repair (Amst). 2007 Aug 1;6(8):1079-99 [17485253.001]
  • [Cites] Pharmacol Res. 2007 Oct;56(4):275-87 [17897837.001]
  • [Cites] Mol Cell. 2007 Nov 30;28(4):522-9 [18042449.001]
  • [Cites] Clin Cancer Res. 2008 Feb 1;14(3):931-8 [18245557.001]
  • [Cites] Nucleic Acids Res. 2008 Apr;36(7):2152-62 [18281311.001]
  • [Cites] Cell Cycle. 2008 Mar 15;7(6):796-807 [18250621.001]
  • [Cites] Nat Clin Pract Oncol. 2008 Aug;5(8):476-86 [18542116.001]
  • [Cites] J Clin Oncol. 2008 Sep 1;26(25):4189-99 [18757334.001]
  • [Cites] DNA Repair (Amst). 2008 Nov 1;7(11):1776-86 [18722555.001]
  • [Cites] Nat Rev Cancer. 2008 Dec;8(12):957-67 [19005492.001]
  • [Cites] PLoS Genet. 2009 Jan;5(1):e1000324 [19119425.001]
  • [Cites] Clin Cancer Res. 2009 Jan 15;15(2):607-12 [19147766.001]
  • [Cites] Nat Chem Biol. 2009 Feb;5(2):82-90 [19148176.001]
  • [Cites] Lancet Oncol. 2009 May;10(5):459-66 [19269895.001]
  • [Cites] Clin Cancer Res. 2009 Jul 15;15(14):4622-9 [19584161.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Nov 15;69(4):1246-53 [17967314.001]
  • [Cites] Br J Cancer. 1999 Nov;81(6):1022-30 [10576660.001]
  • [Cites] Biochemistry. 2002 Jul 23;41(29):9248-55 [12119040.001]
  • (PMID = 20457618.001).
  • [ISSN] 1538-8514
  • [Journal-full-title] Molecular cancer therapeutics
  • [ISO-abbreviation] Mol. Cancer Ther.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA104593-05; United States / NCI NIH HHS / CA / R21 CA131658-02; United States / NCI NIH HHS / CA / R01 CA104593-05; United States / NCI NIH HHS / CA / R01 CA104593; United States / NCI NIH HHS / CA / CA82622; United States / NCI NIH HHS / CA / CA104593
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Tumor Suppressor Proteins; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; EC 2.1.1.- / DNA Modification Methylases; EC 2.1.1.63 / MGMT protein, human; EC 6.5.1.- / DNA Repair Enzymes
  • [Other-IDs] NLM/ NIHMS191730; NLM/ PMC2869471
  •  go-up   go-down


77. Altinoz MA, Santaguida C, Guiot MC, Del Maestro RF: Spinal hemangioblastoma containing metastatic renal cell carcinoma in von Hippel-Lindau disease. Case report and review of the literature. J Neurosurg Spine; 2005 Dec;3(6):495-500
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The literature on tumor-to-tumor metastasis associated with VHL disease of the central nervous system (CNS) is reviewed.
  • A review of the literature revealed that RCC-to-CNS hemangioblastoma is the second most common donor-recipient tumor association among the tumor-to-tumor metastases.
  • [MeSH-major] Carcinoma, Renal Cell / secondary. Hemangioblastoma / pathology. Hemangioblastoma / secondary. Kidney Neoplasms / pathology. Spinal Cord Neoplasms / secondary
  • [MeSH-minor] Adult. Back Pain / etiology. Humans. Laminectomy. Male. Thoracic Vertebrae. Von Hippel-Lindau Tumor Suppressor Protein / genetics. von Hippel-Lindau Disease

  • Genetic Alliance. consumer health - Hemangioblastoma.
  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16381215.001).
  • [ISSN] 1547-5654
  • [Journal-full-title] Journal of neurosurgery. Spine
  • [ISO-abbreviation] J Neurosurg Spine
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 6.3.2.19 / VHL protein, human; EC 6.3.2.19 / Von Hippel-Lindau Tumor Suppressor Protein
  •  go-up   go-down


78. Szelényi A, Hattingen E, Weidauer S, Seifert V, Ziemann U: Intraoperative motor evoked potential alteration in intracranial tumor surgery and its relation to signal alteration in postoperative magnetic resonance imaging. Neurosurgery; 2010 Aug;67(2):302-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraoperative motor evoked potential alteration in intracranial tumor surgery and its relation to signal alteration in postoperative magnetic resonance imaging.
  • METHODS: In 29 patients (age, 42.8 +/- 18.2 years; 15 female patients; 25 supratentorial, 4 infratentorial procedures), intraoperative MEP alterations in isolation (without significant alteration in other evoked potential modalities) were classified as deterioration (> 50% amplitude decrease and/or motor threshold increase) or loss, respectively, or reversible and irreversible.
  • [MeSH-major] Brain Neoplasms / surgery. Evoked Potentials, Motor / physiology. Postoperative Complications / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Anesthesia, Inhalation. Child. Electroencephalography. Evoked Potentials, Somatosensory / physiology. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Monitoring, Intraoperative. Neurosurgical Procedures. Postoperative Period. Signal Processing, Computer-Assisted. Treatment Outcome. Young Adult


79. Miwa K, Matsuo M, Shinoda J, Oka N, Kato T, Okumura A, Ueda T, Yokoyama K, Yamada J, Yano H, Yoshimura S, Iwama T: Simultaneous integrated boost technique by helical tomotherapy for the treatment of glioblastoma multiforme with 11C-methionine PET: report of three cases. J Neurooncol; 2008 May;87(3):333-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The gross tumor volume (GTV)-1 was defined as the area of intensive (11)C-methionine (MET) uptake and GTV-2 was defined as the area of moderate MET uptake.
  • [MeSH-major] Brain Neoplasms / radiotherapy. Glioblastoma / radiotherapy. Neuronavigation. Positron-Emission Tomography. Radiotherapy, Conformal / methods. Tomography, Spiral Computed / methods
  • [MeSH-minor] Adult. Aged. Carbon Radioisotopes. Female. Humans. Male. Methionine. Neoplasm, Residual. Radiotherapy Planning, Computer-Assisted / methods

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. (L)-Methionine .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2004 Nov 1;10(21):7163-70 [15534088.001]
  • [Cites] Cancer. 2001 Sep 15;92 (6):1541-9 [11745233.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Mar 1;58(3):721-6 [14967426.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Aug 1;56(5):1450-63 [12873691.001]
  • [Cites] Technol Cancer Res Treat. 2002 Aug;1(4):311-6 [12625791.001]
  • [Cites] J Neurosurg. 2006 Feb;104(2):238-53 [16509498.001]
  • [Cites] J Neurosurg. 2005 Sep;103(3):498-507 [16235683.001]
  • [Cites] Acta Radiol. 1991 May;32(3):197-202 [2064862.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Sep 1;63(1):64-74 [16111573.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Mar 1;64(3):892-7 [16458777.001]
  • [Cites] J Nucl Med. 2004 Jul;45(7):1146-54 [15235060.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Apr 1;64(5):1317-24 [16580493.001]
  • [Cites] J Neurosurg. 2001 Nov;95(5):746-50 [11702862.001]
  • [Cites] J Nucl Med. 1997 Sep;38(9):1459-62 [9293808.001]
  • [Cites] J Neurosurg. 1988 May;68(5):698-704 [2833587.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2004 Oct;75(10 ):1457-62 [15377696.001]
  • (PMID = 18217211.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carbon Radioisotopes; AE28F7PNPL / Methionine
  •  go-up   go-down


80. Yanada S, Ito H, Tomita M, Wada T, Hatano T, Kishimoto K, Egawa S: [A case of recurrent metastatic testicular cancer, successfully treated with paclitaxel, ifomide and cisplatin]. Hinyokika Kiyo; 2008 Jan;54(1):43-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pathological diagnosis was a mixed type nonseminomatous germ cell tumor.
  • After 8 months of follow-up, he was admitted to our department because of brain, lung, and spleen metastases.
  • Then, two cycles of chemotherapy with paclitaxel, ifosfamide and cisplatin were administered as salvage chemotherapy, which led to a normalization of the serum AFP level, and disappearance of the brain and spleen metastases.
  • Residual lung mass was resected at the surgical department, and microscopically no viable tumor cells remained.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neoplasms, Germ Cell and Embryonal / drug therapy. Testicular Neoplasms / drug therapy
  • [MeSH-minor] Adult. Antineoplastic Agents / administration & dosage. Antineoplastic Agents, Alkylating / administration & dosage. Antineoplastic Agents, Phytogenic / administration & dosage. Brain Neoplasms / secondary. Cisplatin / administration & dosage. Humans. Ifosfamide / administration & dosage. Lung Neoplasms / secondary. Male. Neoplasm Metastasis. Paclitaxel / administration & dosage. Salvage Therapy. Splenic Neoplasms / secondary. alpha-Fetoproteins / analysis

  • Genetic Alliance. consumer health - Testicular cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18260360.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Alkylating; 0 / Antineoplastic Agents, Phytogenic; 0 / alpha-Fetoproteins; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


81. Dunn J, Baborie A, Alam F, Joyce K, Moxham M, Sibson R, Crooks D, Husband D, Shenoy A, Brodbelt A, Wong H, Liloglou T, Haylock B, Walker C: Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapy. Br J Cancer; 2009 Jul 7;101(1):124-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A total of 58 out of 109 glioblastomas showed average methylation >non-neoplastic brain in at least one clinical sample; 86% had homogeneous methylation status in multiple samples.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Brain Neoplasms / genetics. Brain Neoplasms / therapy. DNA Methylation. Dacarbazine / analogs & derivatives. Glioblastoma / genetics. Glioblastoma / therapy. O(6)-Methylguanine-DNA Methyltransferase / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Cell Line, Tumor. Chemotherapy, Adjuvant. Female. Humans. Male. Middle Aged. Promoter Regions, Genetic. Radiotherapy. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Cancer. 2009 Jan;45(1):146-53 [18945611.001]
  • [Cites] Brain Pathol. 2008 Oct;18(4):520-32 [18400046.001]
  • [Cites] N Engl J Med. 2000 Nov 9;343(19):1350-4 [11070098.001]
  • [Cites] Acta Neuropathol. 2001 Apr;101(4):321-33 [11355303.001]
  • [Cites] Clin Cancer Res. 2004 Mar 15;10(6):1871-4 [15041700.001]
  • [Cites] J Clin Oncol. 1998 Dec;16(12):3851-7 [9850030.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):997-1003 [15758010.001]
  • [Cites] Clin Cancer Res. 2005 Jul 15;11(14):5167-74 [16033832.001]
  • [Cites] Br J Cancer. 2006 Feb 27;94(4):561-8 [16449996.001]
  • [Cites] Mol Cancer Ther. 2006 Oct;5(10):2531-9 [17041097.001]
  • [Cites] Lab Invest. 2007 Apr;87(4):392-7 [17260000.001]
  • [Cites] J Clin Oncol. 2007 Apr 20;25(12):1470-5 [17442989.001]
  • [Cites] Clin Cancer Res. 2007 May 1;13(9):2606-13 [17473190.001]
  • [Cites] J Neurooncol. 2007 Jun;83(2):173-9 [17219056.001]
  • [Cites] J Mol Diagn. 2007 Jul;9(3):368-81 [17591937.001]
  • [Cites] Lab Invest. 2007 Oct;87(10):1055-65 [17700563.001]
  • [Cites] Int J Cancer. 2007 Dec 1;121(11):2458-64 [17691113.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2008 Jan;16(1):59-65 [18091318.001]
  • [Cites] J Neuropathol Exp Neurol. 2008 Jan;67(1):1-15 [18091559.001]
  • [Cites] Lancet Oncol. 2008 Jan;9(1):29-38 [18082451.001]
  • [Cites] Jpn J Clin Oncol. 2007 Dec;37(12):897-906 [18156172.001]
  • [Cites] J Neurooncol. 2008 Mar;87(1):71-8 [18004504.001]
  • [Cites] Int J Cancer. 2008 Mar 15;122(6):1391-9 [18000822.001]
  • [Cites] BMC Cancer. 2008;8:61 [18298842.001]
  • [Cites] Br Med Bull. 2008;85:17-33 [18245773.001]
  • [Cites] J Clin Oncol. 2008 May 1;26(13):2192-7 [18445844.001]
  • [Cites] Br J Neurosurg. 2008 Jun;22(3):339-49 [18568722.001]
  • [Cites] Cancer Invest. 2008 Jul;26(6):597-609 [18584351.001]
  • [Cites] J Mol Diagn. 2008 Jul;10(4):308-10 [18556768.001]
  • [Cites] J Mol Diagn. 2008 Jul;10(4):332-7 [18556773.001]
  • [Cites] Am J Surg Pathol. 2008 Aug;32(8):1220-7 [18580490.001]
  • [Cites] Int J Oncol. 2008 Sep;33(3):469-75 [18695875.001]
  • [Cites] J Clin Oncol. 2008 Sep 1;26(25):4189-99 [18757334.001]
  • [Cites] Histol Histopathol. 2009 Apr;24(4):511-8 [19224454.001]
  • (PMID = 19536096.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; EC 2.1.1.63 / O(6)-Methylguanine-DNA Methyltransferase
  • [Other-IDs] NLM/ PMC2713697
  •  go-up   go-down


82. Ishii K, Zaitsu M, Yonemitsu N, Kan Y, Hamasaki Y, Matsuo M: 5-lipoxygenase pathway promotes cell proliferation in human glioma cell lines. Clin Neuropathol; 2009 Nov-Dec;28(6):445-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We investigated 5-LO expression and examined whether the 5-LO pathway is associated with the proliferation of human brain tumors.
  • METHODS: We immunohistochemically evaluated the profile of 5-LO expression in various types of brain tumors obtained from 42 patients, and examined the proliferative effects of the 5-LO pathway in human glioma cell lines using a proliferation assay.
  • RESULTS: Immunohistochemistry of glioblastomas, astrocytomas, meningiomas, medulloblastomas, craniopharyngiomas, ependymomas, neurinomas, oligodendrogliomas, malignant lymphomas, dysembryoplastic neuroepithelial and metastatic brain tumors revealed 5-LO expression in the cytoplasm and nuclei or nuclear envelopes of tumor cells.
  • CONCLUSIONS: We confirmed the expression of 5-LO in various human brain tumors and demonstrated the partial suppression of tumor growth by inhibitors of the 5-LO-LTA4 hydrolase pathway in human glioma cell lines.
  • [MeSH-major] Arachidonate 5-Lipoxygenase / physiology. Brain Neoplasms / pathology. Cell Proliferation. Glioma / pathology. Signal Transduction / physiology
  • [MeSH-minor] Adolescent. Adult. Aged. Astrocytoma / pathology. Astrocytoma / physiopathology. Child. Child, Preschool. Dose-Response Relationship, Drug. Female. Glioblastoma / pathology. Glioblastoma / physiopathology. Humans. Leucine / analogs & derivatives. Leucine / pharmacology. Leukotriene A4 / antagonists & inhibitors. Leukotriene A4 / physiology. Lipoxygenase Inhibitors. Male. Meningioma / pathology. Meningioma / physiopathology. Middle Aged. Protease Inhibitors / pharmacology. Tumor Cells, Cultured. Young Adult

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • Hazardous Substances Data Bank. L-Leucine .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19919819.001).
  • [ISSN] 0722-5091
  • [Journal-full-title] Clinical neuropathology
  • [ISO-abbreviation] Clin. Neuropathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Leukotriene A4; 0 / Lipoxygenase Inhibitors; 0 / Protease Inhibitors; EC 1.13.11.34 / Arachidonate 5-Lipoxygenase; GMW67QNF9C / Leucine; I0J33N5627 / ubenimex
  •  go-up   go-down


83. Okada H, Lieberman FS, Walter KA, Lunsford LD, Kondziolka DS, Bejjani GK, Hamilton RL, Torres-Trejo A, Kalinski P, Cai Q, Mabold JL, Edington HD, Butterfield LH, Whiteside TL, Potter DM, Schold SC Jr, Pollack IF: Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of patients with malignant gliomas. J Transl Med; 2007;5:67
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: In University of Pittsburgh Cancer Institute (UPCI) protocol 95-033, adult participants with recurrent glioblastoma multiforme (GBM) or anaplastic astrocytoma (AA) received gross total resection (GTR) of the recurrent tumors, followed by two vaccinations with autologous fibroblasts retrovirally transfected with TFG-IL4-Neo-TK vector admixed with irradiated autologous glioma cells.
  • In UPCI 99-111, adult participants with newly diagnosed GBM or AA, following GTR and radiation therapy, received two intradermal vaccinations with the TFG-IL4-Neo-TK-transfected fibroblasts admixed with type-1 dendritic cells (DC) loaded with autologous tumor lysate.
  • Four other participants were withdrawn from the trial because of tumor progression prior to production of the cellular vaccine.
  • Moreover, both participants demonstrated clinical and radiological improvement with no evidence of allergic encephalitis, although both participants eventually succumbed with the tumor recurrence.
  • [MeSH-major] Brain Neoplasms / therapy. Cancer Vaccines / therapeutic use. Fibroblasts / metabolism. Glioblastoma / therapy. Interleukin-4 / genetics. Transfection
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Feasibility Studies. Female. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Immunol. 2005 Jun 1;174(11):7194-201 [15905564.001]
  • [Cites] Gene Ther. 2005 May;12(9):733-41 [15772692.001]
  • [Cites] Neoplasia. 2005 Aug;7(8):717-22 [16207473.001]
  • [Cites] Cancer Res. 2006 Jun 1;66(11):5883-91 [16740728.001]
  • [Cites] Cancer Res. 2006 Apr 15;66(8):4478-87 [16618775.001]
  • [Cites] N Engl J Med. 2006 Feb 16;354(7):709-18 [16481638.001]
  • [Cites] J Transl Med. 2007;5:10 [17295916.001]
  • [Cites] Cancer Res. 2007 Jul 1;67(13):6451-8 [17616706.001]
  • [Cites] Hum Gene Ther. 2000 Mar 1;11(4):637-53 [10724042.001]
  • [Cites] Cancer Gene Ther. 2000 Mar;7(3):486-94 [10766355.001]
  • [Cites] J Immunol. 2000 Aug 15;165(4):1877-81 [10925267.001]
  • [Cites] J Exp Med. 2000 Sep 18;192(6):823-33 [10993913.001]
  • [Cites] Cancer Res. 2001 Feb 1;61(3):842-7 [11221866.001]
  • [Cites] J Clin Oncol. 2001 Mar 15;19(6):1848-54 [11251017.001]
  • [Cites] Hum Gene Ther. 2001 Mar 20;12(5):575-95 [11268289.001]
  • [Cites] Gene Ther. 2001 Aug;8(15):1157-66 [11509946.001]
  • [Cites] Nat Immunol. 2001 Nov;2(11):1054-60 [11600887.001]
  • [Cites] Brain Res Brain Res Rev. 2003 May;42(2):97-122 [12738053.001]
  • [Cites] Oncogene. 2003 May 19;22(20):3188-92 [12789295.001]
  • [Cites] Blood. 2003 Jul 1;102(1):36-42 [12560234.001]
  • [Cites] J Neurooncol. 2003 Aug-Sep;64(1-2):13-20 [12952282.001]
  • [Cites] J Clin Oncol. 2003 Oct 15;21(20):3826-35 [14551301.001]
  • [Cites] Curr Neurol Neurosci Rep. 2004 May;4(3):218-27 [15102348.001]
  • [Cites] Cancer Res. 2004 Jul 15;64(14):4973-9 [15256471.001]
  • [Cites] Cancer Res. 2004 Sep 1;64(17):5934-7 [15342370.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Apr 15;90(8):3539-43 [8097319.001]
  • [Cites] Hum Gene Ther. 1994 Jan;5(1):41-55 [8155771.001]
  • [Cites] J Immunother Emphasis Tumor Immunol. 1995 May;17(4):238-48 [7582260.001]
  • [Cites] Hum Gene Ther. 1996 Mar 1;7(4):479-87 [8800742.001]
  • [Cites] Neurosurgery. 1996 Jun;38(6):1096-103; discussion 1103-4 [8727138.001]
  • [Cites] J Invest Dermatol. 1998 May;110(5):762-6 [9579542.001]
  • [Cites] Forum (Genova). 1998 Oct-Dec;8(4):357-64 [9863030.001]
  • [Cites] Science. 1999 Feb 19;283(5405):1183-6 [10024247.001]
  • [Cites] Gene Ther. 1999 Feb;6(2):219-26 [10435106.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] Clin Cancer Res. 2005 Aug 1;11(15):5515-25 [16061868.001]
  • (PMID = 18093335.001).
  • [ISSN] 1479-5876
  • [Journal-full-title] Journal of translational medicine
  • [ISO-abbreviation] J Transl Med
  • [Language] eng
  • [Grant] United States / NCATS NIH HHS / TR / UL1 TR000005
  • [Publication-type] Clinical Trial, Phase I; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cancer Vaccines; 207137-56-2 / Interleukin-4
  • [Other-IDs] NLM/ PMC2254376
  •  go-up   go-down


84. Burakgazi AZ, Wang C, Burger K: A patient with subacute onset of ophthalmoplegia, papilledema, and proptosis. Rev Neurol Dis; 2008;5(4):203-5;213-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • He was found to have a mass in an unusual area of the brain.
  • The differential diagnosis, diagnostic testing, pathology, treatment, and prognosis of this rare tumor are discussed in detail.
  • [MeSH-major] Cerebral Ventricle Neoplasms. Exophthalmos. Ophthalmoplegia. Papilledema
  • [MeSH-minor] Diagnosis, Differential. Humans. Magnetic Resonance Imaging. Male. Prognosis. Tomography, X-Ray Computed. Young Adult

  • Genetic Alliance. consumer health - Papilledema.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19122574.001).
  • [ISSN] 1545-2913
  • [Journal-full-title] Reviews in neurological diseases
  • [ISO-abbreviation] Rev Neurol Dis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


85. Liu X, Hashimoto-Torii K, Torii M, Ding C, Rakic P: Gap junctions/hemichannels modulate interkinetic nuclear migration in the forebrain precursors. J Neurosci; 2010 Mar 24;30(12):4197-209
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Our findings indicate that functional interference with gap junctions/hemichannels during embryonic development may lead to abnormal corticogenesis and dysfunction of the cerebral cortex in adult organisms.

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BORON COMPOUNDS .
  • Hazardous Substances Data Bank. BROMODEOXYURIDINE .
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cereb Cortex. 2003 Mar;13(3):239-51 [12571114.001]
  • [Cites] J Membr Biol. 2002 Jan 15;185(2):93-102 [11891568.001]
  • [Cites] Cancer Res. 2003 Nov 1;63(21):7128-35 [14612506.001]
  • [Cites] Neuroreport. 2003 Dec 2;14(17):2177-81 [14625443.001]
  • [Cites] Genomics. 2004 May;83(5):812-20 [15081111.001]
  • [Cites] Neuron. 2004 Sep 2;43(5):647-61 [15339647.001]
  • [Cites] Am J Physiol Cell Physiol. 2004 Nov;287(5):C1389-95 [15475518.001]
  • [Cites] Nat Neurosci. 2004 Nov;7(11):1195-203 [15475953.001]
  • [Cites] J Comp Neurol. 1966 Jul;127(3):399-411 [5968003.001]
  • [Cites] Ann N Y Acad Sci. 1966 Sep 23;133(3):880-2 [5230203.001]
  • [Cites] J Embryol Exp Morphol. 1969 Feb;21(1):71-83 [5765793.001]
  • [Cites] J Exp Zool. 1972 Sep;181(3):289-301 [4341108.001]
  • [Cites] Brain Res. 1973 Nov 9;62(1):1-35 [4203033.001]
  • [Cites] J Embryol Exp Morphol. 1973 Dec;30(3):661-71 [4772391.001]
  • [Cites] Dev Biol. 1974 Jan;36(1):218-23 [4822837.001]
  • [Cites] Am J Anat. 1978 Jun;152(2):209-21 [567005.001]
  • [Cites] Cell Biol Int Rep. 1983 Dec;7(12):1033-40 [6321039.001]
  • [Cites] J Exp Biol. 1986 Sep;124:993-114 [2428910.001]
  • [Cites] Science. 1988 Jul 8;241(4862):170-6 [3291116.001]
  • [Cites] Prog Brain Res. 1988;73:15-37 [3047794.001]
  • [Cites] Dev Biol. 1989 Dec;136(2):311-20 [2583368.001]
  • [Cites] Radiat Res. 1990 Sep;123(3):241-51 [2217720.001]
  • [Cites] Science. 1991 Apr 26;252(5005):563-6 [1850552.001]
  • [Cites] Neuron. 1992 Jun;8(6):1101-8 [1351732.001]
  • [Cites] Science. 1993 Apr 2;260(5104):95-7 [8096653.001]
  • [Cites] Nature. 1995 Jun 29;375(6534):784-7 [7596410.001]
  • [Cites] Dev Neurosci. 1995;17(2):81-96 [7555741.001]
  • [Cites] J Neurosci. 1997 May 1;17(9):3096-111 [9096144.001]
  • [Cites] J Comp Neurol. 1997 May 12;381(3):335-52 [9133572.001]
  • [Cites] J Neurosci. 1997 Sep 15;17(18):7037-44 [9278539.001]
  • [Cites] J Neurosci. 1998 Jul 15;18(14):5374-88 [9651220.001]
  • [Cites] Nature. 1999 Jan 28;397(6717):350-5 [9950427.001]
  • [Cites] Cereb Cortex. 1999 Mar;9(2):188-95 [10220231.001]
  • [Cites] J Neurosci. 2005 Mar 2;25(9):2338-47 [15745960.001]
  • [Cites] Eur J Neurosci. 2005 Apr;21(7):1859-68 [15869481.001]
  • [Cites] Neuron. 2005 Jun 2;46(5):731-44 [15924860.001]
  • [Cites] Epilepsia. 2005;46 Suppl 7:15-21 [16201991.001]
  • [Cites] Biochim Biophys Acta. 2005 Dec 20;1719(1-2):6-23 [16359940.001]
  • [Cites] Cereb Cortex. 2006 Feb;16(2):237-46 [15930372.001]
  • [Cites] EMBO J. 2006 Jan 11;25(1):34-44 [16341088.001]
  • [Cites] Nat Neurosci. 2006 Sep;9(9):1099-107 [16892058.001]
  • [Cites] Glia. 2006 Oct;54(5):394-410 [16886203.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Aug 22;103(34):12903-10 [16901978.001]
  • [Cites] Glia. 2006 Nov 15;54(7):758-73 [17006904.001]
  • [Cites] Glia. 2007 May;55(7):675-86 [17311295.001]
  • [Cites] Nature. 2007 Aug 23;448(7156):901-7 [17713529.001]
  • [Cites] J Biol Chem. 2007 Sep 28;282(39):28749-58 [17627942.001]
  • [Cites] Neuron. 2007 Oct 4;56(1):79-93 [17920017.001]
  • [Cites] Neuroscience. 2007 Dec 19;150(4):863-79 [18031938.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Aug 19;105(33):11802-7 [18689674.001]
  • [Cites] Nat Rev Mol Cell Biol. 2008 Sep;9(9):690-701 [18719708.001]
  • [Cites] Cell. 2008 Sep 19;134(6):1055-65 [18805097.001]
  • [Cites] Nat Rev Mol Cell Biol. 2008 Nov;9(11):860-73 [18946475.001]
  • [Cites] J Neurosci. 2008 Nov 12;28(46):11746-52 [19005035.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Dec 2;105(48):18770-5 [19047635.001]
  • [Cites] J Neurosci. 2009 Feb 18;29(7):2009-21 [19228955.001]
  • [Cites] Brain Res Brain Res Protoc. 1999 Dec;4(3):425-37 [10592354.001]
  • [Cites] Eur J Cancer. 2000 Jun;36(10):1269-74 [10882865.001]
  • [Cites] Trends Neurosci. 2000 Aug;23(8):352-9 [10906798.001]
  • [Cites] J Biol Chem. 2000 Oct 6;275(40):31061-8 [10913128.001]
  • [Cites] J Pharmacol Exp Ther. 2001 Sep;298(3):1033-41 [11504800.001]
  • [Cites] Curr Biol. 2001 Oct 2;11(19):1536-41 [11591323.001]
  • [Cites] Curr Opin Cell Biol. 2002 Feb;14(1):44-9 [11792543.001]
  • [Cites] J Biol Chem. 2003 Oct 10;278(41):39413-21 [12888567.001]
  • (PMID = 20335455.001).
  • [ISSN] 1529-2401
  • [Journal-full-title] The Journal of neuroscience : the official journal of the Society for Neuroscience
  • [ISO-abbreviation] J. Neurosci.
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / R01 NS014841; United States / NINDS NIH HHS / NS / R01 NS038296-10; United States / NIDA NIH HHS / DA / R01 DA023999-02; United States / Autism Speaks / / AS1574; United States / NINDS NIH HHS / NS / NS038296-10; United States / NINDS NIH HHS / NS / NS014841-31; United States / NINDS NIH HHS / NS / R01 NS038296; United States / NINDS NIH HHS / NS / R01 NS014841-31; United States / NIDA NIH HHS / DA / R01 DA023999; United States / NIDA NIH HHS / DA / DA023999-02
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 2-aminoethoxydiphenyl borate; 0 / Boron Compounds; 0 / Chelating Agents; 0 / Connexin 43; 0 / Cyclooxygenase Inhibitors; 0 / Ki-67 Antigen; 0 / Platelet Aggregation Inhibitors; 139890-68-9 / 1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester; 147336-22-9 / Green Fluorescent Proteins; 149017-66-3 / pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid; 48I5LU4ZWD / Meclofenamic Acid; 526U7A2651 / Egtazic Acid; 5V5IOJ8338 / Pyridoxal Phosphate; 8L70Q75FXE / Adenosine Triphosphate; G34N38R2N1 / Bromodeoxyuridine; MM6384NG73 / Carbenoxolone; Q1O6DSW23R / 4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid; SY7Q814VUP / Calcium
  • [Other-IDs] NLM/ NIHMS189498; NLM/ PMC2861434
  •  go-up   go-down


86. Daniel RA, Rozanska AL, Mulligan EA, Drew Y, Thomas HD, Castelbuono DJ, Hostomsky Z, Plummer ER, Tweddle DA, Boddy AV, Clifford SC, Curtin NJ: Central nervous system penetration and enhancement of temozolomide activity in childhood medulloblastoma models by poly(ADP-ribose) polymerase inhibitor AG-014699. Br J Cancer; 2010 Nov 9;103(10):1588-96
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Temozolomide shows activity against medulloblastoma, the most common malignant paediatric brain tumour.
  • Poly(ADP-ribose) polymerase (PARP) inhibitors enhance temozolomide activity in extracranial adult and paediatric human malignancies.
  • AG-014699 was not toxic, accumulated and reduced PARP activity ≥75% in xenograft and brain tissues.
  • CONCLUSION: We show for the first time central nervous system penetration and inhibition of brain PARP activity by AG-014699.

  • Genetic Alliance. consumer health - Medulloblastoma.
  • Genetic Alliance. consumer health - Medulloblastoma, childhood.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2005 May 1;11(9):3402-9 [15867241.001]
  • [Cites] Nat Rev Drug Discov. 2005 May;4(5):421-40 [15864271.001]
  • [Cites] Genes Chromosomes Cancer. 2006 Jan;45(1):47-60 [16149064.001]
  • [Cites] Neurosurg Focus. 2005 Nov;19(5):E10 [16398460.001]
  • [Cites] Childs Nerv Syst. 2006 Jul;22(7):652-61 [16565851.001]
  • [Cites] Eur J Cancer. 2006 Sep;42(14):2335-42 [16899365.001]
  • [Cites] Clin Cancer Res. 2007 Mar 15;13(6):1663-74 [17363519.001]
  • [Cites] Mol Cancer Ther. 2007 Mar;6(3):945-56 [17363489.001]
  • [Cites] Clin Cancer Res. 2007 May 1;13(9):2728-37 [17473206.001]
  • [Cites] Expert Opin Ther Targets. 2007 Jun;11(6):783-99 [17504016.001]
  • [Cites] Cancer. 2007 Oct 1;110(7):1542-50 [17705175.001]
  • [Cites] Clin Cancer Res. 2007 Nov 15;13(22 Pt 1):6712-8 [18006772.001]
  • [Cites] Nat Clin Pract Oncol. 2008 Aug;5(8):476-86 [18542116.001]
  • [Cites] Arch Dis Child Educ Pract Ed. 2008 Oct;93(5):137-44 [18809691.001]
  • [Cites] Clin Cancer Res. 2008 Dec 1;14(23):7917-23 [19047122.001]
  • [Cites] Cancer Res. 2009 Jan 1;69(1):120-7 [19117994.001]
  • [Cites] Clin Cancer Res. 2009 Feb 15;15(4):1241-9 [19174487.001]
  • [Cites] Childs Nerv Syst. 2009 May;25(5):535-41 [19107490.001]
  • [Cites] N Engl J Med. 2009 Jul 9;361(2):123-34 [19553641.001]
  • [Cites] Br J Neurosurg. 2009 Aug;23(4):364-75 [19637007.001]
  • [Cites] Clin Cancer Res. 2009 Oct 1;15(19):6106-12 [19789326.001]
  • [Cites] Semin Oncol. 2001 Aug;28(4 Suppl 13):3-12 [11550133.001]
  • [Cites] Clin Cancer Res. 2000 Mar;6(3):998-1007 [10741727.001]
  • [Cites] Neuro Oncol. 2009 Oct;11(5):458-67 [19179424.001]
  • [Cites] J Clin Oncol. 2003 Jul 1;21(13):2525-8 [12829671.001]
  • [Cites] Clin Cancer Res. 2003 Nov 1;9(14):5370-9 [14614022.001]
  • [Cites] J Natl Cancer Inst. 2004 Jan 7;96(1):56-67 [14709739.001]
  • [Cites] Clin Cancer Res. 2004 Feb 1;10(3):881-9 [14871963.001]
  • [Cites] J Med Chem. 2004 Aug 12;47(17):4151-4 [15293985.001]
  • [Cites] Cancer Res. 1995 Jul 1;55(13):2853-7 [7796412.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):997-1003 [15758010.001]
  • [Cites] Mol Cancer Ther. 2005 Sep;4(9):1364-8 [16170028.001]
  • (PMID = 20978505.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] ENG
  • [Grant] United Kingdom / Cancer Research UK / / C8464/A5414; United Kingdom / Department of Health / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Indoles; 0 / Poly(ADP-ribose) Polymerase Inhibitors; 7GR28W0FJI / Dacarbazine; 8237F3U7EH / rucaparib; 85622-93-1 / temozolomide; EC 2.4.2.30 / PARP1 protein, human; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  • [Other-IDs] NLM/ PMC2990587
  •  go-up   go-down


87. Huang CJ, Gurlo T, Haataja L, Costes S, Daval M, Ryazantsev S, Wu X, Butler AE, Butler PC: Calcium-activated calpain-2 is a mediator of beta cell dysfunction and apoptosis in type 2 diabetes. J Biol Chem; 2010 Jan 1;285(1):339-48
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The islet in type 2 diabetes (T2DM) and the brain in neurodegenerative diseases share progressive cell dysfunction, increased apoptosis, and accumulation of locally expressed amyloidogenic proteins (islet amyloid polypeptide (IAPP) in T2DM).

  • Genetic Alliance. consumer health - Diabetes.
  • Genetic Alliance. consumer health - Diabetes, Type 2.
  • MedlinePlus Health Information. consumer health - Diabetes Type 2.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 2003 Apr 18;300(5618):486-9 [12702875.001]
  • [Cites] Cell Calcium. 2003 Feb;33(2):83-9 [12531184.001]
  • [Cites] J Cell Sci. 2004 Aug 15;117(Pt 18):4135-42 [15280427.001]
  • [Cites] J Biol Chem. 2004 Oct 8;279(41):43126-35 [15302874.001]
  • [Cites] Circ Res. 1990 Jul;67(1):84-96 [2163777.001]
  • [Cites] Nature. 1991 Oct 31;353(6347):844-6 [1944558.001]
  • [Cites] Endocrinology. 1992 Mar;130(3):1387-93 [1371447.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Apr 1;90(7):2628-32 [8464868.001]
  • [Cites] Virchows Arch. 1994;425(1):73-7 [7921417.001]
  • [Cites] Neuroscience. 1994 Aug;61(4):983-90 [7838392.001]
  • [Cites] J Virol. 1995 Jun;69(6):3838-47 [7745732.001]
  • [Cites] J Biol Chem. 1996 Jan 26;271(4):1988-92 [8567648.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Jul 9;93(14):7283-8 [8692984.001]
  • [Cites] J Cereb Blood Flow Metab. 1996 Nov;16(6):1189-202 [8898691.001]
  • [Cites] Biochemistry. 1997 Jan 7;36(1):57-65 [8993318.001]
  • [Cites] Annu Rev Immunol. 1997;15:707-47 [9143705.001]
  • [Cites] Bioessays. 1997 Nov;19(11):1011-8 [9394623.001]
  • [Cites] Diabetes. 1999 Mar;48(3):491-8 [10078548.001]
  • [Cites] Am J Physiol. 1999 May;276(5 Pt 1):G1204-12 [10330011.001]
  • [Cites] Am J Pathol. 1999 Sep;155(3):853-62 [10487842.001]
  • [Cites] J Clin Invest. 1999 Sep;104(6):787-94 [10491414.001]
  • [Cites] FEBS Lett. 2004 Nov 5;577(1-2):117-20 [15527771.001]
  • [Cites] J Biol Chem. 2005 Apr 22;280(16):16175-84 [15691848.001]
  • [Cites] J Biol Chem. 2005 Apr 29;280(17):17294-300 [15722360.001]
  • [Cites] J Cereb Blood Flow Metab. 2005 Nov;25(11):1433-44 [15902199.001]
  • [Cites] Blood. 2006 May 15;107(10):4003-10 [16469868.001]
  • [Cites] ILAR J. 2006;47(3):225-33 [16804197.001]
  • [Cites] Mol Neurobiol. 2006 Jun;33(3):215-36 [16954597.001]
  • [Cites] Mol Genet Metab. 2007 Apr;90(4):393-401 [17185018.001]
  • [Cites] Diabetes. 2007 May;56(5):1324-32 [17353506.001]
  • [Cites] Arch Biochem Biophys. 2007 Jun 1;462(1):115-21 [17481572.001]
  • [Cites] Diabetes. 2007 Aug;56(8):2016-27 [17475933.001]
  • [Cites] Biochim Biophys Acta. 2007 Aug;1768(8):2002-9 [17349968.001]
  • [Cites] Hum Mol Genet. 2007 Dec 1;16(23):2960-71 [17855447.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2007 Dec;293(6):E1656-62 [17911343.001]
  • [Cites] J Cereb Blood Flow Metab. 2008 Apr;28(4):655-73 [18073773.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Apr 22;105(16):6033-8 [18408164.001]
  • [Cites] Endocr Rev. 2008 May;29(3):303-16 [18314421.001]
  • [Cites] Exp Diabetes Res. 2008;2008:421287 [18483616.001]
  • [Cites] Neurobiol Dis. 2008 Jun;30(3):331-42 [18420416.001]
  • [Cites] J Neurosci Res. 2008 Jul;86(9):2091-9 [18335524.001]
  • [Cites] J Clin Invest. 2008 Aug;118(8):2796-807 [18596919.001]
  • [Cites] Diabetologia. 2008 Dec;51(12):2252-62 [18751967.001]
  • [Cites] Cell Death Differ. 2008 Dec;15(12):1857-64 [18806756.001]
  • [Cites] J Neurosci. 2008 Nov 26;28(48):12725-35 [19036965.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2009 Jan;296(1):E89-96 [18940937.001]
  • [Cites] Neuroscience. 2009 Jan 23;158(2):558-69 [19007862.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2009 Apr;296(4):E690-701 [19141690.001]
  • [Cites] Diabetes. 2000 Mar;49(3):424-30 [10868964.001]
  • [Cites] Neurosci Lett. 2002 Mar 22;321(3):187-91 [11880203.001]
  • [Cites] Biol Chem. 2002 May;383(5):785-91 [12108543.001]
  • [Cites] Science. 2002 Jul 19;297(5580):353-6 [12130773.001]
  • [Cites] Brain Res Mol Brain Res. 2002 Nov 15;107(2):166-75 [12425945.001]
  • [Cites] Diabetes. 2003 Jan;52(1):102-10 [12502499.001]
  • [Cites] J Mol Neurosci. 2004;23(1-2):97-104 [15126695.001]
  • (PMID = 19861418.001).
  • [ISSN] 1083-351X
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / R01 DK059579; United States / NIDDK NIH HHS / DK / DK059579
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Amyloid; 0 / Dipeptides; 0 / Islet Amyloid Polypeptide; 0 / Recombinant Fusion Proteins; 117591-20-5 / calpeptin; 12634-43-4 / Spectrin; EC 3.4.22.- / Calpain; EC 3.4.22.53 / calpain 2, human; SY7Q814VUP / Calcium
  • [Other-IDs] NLM/ PMC2804181
  •  go-up   go-down


88. Kikuchi Y, Sasaki T, Matsumoto M, Oikawa T, Itakura T, Kodama N: Optic nerve evoked potentials elicited by electrical stimulation. Neurol Med Chir (Tokyo); 2005 Jul;45(7):349-55; discussion 354-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the clinical study, recordings were obtained from 15 patients after craniotomy to treat parasellar tumors or cerebral aneurysms.
  • In the remaining patient, the ONEP, recorded only after tumor removal because the optic nerve was stretched and extremely thin, was remarkably small and the patient developed unilateral blindness postoperatively.
  • [MeSH-major] Brain Neoplasms / surgery. Evoked Potentials. Intracranial Aneurysm / surgery. Monitoring, Intraoperative / methods. Optic Nerve / physiopathology. Vision, Ocular
  • [MeSH-minor] Adult. Aged. Animals. Dogs. Electric Stimulation. Humans. Middle Aged

  • MedlinePlus Health Information. consumer health - Brain Aneurysm.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16041180.001).
  • [ISSN] 0470-8105
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


89. Basa J, Wolska-Smoleń T, Walter Z, Skotnicki AB: [Granulocytic sarcoma with late transformation into acute myeloblastic leukemia--case report]. Przegl Lek; 2006;63(8):706-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Case presentation of a 28-year-old patient with acute myeloblastic leukemia (FAB AML-M4), who underwent surgery of an inguinal tumor a year before the diagnosis of leukemia was made.
  • [MeSH-major] Brain Neoplasms / secondary. Leukemia, Myeloid, Acute / diagnosis. Leukemia, Myeloid, Acute / etiology. Sarcoma, Myeloid / complications. Sarcoma, Myeloid / diagnosis
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Marrow Transplantation. Cell Transformation, Neoplastic / pathology. Disease-Free Survival. Fatal Outcome. Groin. Humans. Male. Neoplasm Recurrence, Local / diagnosis. Remission Induction / methods. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17441389.001).
  • [ISSN] 0033-2240
  • [Journal-full-title] Przegla̧d lekarski
  • [ISO-abbreviation] Prz. Lek.
  • [Language] pol
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


90. Chen W, Cloughesy T, Kamdar N, Satyamurthy N, Bergsneider M, Liau L, Mischel P, Czernin J, Phelps ME, Silverman DH: Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG. J Nucl Med; 2005 Jun;46(6):945-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG.
  • 3'-Deoxy-3'-(18)F-fluorothymidine ((18)F-FLT) is a recently developed PET tracer to image tumor cell proliferation.
  • We characterized (18)F-FLT PET of brain gliomas and compared (18)F-FLT with (18)F-FDG PET in side-by-side studies of the same patients.
  • Tracer kinetics in normal brain and tumor were measured.
  • Uptake of (18)F-FLT and (18)F-FDG was quantified by the standardized uptake value (SUV) and the tumor-to-normal tissue (T/N) ratio.
  • The predictive power of PET for tumor progression and survival was analyzed using Kaplan-Meier statistics.
  • RESULTS: (18)F-FLT uptake in tumors was rapid, peaking at 5-10 min after injection and remaining stable up to 75 min.
  • Hence, a 30-min scan beginning at 5 min after injection was sufficient for imaging. (18)F-FLT visualized all high-grade (grade III or IV) tumors.
  • Grade II tumor did not show appreciable (18)F-FLT uptake and neither did the stable lesions.
  • The absolute uptake of (18)F-FLT was low (maximum-pixel SUV [SUV(max)], 1.33) but image contrast was better than with (18)F-FDG (T/N ratio, 3.85 vs. 1.49). (18)F-FDG PET studies were negative in 5 patients with recurrent high-grade glioma who subsequently suffered tumor progression within 1-3 mo. (18)F-FLT SUV(max) correlated more strongly with Ki-67 index (r = 0.84; P < 0.0001) than (18)F-FDG SUV(max) (r = 0.51; P = 0.07). (18)F-FLT uptake also had more significant predictive power with respect to tumor progression and survival (P = 0.0005 and P = 0.001, respectively).
  • CONCLUSION: Thirty-minute (18)F-FLT PET 5 min after injection was more sensitive than (18)F-FDG to image recurrent high-grade tumors, correlated better with Ki-67 values, and was a more powerful predictor of tumor progression and survival.
  • [MeSH-major] Brain Neoplasms / diagnosis. Dideoxynucleosides. Fluorodeoxyglucose F18. Glioma / diagnosis. Radiopharmaceuticals
  • [MeSH-minor] Adult. Aged. Cell Proliferation. Female. Fluorine Radioisotopes. Humans. Ki-67 Antigen / metabolism. Male. Middle Aged. Positron-Emission Tomography. Prognosis. Prospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15937304.001).
  • [ISSN] 0161-5505
  • [Journal-full-title] Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  • [ISO-abbreviation] J. Nucl. Med.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50 CA 086306
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Dideoxynucleosides; 0 / Fluorine Radioisotopes; 0 / Ki-67 Antigen; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18; PG53R0DWDQ / alovudine
  •  go-up   go-down


91. Beeghly-Fadiel A, Long JR, Gao YT, Li C, Qu S, Cai Q, Zheng Y, Ruan ZX, Levy SE, Deming SL, Snoddy JR, Shu XO, Lu W, Zheng W: Common MMP-7 polymorphisms and breast cancer susceptibility: a multistage study of association and functionality. Cancer Res; 2008 Aug 1;68(15):6453-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Known to be vital for tumor invasion and metastasis, accumulating evidence also implicates MMP-7 in cancer development.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Carcinogenesis. 2005 May;26(5):892-9 [15695237.001]
  • [Cites] Genome Res. 2005 Feb;15(2):269-75 [15687290.001]
  • [Cites] Genet Epidemiol. 2005 Dec;29(4):299-312 [16240443.001]
  • [Cites] Exp Biol Med (Maywood). 2006 Jan;231(1):20-7 [16380641.001]
  • [Cites] Gynecol Oncol. 2006 Apr;101(1):92-6 [16278009.001]
  • [Cites] Br J Cancer. 2006 Sep 18;95(6):744-51 [16940985.001]
  • [Cites] J Cell Mol Med. 2006 Jul-Sep;10(3):554-68 [16989720.001]
  • [Cites] Nat Genet. 2006 Oct;38(10):1166-72 [16998491.001]
  • [Cites] Brain Res. 2006 Nov 6;1118(1):6-12 [16956593.001]
  • [Cites] Cell. 2007 Mar 23;128(6):1231-45 [17382889.001]
  • [Cites] Breast Cancer Res Treat. 2007 Nov;106(1):121-6 [17431766.001]
  • [Cites] Nucleic Acids Res. 2008 Jan;36(Database issue):D707-14 [18000006.001]
  • [Cites] Cancer. 2000 May 15;88(10):2201-9 [10820340.001]
  • [Cites] Int J Cancer. 2000 Jul 15;87(2):295-300 [10861490.001]
  • [Cites] Trends Genet. 2001 Sep;17(9):520-7 [11525835.001]
  • [Cites] Cancer Lett. 2001 Nov 28;173(2):175-82 [11597792.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2001 Nov;21(11):1834-9 [11701474.001]
  • [Cites] Neoplasia. 2001 Nov-Dec;3(6):459-68 [11774028.001]
  • [Cites] Cancer Lett. 2002 Mar 8;177(1):95-100 [11809536.001]
  • [Cites] Dev Biol. 2002 Apr 1;244(1):114-33 [11900463.001]
  • [Cites] Nat Rev Cancer. 2002 Mar;2(3):161-74 [11990853.001]
  • [Cites] J Clin Invest. 2002 Jun;109(11):1437-44 [12045257.001]
  • [Cites] Science. 2002 Jun 21;296(5576):2225-9 [12029063.001]
  • [Cites] Pathol Int. 2003 Oct;53(10):659-66 [14516315.001]
  • [Cites] Clin Chem. 2003 Nov;49(11):1940-2 [14578330.001]
  • [Cites] Br J Cancer. 2003 Nov 17;89(10):1817-21 [14612884.001]
  • [Cites] Mol Cell Biochem. 2003 Nov;253(1-2):269-85 [14619979.001]
  • [Cites] Nature. 2003 Dec 18;426(6968):789-96 [14685227.001]
  • [Cites] J Gastroenterol. 2004;39(5):434-40 [15175941.001]
  • [Cites] Oncol Rep. 2004 Jul;12(1):13-7 [15201952.001]
  • [Cites] Oncol Rep. 2004 Oct;12(4):717-23 [15375490.001]
  • [Cites] Cancer. 1995 Mar 15;75(6 Suppl):1516-9 [7889484.001]
  • [Cites] J Invest Dermatol. 1995 Aug;105(2):190-6 [7636300.001]
  • [Cites] Int J Biochem Cell Biol. 1996 Feb;28(2):123-36 [8729000.001]
  • [Cites] Cancer Res. 1998 Dec 1;58(23):5500-6 [9850086.001]
  • [Cites] Clin Exp Metastasis. 1998 Oct;16(7):577-85 [9932604.001]
  • [Cites] Bioinformatics. 2005 Jan 15;21(2):263-5 [15297300.001]
  • [Cites] Carcinogenesis. 2005 Oct;26(10):1748-53 [15930031.001]
  • (PMID = 18648013.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA090899-08; United States / NIDDK NIH HHS / DK / P60 DK020593; United States / NCI NIH HHS / CA / R01 CA090899-08; United States / NCI NIH HHS / CA / R01CA64277; United States / NEI NIH HHS / EY / P30 EY08126; United States / NCI NIH HHS / CA / P30 CA68485; United States / NIDDK NIH HHS / DK / P30 DK058404; United States / NCI NIH HHS / CA / R01 CA064277-10A1; United States / NCI NIH HHS / CA / R01 CA090899; United States / NCI NIH HHS / CA / R01 CA064277; United States / NEI NIH HHS / EY / P30 EY008126; United States / NCI NIH HHS / CA / P30 CA068485; United States / NCI NIH HHS / CA / CA064277-10A1; United States / NCI NIH HHS / CA / R01 CA090899-09; United States / NIDDK NIH HHS / DK / P60 DK20593; United States / NCI NIH HHS / CA / R01CA90899; United States / NIDDK NIH HHS / DK / P30 DK58404; United States / NCI NIH HHS / CA / R01 CA064277-05; United States / NCI NIH HHS / CA / CA064277-05; United States / NCI NIH HHS / CA / CA090899-09
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers; EC 3.4.24.23 / Matrix Metalloproteinase 7
  • [Other-IDs] NLM/ NIHMS66099; NLM/ PMC2718434
  •  go-up   go-down


92. Rozmovits L, Khu KJ, Osman S, Gentili F, Guha A, Bernstein M: Information gaps for patients requiring craniotomy for benign brain lesion: a qualitative study. J Neurooncol; 2010 Jan;96(2):241-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Information gaps for patients requiring craniotomy for benign brain lesion: a qualitative study.
  • Twenty-five semi-structured interviews were conducted with ambulatory adult patients who had undergone surgery for a benign brain tumor, arteriovenous malformation, or unruptured aneurysm.

  • MedlinePlus Health Information. consumer health - Choosing a Doctor or Health Care Service.
  • MedlinePlus Health Information. consumer health - Talking With Your Doctor.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] ANZ J Surg. 2001 Jan;71(1):24-6 [11167593.001]
  • [Cites] Heart. 2001 Dec;86(6):626-31 [11711453.001]
  • [Cites] BMJ. 2003 Nov 15;327(7424):1159-61 [14615345.001]
  • [Cites] Br Heart J. 1984 Oct;52(4):468-70 [6477788.001]
  • [Cites] J R Soc Med. 1994 Mar;87(3):149-52 [8158593.001]
  • [Cites] Neurosurgery. 2009 Jan;64(1):40-7; discussion 47 [19145155.001]
  • [Cites] Eur J Cardiothorac Surg. 2005 Sep;28(3):407-14 [16055340.001]
  • [Cites] Mayo Clin Proc. 2006 Mar;81(3):307-12 [16529133.001]
  • [Cites] J Med Ethics. 2006 Oct;32(10):612-6 [17012508.001]
  • [Cites] Int J Qual Health Care. 2007 Apr;19(2):113-9 [17277008.001]
  • [Cites] N Z Med J. 1998 Sep 11;111(1073):340-2 [9785548.001]
  • (PMID = 19575147.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] ENG
  • [Grant] Canada / Canadian Institutes of Health Research / / MOP 77670
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2808535
  •  go-up   go-down


93. Chamberlain MC, Tsao-Wei DD, Groshen S: Salvage chemotherapy with cyclophosphamide for recurrent temozolomide-refractory anaplastic astrocytoma. Cancer; 2006 Jan 1;106(1):172-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: A prospective Phase II study of cyclophosphamide (CYC) was conducted in adult patients with recurrent temozolomide-refractory anaplastic astrocytoma (AA) with a primary objective of evaluating 6-month progression-free survival (PFS).
  • Time to tumor progression ranged from 2-19 months (median, 4 mos; 95% CI, 2-6 mos).
  • CONCLUSIONS: CYC demonstrated modest efficacy with acceptable toxicity in this cohort of adult patients with recurrent anaplastic astrocytoma, all of whom had failed prior TMZ chemotherapy.
  • [MeSH-major] Astrocytoma / drug therapy. Brain Neoplasms / drug therapy. Cyclophosphamide / therapeutic use. Dacarbazine / analogs & derivatives. Neoplasm Recurrence, Local / drug therapy. Salvage Therapy
  • [MeSH-minor] Adult. Anaplasia. Antineoplastic Agents, Alkylating / administration & dosage. Antineoplastic Agents, Alkylating / adverse effects. Antineoplastic Agents, Alkylating / therapeutic use. Drug Administration Schedule. Drug Resistance, Neoplasm. Fema